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Abstract
Group A Streptococcus (GAS; group A streptococci; Streptococcus pyogenes) is a
globally significant bacterial pathogen. The primary biological host for GAS is
humans, and GAS is responsible for a plethora of non-invasive and invasive
infections. Generally, GAS colonisation of superficial tissue sites, including the
epidermal surface of the skin or the mucosal epithelium of the upper respiratory
tract, results in non-invasive conditions such as impetigo and pharyngitis. Less
commonly, GAS can gain access and disseminate into more sterile tissue areas. This
leads to invasive life-threatening conditions, including necrotising fasciitis and
streptococcal toxic shock syndrome, which involve destruction of the skin and soft
tissue. Infection with GAS can also give rise to delayed nonsuppurative sequelae,
such as rheumatic fever and acute glomerulonephritis, which are responsible for high
rates of morbidity and mortality worldwide. The last comprehensive study assessing
the global impact of diseases attributable to GAS estimated over 500,000 deaths per
annum, placing this bacterium among the world’s most significant human pathogens.
In the past few decades, there has been an increase in the severity and incidence of
invasive GAS disease in Western countries, though currently it remains endemic in
developing nations and Indigenous populations.
Subversion of the host plasminogen activation system is critical for streptococcal
virulence. Central to this system is the blood-circulating zymogen plasminogen, that
is activated to plasmin by host activators, urokinase plasminogen activator (uPA) or
tissue plasminogen activator (tPA), as well as by bacterial activators, including the
secreted GAS protein streptokinase. GAS recruits plasminogen to the bacterial cell
surface via multiple cell surface receptors, and activation of bound plasminogen
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results in plasmin-coated GAS. Under physiological conditions, plasmin is strictly
regulated by circulating inhibitors such as 2-antiplasmin, however under certain
circumstances, plasmin localised at the GAS cell surface is protected from inhibition.
Consequently, GAS can acquire an unregulated source of potent proteolytic activity
at its cell surface, which is believed to facilitate the breakdown of host tissue barriers
and extracellular matrix components (ECM). The human innate immune system
serves as a protective shield against invading microbes during the early stages of
infection. Plasmin-mediated immune evasion has recently emerged as a key
mechanism in bacterial pathogenesis. In order to establish systemic infection, GAS
must overcome the bactericidal effects of complement, a fundamental component of
the innate immune response. A number of human pathogens have thwarted the
complement system via either binding plasminogen directly to the cell surface or
expressing plasminogen activators; both mechanisms result in proteolytic plasmin
activity. Bacterial-generated plasmin has been shown to degrade essential
components of the complement system, thereby preventing complement-driven
phagocytosis, and enhancing the survival of the organism. However, there is limited
knowledge on the impact of plasminogen activation and plasmin acquisition by GAS
on host innate immunity. Furthermore, for a wide range of pathogenic
microorganisms, surface bound plasminogen can be converted to plasmin by uPA
and tPA, with the resulting plasmin activity facilitating host invasion by the
bacterium. Streptokinase-generated plasmin activation has been thoroughly studied,
however, the contribution of host activators to GAS pathogenesis has yet to be
explored. To further clarify the role of the fibrinolytic system in GAS virulence, this
project used two clinically important GAS isolates to investigate the impact of
plasminogen activation and cell surface plasmin acquisition on the host innate
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immune response to GAS, and elucidate the contribution of uPA and tPA to invasive
GAS disease.
Several bacterial species have demonstrated the ability to modulate the functions of
C3b, a key opsonin. One consequence of C3b deposition on the bacterial cell surface
is complement-mediated neutrophil killing. We demonstrate that the acquisition of
plasmin to the GAS cell surface results in degradation of C3b, and this was
correlated with a significant decrease in C3b opsonisation and neutrophil killing in
vitro. Further, in a transgenic humanised plasminogen mouse model of GAS
infection, the ability of GAS to accumulate cell surface plasmin was associated with
reduced C3b deposition, neutrophil phagocytosis, and increased bacterial survival in
vivo. Our findings highlight a significant role for cell-bound plasmin in protecting
GAS from complement-mediated neutrophil killing, and provide new insight for the
mechanisms involved during the early phases of invasive GAS infection.
We next assessed the role of uPA-mediated plasminogen activation in GAS
pathogenesis. In the absence of streptokinase, uPA can facilitate GAS cell surface
plasmin acquisition during incubation with human plasminogen in vitro, and in
human plasma ex vivo. Using a newly described transgenic humanised plasminogen
uPA-knockout mouse model, the absence of host uPA significantly increased mice
survival compared to wild-type mice following subcutaneous GAS infection. This
correlated with the reduced ability of GAS to disseminate in vivo, and accumulate
cell surface plasmin ex vivo in the absence of uPA. Given the key contribution of
uPA in GAS virulence, we explored the therapeutic potential of commercial and
previously undescribed uPA inhibitors to block uPA-mediated plasminogen
activation. Minimal inhibitory concentration data demonstrated that these inhibitors
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displayed antimicrobial activity against GAS, and enhanced potency against uPA
activity in vitro. However, treatment with these inhibitors did not delay or prevent
the progression of invasive GAS disease in this particular mouse model of infection.
The absence of uPA and streptokinase did not completely abrogate GAS virulence in
the humanised mouse plasminogen infection model, suggesting a potential role for
tPA in GAS disease. Whilst we confirmed that tPA can facilitate plasminogen
activation at the bacterial cell surface in vitro, the absence of tPA did not have an
impact on bacterial dissemination, or mice survival in humanised plasminogen tPAknockout mice compared to wild-type mice post-GAS infection. Similarly, no
differences were observed in skin lesion size, or the pathology of GAS infection in
the absence of tPA. While we cannot completely dismiss the role of tPA during GAS
virulence, these data suggest that tPA plays a limited role in this particular mouse
model of infection, and further highlights the significance of uPA and streptokinase
during the course of GAS infection.
The findings in this project define a new role for the acquisition of plasmin(ogen) in
evasion of the host innate immune response, and establishes a role for uPA, but not
tPA, in a mouse model of invasive GAS disease. These data further extend our
knowledge of the complex interactions between GAS and the host fibrinolytic
system, and the critical role that plasmin(ogen) plays during GAS pathogenesis.
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1.1

Overview

Subversion of the human plasminogen activation system is critical for initiation of
invasive disease by many pathogenic bacteria. Plasminogen is the central mediator of
the plasminogen activation system, and its activation to the broad spectrum protease
plasmin is facilitated by urokinase (uPA) and tissue (tPA) plasminogen activators.
Plasmin has wide substrate recognition and is physiologically important in a number
of roles. Primarily, plasmin degrades fibrin blood clots, but is also involved in the
breakdown of extracellular matrix (ECM) components, blood coagulation, immune
factors and matrix prometalloproteinases (Collen and Lijnen 1991; Lahteenmaki et
al. 2000; Aisina and Mukhametova 2014). Plasmin is also implicated in other
biological processes such as cell migration, wound healing and infiltration of
immune cells to sites of infection (Vassalli et al. 1991; Del Rosso et al. 2008).
Consequently, the plasminogen activation system is an attractive target for
exploitation by microorganisms including the Gram-positive pathogen, Group A
Streptococcus (GAS; group A streptococci; Streptococcus pyogenes). GAS is a
significant pathogen, with humans the only natural reservoir identified to date. The
heavy global burden of GAS disease is attributable to the plethora of virulence
factors that result in clinically diverse manifestations. Localised and superficial GAS
infections may result in pharyngitis, scarlet fever and impetigo, which can further
progress into life-threatening invasive diseases such as bacteremia, streptococcal
toxic shock syndrome (STSS) and the ‘flesh-eating disease’, necrotising fasciitis
(Bisno and Stevens 1996; Cunningham 2000). The severity of invasive GAS
infections has resurged in recent decades, and over 700 million cases of GAS
infection worldwide are estimated each year (Carapetis et al. 2005). The acquisition
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of the host protease plasmin has been shown to be a pre-requisite for a subset of
GAS isolates for full virulence in a mouse model of infection (Sun et al. 2004; Cole
et al. 2006; Sanderson-Smith et al. 2008). There is some evidence that pathogens
hijack plasmin to resist host innate immunity by targeting the complement system
(Rooijakkers et al. 2005). Additionally, host uPA- and tPA-mediated plasminogen
activation at the cell surface of a number of pathogenic bacteria results in localised
plasmin activity that leads to bacterial host invasion (Rooijakkers and van Strijp
2007). Despite intensive research efforts, the molecular mechanisms governing GAS
pathogenesis are yet to be fully characterised. Understanding of host-GAS
interactions is vital for identifying key virulence factors and pathways. Presented
here is work further investigating the role of the host fibrinolytic system in GAS
pathogenesis. Two clinically important GAS isolates were employed to explore the
impact of plasminogen acquisition and activation by GAS on evasion of
complement-mediated neutrophil phagocytosis during the early stages of infection,
and to elucidate the roles of host activators uPA and tPA in GAS virulence in vivo.
1.2

Classification of streptococci

1.2.1

Lancefield classification

The genus Streptococcus is a diverse group comprised of 50 species originating from
both human and domesticated animals (Innings et al. 2005). Rebecca Lancefield first
described a serological classification system based on the antigenic variation in
polysaccharides located in the bacterial cell walls of Groups A, B, C, F and G
streptococci, or lipoteichoic acids in Group D streptococci (Cunningham 2000).
Among these streptococci, GAS is considered one of the most virulent species
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causing human infections (Facklam 2002). Accurate identification of Group A
streptococci is fundamental to epidemiological and pathogenic studies of
streptococcal diseases. Characterisation of GAS has been highly dependent on the M
protein, an important virulence factor of GAS. M protein evokes a type-specific host
immune response, and antibodies directed against the M protein confer protective
immunity (Smeesters et al. 2010). This has led to the development of the traditional
M-serotyping method, which has now been replaced by a technique termed emmsequencing.
1.2.2

M-serotyping

The surface-exposed M protein is one of the most extensively studied streptococcal
proteins. Encoded by the emm gene, M proteins are dimeric α-helical, coiled-coil in
structure and are tethered to the cell membrane via the conserved carboxy-terminal
region (Figure 1.1). The N-terminus of the M protein faces the extracellular mileu
and is extremely hypervariable (Figure 1.1) (Phillips et al. 1981). Antigenic variation
in this hypervariable region marks the foundation of M-serotyping, and antibodies
raised against this region are serotype specific (Smeesters et al. 2009). The
hypervariable region of the M protein is considered one of the most important
epidemiological markers for characterising GAS (Vitali et al. 2002). However, the
M-serotyping method has major shortcomings that have limited its use. With an
increasing discovery rate of GAS isolates, providing type-specific antisera for all
known and newly encountered serotypes is difficult. Additionally, many GAS
isolates are non-typeable, particularly those found in tropical regions, due to the lack
of reactivity against available standard antisera (Relf et al. 1992). These deficiencies
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challenged the continued use of this M-serotyping and were overcome by the
development of a molecular based method called emm-sequence typing.
NH2 terminal
Hypervariable region

Conserved
repeat region

Group carbohydrate
Peptidoglycan
Membrane

COOH terminal

GAS cytosol

Figure 1.1 Schematic of the GAS M protein. The M protein is a key virulence factor of GAS. M
proteins extend approximately 50-60 nm from the bacterial surface and are anchored via the highly
conserved carboxy (COOH) terminal region. They are coiled-coil, α-helical structures that form
dimers stabilised by intermolecular interactions with neighboring M protein molecules. The
hypervariable region is found at the amino (NH2) terminus and is highly variable among GAS
isolates. The M protein contains multiple repeat regions (not shown) which bind to a diverse number
of host molecules, contributing to the virulence of this pathogen. Adapted from Fischetti (1989) and
Georgousakis et al. (2009).

1.2.3

emm-sequence typing

The emm-sequence typing method is a widely used and accepted genotyping scheme
for characterising GAS isolates. This simple method is based on sequence analysis of
polymerase chain reaction (PCR) products comprising the first 160 bases of the
5’end of the emm gene, encoding the N-terminal hypervariable portion of the M
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protein (Figure 1.1) (Facklam 2002). This typing system has led to the detection of
previously unidentified emm types, and differentiation between M-nontypeable
strains. Virtually all GAS isolates are epidemiologically defined by their emm type,
and to date, 234 different emm types have been documented worldwide (McMillan et
al. 2013).
1.3

Clinical spectrum of GAS disease and epidemiology

GAS is among the most common and versatile of human-adapted pathogens. An
analysis of deaths attributable to infectious disease indicated that the number of
GAS-associated deaths is only exceeded by HIV, Mycobacterium tuberculosis,
Plasmodium falciparum and Streptococcus pneumoniae (WHO 2005). A plethora of
host and GAS proteins contribute to the diversity of clinical GAS manifestations,
ranging from pyogenic infections to necrotising fasciitis, as well as post-infectious
immune-mediated sequelae (Walker et al. 2014). A summary of GAS disease and
epidemiology is provided in Table 1.1.
1.3.1

Superficial GAS infections

The epithelium of the throat and skin are the main physiological niches of GAS, and
as such, is the most common bacterial cause of acute pharyngitis, accounting for 1530% of childhood cases and 10% of adult cases (Carapetis et al. 2005). Individuals
in developed countries are more likely to experience pharyngitis at least once a year,
whilst this rate is increased by 5 to 10 times in developing regions (Carapetis et al.
2005; Henningham et al. 2012). In some cases, scarlet fever has been known to
accompany GAS pharyngitis (Wessels 2011). Cases of scarlet fever have remained
low during the twentieth century, but the disease burden has reappeared in the past
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decade and currently remains problematic (Wong and Yuen 2012; Walker et al.
2014). Localised skin infection caused by GAS can also result in impetigo, a
contagious skin infection. The global burden of superficial GAS infection is
significant; over 616 million cases of GAS pharyngitis, and 111 million cases of
GAS pyoderma are reported each year (Carapetis et al. 2005).
1.3.2

Invasive GAS disease

Although less frequent than superficial infections, systemic GAS disease can
develop from any streptococcal infection. Penetration of host epithelial barriers via
skin or mucous membranes provides an invasive pathway for GAS and facilitates
bacterial dissemination into distant, sterile organs. For a substantial number of
invasive GAS infections however, the portal of bacterial entry is unknown, although
several studies have associated previous blunt trauma with invasive GAS infections
(Stevens et al. 1989; Kaul et al. 1997; Johansson et al. 2010). Up to 23% of patients
with invasive disease die within seven days of GAS infection (Walker et al. 2014).
The most common forms of invasive streptococcal disease are cellulitis and
bacteremia; each accounting for approximately 20-40% of invasive GAS disease
(O'Loughlin et al. 2007; Lamagni et al. 2008). Further progression of these
infections may lead to necrotising fasciitis that often occurs in combination with
streptococcal toxic shock syndrome (STSS), a systemic inflammatory disease.
Necrotising fasciitis and STSS are considered the most severe manifestations of
GAS infection, with a staggering 85.7% case-fatality rate resulting from patients
with necrotising fasciitis that do not receive any surgical treatment (Johansson et al.
2010; Walker et al. 2014).
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1.3.3

Post-immune sequelae

Post-infectious complications can result from prior GAS infections. Rheumatic fever
(RF) is the leading cause of heart disease amongst school-aged children, and is the
most significant contributor to the death toll of GAS disease worldwide, resulting in
23,300 deaths annually (Ellis et al. 2010; Guilherme and Kalil 2010). Pharyngitis is
classically a precursor for RF, but is not a pre-requisite (Carapetis et al. 2005). The
disease has also been detected following cases of STSS and is endemic in
populations which have low incidences of GAS throat colonisation (Carapetis et al.
2000; McDonald et al. 2004; Smeesters et al. 2010). RF is considered the most
significant of non-suppurative immune sequelae following GAS infection, but others
may arise including acute post-streptococcal glomerulonephritis, Sydenham chorea
and the more controversial, pediatric autoimmune neuropsychiatric disorders
associated with streptococcal infections (Henningham et al. 2012; Walker et al.
2014).
1.3.4

Molecular epidemiology and diversity of emm-types

Molecular epidemiology studies have highlighted the genetic diversity and varied
distribution of emm-types, particularly between temperate and tropical environments
(Smeesters et al. 2009). GAS diseases are most common in areas of poverty, where
living conditions are poor and inadequate medical assistance facilitates bacterial
transmission. In low-income settings, the diversity of emm-types far exceeds that
seen in isolates circulating in high-income settings, where a small subgroup of emmtypes dominate (Smeesters et al. 2009). Further, emm-types found within
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Table 1.1 Summary of GAS diseases and their current epidemiology.
Pathology and/or symptoms

Epidemiology

References

Non-invasive

Pharyngitis

Sore throat with swollen uvula, fever, malaise, headache, nausea and
vomiting; often remains benign and self-limiting.

Predominant in crowded conditions, school-aged children and in
less-developed countries.

(Bisno and Stevens
1996; Cunningham
2000; Choby 2009;
Henningham et al.
2012)

Scarlet fever

Characterised by ‘strawberry,’ furry tongue with enlarged papillae that later
develops into a deep red rash, and can spread from the face down to the
neck and upper trunk.

Outbreak in Hong Kong and mainland China.

(Wong and Yuen
2012)

Impetigo

Epidermal disorder characterised by numerous lesions which transition to
pustules followed by the formation of thick, honey-coloured crusts.

Widespread among economically disadvantaged
Prevalent in tropical or subtropical climates.

children.

(Bisno and Stevens
1996; Valery et al.
2008; Walker et al.
2014).

Invasive
Necrotising fasciitis

Soft-tissue infection characterised by rapid inflammation and subsequent
necrosis of subcutaneous and deep soft tissue, leading to destruction of
fascia, connective tissue and fat, usually on the face or extremities.
Accompanied by local pain, fever and systemic toxicity.

Streptococcal toxic
shock syndrome

Systemic inflammatory disease caused by the production of toxins that are
released into the bloodstream. Patients experience myalgia, nausea,
vomiting and a rapid onset of shock, and multiorgan failure (kidney, liver
and lung).

Erypsipelas and
cellulitis

Invasive GAS diseases occur more commonly in the USA and in
northern European countries. Primarily targets school-aged
children who have previously been infected with pharyngitis,
though it also manifests in young, previously healthy individuals.

(Bisno and Stevens
1996; Green et al.
1996; Olsen et al.
2009; Henningham et
al. 2012)

Erysipelas occurs as an acute, diffuse, spreading infection in superficial
layers of the skin. Cellulitis occurs deep in subcutaneous tissues,
characterised by redness and inflammation pain and swelling of the skin.

Erysipelas occurs in young children and the elderly. Cellulitis is
most frequent among middle-aged and elderly individuals.

(Bisno and Stevens
1996; Simonsen et al.
2006)

Rheumatic fever

Characterised by inflammation of the joints, central nervous system, skin
and subcutaneous nodules, and the heart and heart valves. Delayed sequel
to pharyngeal infections.

Highest prevalence in Indigenous communities in the Northern
Territory of Australia and Pacific Island nations.

(Carapetis et al. 1996;
Cunningham 2000)

Acute poststreptococcal
glomerulonephritis

Causes irreversible, chronic renal failure and manifests as discoloured
urine, edema of the face and extremities, and circulatory congestion.
Develops from pharyngeal or skin infections.

Post-infection sequelae
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developing countries differ substantially from one another, hampering the
development of an effective vaccine, and increasing the complexity of characterising
the virulence mechanisms of the large repertoire of GAS strains (Dey et al. 2005;
Abdissa et al. 2006; Smeesters et al. 2006; Sanderson-Smith et al. 2014). Vaccines
targeting common emm types may not be effective in poor-resourced countries,
highlighting the need for the development of a multivalent vaccine which provides
coverage against multiple emm-types. A recently developed emm cluster typing
system that divides GAS emm-types into 48 discrete clusters has enabled better
analysis of closely related M proteins that share binding and structural properties
(Sanderson-Smith et al. 2014). This system has added a new dimension to
identifying not only strains circulating in high-income areas, but also the diverse
number of emm-types found in low-income settings.
The reappearance of severe global invasive streptococcal disease in Western
countries has been associated with circulating emm1 and emm3 GAS (Lynskey et al.
2011). Whilst emm3 displays cyclic episodes of 4-7 year outbreaks, emm1 has nontraditionally persisted for over 25 years and remains the most predominantly isolated
GAS clone from the Western world (Schwartz et al. 1990; Aziz and Kotb 2008).
This may be explained by the unique feature of the emm1 clone to switch to a
hypervirulent phenotype during infection, however the exact molecular basis for this
remains elusive (Cole et al. 2006; Sumby et al. 2006; Walker et al. 2007; Hollands
et al. 2010). Other emm-types are frequently associated with outbreaks such as
emm59 and emm81 GAS causing bacteremia and cellulitis, and ecthyma respectively
(Henningham et al. 2012).
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1.3.5

Current treatment for GAS infections

Despite increased research in recent decades, morbidity and mortality due to GAS
infection continue to be a major problem worldwide. Whilst non-invasive infections
such as pharyngitis remain susceptible to penicillin, severe invasive diseases are
limited to extremely high doses of intravenous penicillin or surgical debridement. A
thorough understanding of the mechanisms governing host-pathogen interactions is
paramount to developing effective treatments for invasive GAS disease. GAS is still
sensitive to penicillin, despite being exposed to this antibiotic for over five decades
(Passali et al. 2007). However, a safe and effective vaccine is still unavailable.
Currently, vaccine development has largely focused on targeting the M protein,
which have shown promise as GAS vaccine candidates in animal-based trials
(Walker et al. 2014).
1.4

GAS immune evasion

Multicellular organisms have evolved a complex immune system composed of
intertwining networks and strategies in order to protect the host organism. The
human immune system has traditionally been divided into innate and adaptive
(acquired) immunity, though both systems cooperate to provide efficient defence
against potential pathogens (Turvey and Broide 2010). The innate immune response
serves as host protection against the initial stages of bacterial infection. Both the
ability to elude host defence and produce surface and secreted virulence factors by
GAS is critical for establishing invasive disease. The role of plasminogen acquisition
and activation by GAS on evasion of the complement system has yet to be explored,
and will be a major focus of this thesis.
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1.4.1

The innate immune system

While anatomical and physiological barriers offer protection against the initial
encounter with microbial organisms, the innate immune system represents the first
line of defence once these barriers are breached. Innate immunity is characterised by
its rapid response to foreign material and lack of immunological memory. Innate
immune protection is attributed to a large repertoire of immunocytes that engulf and
destroy pathogens (Beutler 2004). These myeloid cells include mononuclear
leukocytes, which consist of macrophages, dendritic cells and natural killer cells, and
polymorphonuclear leukocytes (PMNs), which can be further subdivided into
neutrophils, basophils and eosinophils. The complement system is a critical
component of innate immunity, and together with phagocytic cells, in particular
neutrophils, plays a major role against controlling GAS infection.
1.4.1.1 Neutrophils
Neutrophils are the most abundant circulating leukocytes (Kumar and Sharma 2010).
They are endowed with numerous cytotoxic granules enriched with powerful and
lethal antimicrobial molecules (Kumar and Sharma 2010). Neutrophils however, are
short-lived, surviving in the bloodstream for approximately six hours before
undergoing apoptosis (Beutler 2004). Neutrophils are synthesised and continuously
replenished from bone marrow and once matured, are recruited by inflammatory
mediators and enter the bloodstream to migrate to the site of bacterial infection.
Neutrophils directly eliminate pathogens via three effective strategies (Figure 1.2).
Neutrophils can undergo degranulation, where antimicrobial substances are delivered
to the phagosome or to the exterior of the cell (Brinkmann and Zychlinsky 2007). In
the phagolysosome, bacteria are killed via the action of reactive oxygen species and
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antimicrobial peptides which permeabilise the bacterial membrane and lyse microbes
(Borregaard and Cowland 1997). In addition to their phagocytic properties against
pathogenic bacteria, activated neutrophils also secrete neutrophil extracellular traps
(NETs) which further enhance the killing capacity of these cells (Brinkmann et al.
2004). NETs, composed of a network of fibres containing chromatin, some granular
and cytoplasmic proteins, are formed as a result of extracellular release of neutrophil
nuclear contents (Brinkmann et al. 2004). NETs play an important role in
containment of infection and inflammation, and have been shown to kill GAS, as
well as other microorganisms such as Staphylococcus aureus (S. aureus), Bacillus
anthracis and Mycobacterium tuberculosis (Buchanan et al. 2006; Brinkmann and
Zychlinsky 2007; Fuchs et al. 2007; Ramos-Kichik et al. 2009).
1.4.2

The complement system

The complement system is the major arm of innate immunity and functions in
concert with neutrophils primarily to recognise and destroy invading pathogens
(Potempa and Potempa 2012). The complement system serves as the first line of
defence against bacterial invasion and is comprised of a network of over 30 plasma
proteolytic enzymes that behave in a cascade-like manner. Complement is present in
the human bloodstream as well as at mucosal surfaces, and its activation is tightly
regulated by multiple soluble and membrane-bound regulators (Kolev et al. 2014).
Many bacterial pathogens have evolved mechanisms to manipulate and overcome
complement activation and evade host defence (Okumura and Nizet 2014). GAS
interacts with the complement system via a multitude of strategies which target the
multiple stages of the complement cascade, and will be briefly described below.
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Neutrophil

Pathogen

NETs
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Production of NETs

Figure 1.2 Neutrophil killing mechanisms. Neutrophils employ three effective strategies for the
eradication of pathogens. Firstly, phagocytosis of bacteria involves the formation of a membranebound compartment called a phagosome which fuses with granules to generate a phagolysosome. In
the phagolysosome, bacteria are exposed to lethal components, such as reactive oxygen species and
antimicrobial peptides. Neutrophils can also undergo degranulation, where they employ their granuleassociated arsenal, leading to the release of antimicrobial factors into the extracellular medium, or into
phagosomes to enrich phagocytic vacuoles. Neutrophils also secrete neutrophil extracellular traps
(NETs) which entrap and kill bacteria extracellularly.

1.4.2.1 Activation of complement
Detection of microorganisms that have breached external host barriers leads to
complement activation via three distinct pathways; the classical, mannose-binding
lectin or alternate pathways (Figure 1.3). These pathways can be triggered via
binding of the C1q complex to bacteria either directly or via immunoglobulins
(classical pathway), recognition of polysaccharides present on microbial surfaces via
mannose-binding lectin (lectin pathway), or spontaneously due to the inherent
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instability of C3 (alternative pathway) (Gotze and Muller-Eberhard 1971; Potempa
and Potempa 2012). Combined, these pathways result in either bacterial opsonisation
for phagocytic uptake, or direct bacterial killing by the membrane attack complex
(MAC). Although complex, these pathways converge to generate C3 and C5
convertases, which cleave C3 into fragments C3a and C3b, and C5 into C5a and
C5b, respectively (Figure 1.3). C3b opsonises bacteria and promotes bacterial uptake
by phagocytic cells such as neutrophils and macrophages via specific receptors
(CD35, CD11b/18 and CD11c/18). C3b deposition also facilitates an amplification
process involving the formation of C3 convertase, leading to the rapid deposition of
additional C3b on bacterial surfaces (Pangburn et al. 2008). C5a and C3a are
powerful chemoattractants that recruit immune cells to the site of infection (Peng et
al. 2009). Deposition of C5b initiates the terminal pathway and assembly of the
MAC, consisting of components C5-C9. The formation of MAC results in the
generation of lipophilic, membrane-insertion complexes that initiate cell lysis via
inducing pores in the bacterial cell membrane (Muller-Eberhard 1986; Potempa and
Potempa 2012).
1.4.3

GAS complement evasion strategies

GAS has evolved a multitude of sophisticated mechanisms for evading complement
attack. Acquisition of key host complement regulatory proteins and degradation or
inactivation of complement proteins by proteases are proposed mechanisms
employed

by

GAS

for

impeding

complement

activation

and

avoiding

opsonophagocytosis (Nizet 2007). The ability of GAS to inhibit complement
functions at multiple levels plays a significant role in overcoming host immunity and
facilitating GAS survival. Figure 1.4 provides a summary of various streptococcal
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virulence factors which interfere and inhibit the function of complement proteins and
regulators.

Peptide mediators of
inflammation, phagocyte
recruitment

Classical
antigenantibody
complexes

C3

C3a

C5

C5a

Lysis

Lectin

C3b

mannose

Alternative

Opsonisation of
pathogens

C3 convertase

C5b

C5 convertase

spontaneous

Membrane
attack
complex

Bacterial cell surface
Figure 1.3 Activation and function of complement. Complement activation occurs via three distinct
pathways; classical, mannose-binding lectin or alternate pathways. Each pathway activates the
complement cascade to converge at the formation of C3 convertase, which cleaves C3 to activate C3a
and C3b fragments. Opsonisation of bacterial surfaces by C3b leads to cell clearance by phagocytes,
amplification of complement activation via the formation of C3 convertase, and the assembly of C5
convertases, which generate C5a and C5b. The release of the anaphylatoxins, C3a and C5a, trigger
chemotactic and pro-inflammatory responses. Terminal complement components (C5b) induce the
formation of the membrane-attack complex (MAC) which facilitates bacterial cell lysis. Adapted from
Kolev et al. (2014), Okumura and Nizet (2014) and Barthel et al. (2012a).

1.4.3.1 Acquisition of host complement regulators
The interaction of microbial pathogens and host complement regulators has been
well-documented (Rooijakkers and van Strijp 2007). C4-binding protein (C4BP) is a
key fluid phase inhibitor of the classical and lectin pathways that binds to C4b,
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thereby dissociating formation of C3 convertase, as well as functioning as a cofactor
in the proteolytic inactivation of C4b (Oliver et al. 2008). GAS exhibits high affinity
binding to C4BP via M protein and M protein family members Sir and Arp (Thern et
al. 1995; Jarva et al. 2003; Sanderson-Smith et al. 2014). This interaction is
mediated by the hypervariable N-terminal region of the GAS M protein (Accardo et
al. 1996). Binding of the M protein to C4BP has been shown to mimic the binding to
that of C4b, resulting in an overlap in binding site and preventing subsequent C4b
regulation and down-regulation of complement activation (Berggard et al. 2001).
The acquisition of C4BP by GAS has also been correlated with evasion of
phagocytosis (Carlsson et al. 2003; Blom et al. 2009). Acquisition of C4BP is a
common phenomenon amongst human pathogens and has been demonstrated by
Neisseria meningitides (Schneider et al. 2007), Escherichia coli (E. coli) (Wooster et
al. 2006) and Bordetella pertussis (Berggard et al. 1997; Berggard et al. 2001).
Another mechanism by which GAS subverts complement attack is binding to
regulators of the alternative pathway such as factor H (FH) and its spliced gene
product, factor H-related (FHL)-1 proteins. These inhibitors compete with factor B
for binding with C3b, control the formation of C3 convertase and act as cofactors for
degradation of C3b (Zipfel et al. 1999). The GAS M protein has been shown to bind
FH and FHL-1 via the conserved C-repeated domain and hypervariable region
respectively (Blackmore et al. 1998). Acquisition of both these proteins promotes
bacterial survival in the bloodstream (Kraiczy and Wurzner 2006). However, GAS
strains exhibit varying affinities for these proteins; invasive strains M1 and M3 show
little binding capacity compared to M18, which demonstrates the highest binding
affinity (Perez-Casal et al. 1995). A recent study has demonstrated that enhanced
Page | 17

Chapter 1 Review of the Literature

mouse mortality was observed upon infection with GAS strains that bind C4BP
and/or FH in a humanised transgenic mouse model expressing human complement
inhibitors (Ermert et al. 2015). This further emphasises the importance of the
recruitment of host complement inhibitors by GAS to attenuate complement
opsonisation and phagocytic killing.
1.4.3.2 Degradation of complement factors by GAS proteases
Degradation and inactivation of complement components by bacterial virulence
factors are key mechanisms for evading complement activation by a number of
human pathogens. GAS produces a number of virulence factors directed at evading
complement including those that directly degrade complement components. GAS
expresses a multidomain surface-bound endopeptidase, C5a peptidase (ScpA) that
specifically degrades complement factor C5a via limited proteolysis of the Cterminus, a critical region that is recognised by receptors of polymorphonuclear
leukocytes (Hynes 2004; Kagawa et al. 2009). Consequently, this leads to impaired
C5a-mediated pro-inflammatory and chemotactic responses and impedes the
migration of inflammatory cells to the site of infection. In a mouse model of
infection, this has been shown to promote increased GAS dissemination (Ji et al.
1996). Similarly, GAS plasminogen binding anchorless proteins surface -enolase
(SEN) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (discussed in
1.8.2.2) have also been shown to capture and inhibit C5a function (Terao et al.
2006). Furthermore, GAS secretes streptococcal pyrogenic exotoxin B (SpeB), a
cysteine protease that plays a pivotal role in complement evasion by GAS (HondaOgawa et al. 2013). SpeB directly degrades C3 and C3b, thereby inhibiting all three
pathways of complement activation at the level of C3 convertase and opsonisation
Page | 18

Chapter 1 Review of the Literature
(2) Neutrophil lysis
(3) Chemokine
degradation

(1)Breakdown
of NETs
SLO
SLS

ScpA (C5a)
ScpC (IL-8)

C4BP
SIC

Sda1
(DNase)

(8) Resistance to
antimicrobial
peptides
SpeB

GAS

(4) Interference with
complement
deposition
C3b

?? Factor H
M protein

Resistance to host phagocyte defences
C3b
C3b
M protein

SIC
(7) Impairment of
phagocyte uptake

(5) Nonopsonic binding of
immunoglobulins

Hyaluronic acid
capsule

Fibronectin
Fibrinogen
Albumin

M protein
M-like proteins
(6) Cloaking
of opsonins

Figure 1.4 Overview of virulence mechanisms employed by GAS to thwart the host innate
immune response. (1) GAS secreted DNase Sda1 promotes degradation of neutrophil extracellular
traps (NETs) and resistance to neutrophil killing. (2) Impaired phagocytic activity is also
accomplished via lysis of neutrophils by streptolysin O (SLO) and streptolysin S (SLS). (3) The
chemokine interlukin-8 (IL-8) and complement-derived chemoattractant peptide C5a are degraded by
peptidase ScpC and ScpA, respectively. (4) Deposition of C3b, required for opsonisation on the
bacterial surface, is inhibited via acquisition of host complement regulators C4-binding protein
(C4BP) and Factor H (FH) by the GAS M protein. (5) The M protein nonopsonically binds
immunoglobulin, which is also degraded by the GAS protease, SpeB. (6) Recruitment of host matrix
proteins by M and M-like proteins, as well as mimicry by the hyaluronic acid capsule provides GAS
with a protective cloak against opsonin recognition. (7) Impediment of phagocytic uptake is caused by
inhibition of the membrane-attack complex (MAC) formation as a result of colocalisation of
streptococcal inhibitor of complement (SIC) with actin cytoskeletal arrangements. (8) Both SpeB and
SIC also protect GAS against the bactericidal activities of antimicrobial peptides. Adapted from
Kwinn and Nizet (2007).
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respectively (Terao et al. 2008). SpeB also degrades properdin, a protein critical for
maintaining the stability of convertases of the alternative pathway (Tsao et al. 2006).
Infection with a SpeB-deficient GAS strain results in an influx of neutrophils to the
site of infection, enhanced neutrophil uptake and bacterial clearance in a mouse
model of infection (Nelson et al. 2011).
1.4.3.3 Inhibitors of complement
GAS also targets the final stage of the complement cascade via expression of the
streptococcal inhibitor of complement (SIC). SIC binds to the soluble C5b7 and
C5b8 complexes that are necessary for the assembly of MAC on the target
membrane, thereby hampering the formation of pores and impairing bacterial
complement-mediated lysis (Akesson et al. 1996). However in this regard, the
function of SIC appears to be redundant at least in part as GAS is naturally resistant
to MAC-mediated cell lysis due to its cell wall structure (Lambris et al. 2008). Other
functions of SIC have been identified that do not involve complement, which
indicates that complement inhibition is not the sole function of SIC. These include
playing a role in altering cellular processes and inactivating antibacterial peptides in
neutrophils (Hoe et al. 2002; Frick et al. 2003).
1.4.4 Neutrophils in controlling GAS infection
The major immune cells contributing to the control of GAS infection are neutrophils,
macrophages and dendritic cells. As already discussed, neutrophils are one of the
first immune cells to encounter invading GAS and therefore play an important early
defence mechanism. Studies have shown that GAS has evolved powerful escape
mechanisms to the phagocytosis, phagosome maturation, and NETs of neutrophils
(von Pawel-Rammingen et al. 2002; Carlsson et al. 2003). Furthermore, fewer
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neutrophils have been reported to migrate to sites of invasive GAS infection, while
degradation of anaphylatoxins C5a and IL-8 by ScpA and SpyCEP respectively, is
associated with GAS resistance to neutrophil killing (Wexler and Cleary 1985;
Brinkmann et al. 2004; Hidalgo-Grass et al. 2004; Zinkernagel et al. 2008). In a
lethal GAS infection mouse model, a diminished source of bone-marrow derived
neutrophils led to a decreased infiltration of neutrophils to the site of bacterial
infection, resulting in high mice mortality (Navarini et al. 2009). The functions of
neutrophils are therefore critical for host protection in response to GAS invasion.
1.4.5

Subversion of host proteins to evade complement attack

Several pathogens over the past decade have been found to subvert host proteases to
avoid complement attack (Rooijakkers and van Strijp 2007). Hijacking of the human
plasminogen activation system to convert the endogenous plasminogen into the
protease plasmin on bacterial surfaces can lead to degradation of key complement
proteins and host factors. Establishment of severe invasive GAS disease has been
attributed to its interaction with the host plasminogen activation system, and
represents one of the most intensively studied mechanisms of GAS virulence
(Walker et al. 2014). The interaction of GAS and the human plasminogen activation
system forms the foundation of this thesis, and is described in detail below.
1.5

The human plasminogen activation system

Activation and subversion of the human fibrinolytic system is emerging as a
common mechanism in invasive bacterial infection. The highly regulated
plasminogen activation system is central to a spectrum of biological processes
including, but not limited to fibrinolysis, inflammation, matrix remodelling, wound
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healing, tumor invasion and cell invasion. This system involves the conversion of the
ubiquitous inactive plasminogen by host uPA and tPA, to the broad spectrum serine
protease plasmin (Figure 1.5). Regulation of this system is primarily mediated by
inhibitors of plasminogen activators (PAI-1, PAI-2) and plasmin (α2-antiplasmin, α2macroglobulin).
1.5.1

Plasmin(ogen)

Plasminogen, the 92 kDa inactive precursor of plasmin, is synthesised in the liver,
abundant in plasma and circulates at approximate concentrations of 2 µM (Ogston
1980; Raum et al. 1980). Cleavage of plasminogen by uPA or tPA occurs at the
single peptide bond Arg561-Val562, and leads to the formation of two-chain plasmin
that is composed of a heavy and light chain that remain joined by disulphide bridges
(Figure 1.6) (Rijken and Lijnen 2009). Plasminogen consists of five homologous
kringle domains with lysine-binding sites, which allows for recognition of substrates
and plasminogen receptors, and a serine protease domain which contains the
catalytic triad (His603, Asp643 and Ser741) that is responsible for the proteolytic
activity of plasmin (Figure 1.6) (Castellino and Ploplis 2005; Law et al. 2013). Two
conformational states of plasminogen exist in plasma; both display differing binding
affinities for ligands. Glu-plasminogen is the native form of plasminogen (named
after the first N-terminal amino acid) and circulates in plasma in a closed
conformation. It contains an N-terminal 8 kDa activation peptide that, when cleaved
by plasmin, forms Lys-plasminogen, an 83 kD protein that exhibits a more open and
relaxed conformation. This truncated form renders plasminogen more accessible for
higher affinity and faster interactions with receptor and target molecules than the
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Figure 1.5 Schematic diagram of the mammalian plasminogen activation system. Inactive prouPA binds to the uPA receptor, uPAR, which is then converted to active uPA by plasmin. Host uPA
and tPA proteolytically convert the proenzyme plasminogen to active protease plasmin. Plasmin
through its own proteolytic function degrades fibrin clots to produce fibrin degradation products
(FDPs), and can degrade extracellular matrices (ECM). Alternatively, upon plasmin-mediated
activation of precursors of matrix metalloproteases (Pro-MMPs), matrix metalloproteases (MMPs)
degrade collagen and gelatins of basement membranes, and ECM components that form barriers for
cellular migration. The plasminogen activation system is regulated by plasminogen activator
inhibitors (PAIs) and the anti-proteases, α2-antiplasmin and α2-macroglobulin, which inhibit
plasminogen action and plasmin, respectively (dashed arrows). Adapted from Lähteenmäki et al.
(2005), Mekkawy et al. (2014) and Fuhrman (2012).
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Figure 1.6 Domain structure of human plasminogen. Plasminogen is cleavaged by plasminogen
activators (uPA/tPA) at the Arg561-Val562 peptide bond to form the broad spectrum two-chain
protease plasmin, consisting of a heavy and a light chain. The heavy chain (amino terminal, NH 2)
contains the five kringle domains which primarily mediate fibrin and matrix protein interactions via
lysine-binding sites. The light chain (carboxy terminal, COOH) harbours the catalytic triad (His603,
Asp643 and Ser741) which forms the active site of plasmin. Plasmin-mediated cleavage of the Nterminal activation peptide converts the native and closed form of plasminogen (Glu-plasminogen)
into a more open conformation (Lys-plasminogen). Cleavage sites for plasminogen activators and
plasmin are indicated by arrows; disulfide bridges are indicated by dotted lines. Adapted from
Andreasen (2001).

parent molecule, and also facilitates conversion to plasmin (Ranson and Andronicos
2003; Castellino and Ploplis 2005; Law et al. 2013).
1.5.2

Host plasminogen activators

Two physiologically distinct eukaryotic activators of plasminogen have been
identified; uPA and tPA. Whilst both activators share the ability to activate
plasminogen, they differ in their genetic makeup, have distinct structures with tissuespecific expression and more important, play different biological roles (Vassalli et
al. 1991; Collen 2001). tPA is the principle plasminogen activator in fibrinolysis and
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is highly dependent on the presence of cofactors, such as fibrin, that bind to, and
alter the conformation of plasminogen (Irigoyen et al. 1999). In contrast, uPA
doesn’t directly bind fibrin, but rather it is the critical trigger for the generation of
localised proteolytic plasmin activity during inflammation, wound healing, tissue
remodelling, metastasis and invasion (Kolev and Machovich 2003). Despite this
apparent functional distinction, studies using uPA- and tPA-deficient mice suggest
an overlap in function. In the absence of either activator, the skin wound healing
process continues normally in mice, suggesting that uPA and tPA can substitute for
each other in fibrinolysis (Lund et al. 2006). However, inactivation of both genes
severely impairs this process (Romer et al. 1996), causes rectal prolapse, runting and
extensive fibrin deposition in multiple organs (Carmeliet et al. 1994). These findings
clearly demonstrate that uPA and tPA are crucial for thrombolytic and fibinolytic
processes in the host.
1.5.2.1 urokinase plasminogen activator (uPA)
uPA is a 54 kDa multidomain protein consisting of 411 aa. It is synthesised and
secreted as a single-chain latent pro-enzyme (pro-uPA) by neutrophils, macrophages
and endothelial and renal epithelial cells (Riccio et al. 1985). uPA contains a growth
factor domain and one kringle domain homologous to that found in plasminogen and
tPA at the N-terminus, as well as a serine protease domain containing the catalytic
triad (His204, Asp255, Ser356) at the C-terminus (Figure 1.7) (Kasai et al. 1985). ProuPA, which exhibits minimal intrinsic plasminogen activating capacity (Lijnen et al.
1990), is cleaved at Lys158- Ile159 by plasmin or other proteases to yield a two-chain
uPA molecule connected by a disulphide bond (Figure 1.7). The catalytically active
two-chain uPA exhibits 250-fold greater activity than pro-uPA in humans, and exists
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in both high (HMW) and low (LMW) molecular weight forms (Petersen et al. 1988;
Schmitt et al. 1991; Andreasen et al. 1997; Cesarman-Maus and Hajjar 2005).
Further proteolysis of two-chain uPA at the peptide bond Lys135-Lys136 results in the
formation of a fully functional HMW uPA, whilst additional proteolysis at position
Glu143-Leu144 by specific metalloproteases generates a LMW 33 kDa uPA product
(Barlow et al. 1981). Although both forms of uPA can activate plasminogen, LMW
uPA does not bind to uPAR, a well-characterised uPA-specific cell surface receptor
(Ellis et al. 1989; Ulisse et al. 2009). uPAR is expressed by a wide variety of cells
including monocytes, macrophages and neutrophils (Blasi and Carmeliet 2002).
Binding of uPA to uPAR accelerates the plasminogen activation cascade and
activates plasminogen more efficiently than the fluid phase enzyme. This enhanced
plasmin formation is a consequence of a phenomenon known as ‘reciprocal zymogen
activation,’ where a feedback activation loop facilitates pro-uPA activation by
plasmin and in a reciprocal fashion, uPA catalyses the activation of plasmin, thereby
enhancing its own production (Blasi and Carmeliet 2002). uPAR is tethered to the
cell plasma membrane, and as such, the pericellular localisation of uPA and plasmin
activity is readily available during cell migration and invasion (Ulisse et al. 2009).
Due to the absence of a lysine binding site in the kringle domain, uPA has low
affinity for fibrin, however when fibrin is present, plasminogen activation by twochain uPA is enhanced by almost 10-fold (Gurewich et al. 1984).
1.5.2.2 tissue plasminogen activator (tPA)
tPA is a 70 kDa protein composed of 527 aa and is the principle activator in
fibrinolysis (Lijnen and Collen 1988). tPA has five functionally distinct domains
(finger-like domain of fibronectin, epidermal growth factor, two kringle domains and
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serine protease domain), each with a different role including rapid binding to fibrin,
fibrin-specific plasminogen activation, rapid clearance in hepatocytes and binding to
cellular receptors (Figure 1.7) (Cesarman-Maus and Hajjar 2005). The serine
protease region consists of three residues (His322, Asp371, Ser478) located at the Cterminus. Plasmin digestion at the specific Arg275-Ile276 peptide bond of tPA yields a
disulfide-linked, two-chain molecule. However, unlike other single-chain precursors
of most serine proteases, single-chain tPA is unique in that it also displays enzymatic
activity (Nienaber et al. 1992). While single-chain tPA shows reduced enzymatic
activity compared to two-chain tPA, both forms of tPA demonstrate equivalent
activity in the presence of fibrin (Tate et al. 1987). tPA is primarily produced and
secreted by endothelial cells, but also by keratinocytes, neurons and melanocytes,
and it is most abundant in areas that are within close vicinity to fibrin clots (Levin
1983; Chen et al. 1993; Kooistra et al. 1994; Teesalu et al. 2004). The high affinity
of tPA for fibrin is due to the combination of the second kringle domain and the
finger-like amino terminal domain of tPA, that is homologous to the fibrin-binding
finger domain of fibronectin (Verheijen et al. 1986). The release of tPA is induced
by various stimuli, some of which include thrombin, histamine, bradykinin and
adrenalin. Plasminogen activation by tPA is highly dependent on the presence of
cofactors, such as fibrin (Irigoyen et al. 1999). tPA is also involved in other
biological functions such as potentiation in the hippocampus and excitotoxic
damage, as well as participating in physiological and pathological roles in the brain
(Huang et al. 1996; Lemarchant et al. 2012). To date, a cell-surface receptor which
exclusively binds tPA, has yet to be identified.

Page | 27

Chapter 1 Review of the Literature

uPA

Plasmin, kallikrein

NH2
terminal

COOH
terminal

K1

tPA

Plasmin

NH2

COOH
terminal

K2
K2

K1
K1

terminal

Fibronectin
finger

Epidermal
growth factor

Kringle
domain

Catalytic
domain

Figure 1.7 Schematic domain organisation of human plasminogen activators. tPA is composed of
five domains; the N-terminal (NH2) finger-like domain of fibronectin responsible for binding fibrin,
the epidermal growth factor domain, two kringle domains of plasminogen, and the catalytic domain at
the carboxy terminal region (COOH). Single-chain tPA is cleaved by plasmin at the Arg275-Ile276
peptide bond to yield two-chain tPA. Both single-chain and two-chain tPA are enzymatically active,
making tPA a unique protease. Inactive pro-uPA (or single-chain uPA) is comprised of the epidermal
growth factor domain and a single kringle and catalytic domain. Activation of pro-uPA at Lys158-Ile159
by plasmin or kallikrein leads to the formation of fully active two-chain uPA. In contrast to tPA, uPA
has no fibrin binding capacity, but instead interacts with its own receptor, uPAR, that is expressed on
many cell types. Dotted lines represent disulphide bonds; red arrows indicate cleavage sites where
two-chain proteases are generated from their single-chain precursors. Adapted from Andreasen
(2001), and Dobrovolsky and Titaeva (2002).

1.5.3

Regulation of plasmin

In order to avoid widespread tissue destruction by the action of plasmin, the
plasminogen activation system is tightly regulated both at the levels of direct enzyme
binding, plasmin generation, and control of plasmin activator activity (Figure 1.5).
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Plasmin has two physiological inhibitors in plasma; 2-antiplasmin and 2macroglobulin. Inhibition by 2-antiplasmin occurs in two stages; the reversible and
rapid interaction of 2-antiplasmin with the lysine-binding kringles 1-3 of plasmin,
followed by the irreversible and slow reaction leading to formation of a covalent
bond between the inhibitor and the active site serine residue of plasmin
(Lahteenmaki et al. 2001; Peetermans et al. 2015). Occupation of the lysine-binding
sites during plasmin(ogen) binding to fibrin and cell surface receptors results in
plasmin being protected from inhibition by 2-antiplasmin (Longstaff and Gaffney
1991; Lahteenmaki et al. 2001; Rijken and Lijnen 2009). 2-macroglobulin is a
proteinase inhibitor with broad specificity, and is more abundant of the two plasmin
inhibitors. Plasmin inhibition by 2-macroglobulin generally takes place when the
limited supply of 2-antiplasmin in plasma is significantly decreased (Saksela 1985).
Plasminogen activators are primarily regulated by plasminogen activator inhibitors
(PAIs). Whilst uPA is susceptible to inhibition by both PAIs, tPA is more readily
inhibited by PAI-1. PAI-1 is secreted by multiple cell types, including endothelial
cells, and is implicated in cell migration, tumour development and cardiovascular
diseases (Rijken and Lijnen 2009; Peetermans et al. 2015). Comparatively, PAI-2 is
located in monocytes/macrophages and endothelial cells, and although several
functions have been ascribed to PAI-2 including a cytoprotective role (Lee et al.
2015), its exact physiological role remains an enigma (Lee et al. 2011). Other
alternative inhibitors of uPA and tPA are protease nexin and PAI-3, which have been
found in tissue and urine, respectively (Potempa et al. 1994; Rijken 1995). Protease
nexin is a broad spectrum inhibitor, with antagonistic effects against plasmin,
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thrombin and uPA, whereas PAI-3 inhibits uPA and tPA, but at a slower rate than
PAI-1 and PAI-2 (Saksela and Rifkin 1988; Rijken 1995). Of the four plasminogen
activator inhibitors, PAI-1 accounts for approximately 60% of inhibition of
plasminogen activators (Correia and Haynes 2006).
1.5.4

Physiology of the plasminogen activation system

The plasminogen activation system primarily acts to generate localised cellular
proteolytic plasmin activity that is implicated in a vast number of biological roles; its
classical role being fibrinolysis. Fibrin is considered the major target substrate for
plasmin-mediated degradation, such that binding of plasminogen and tPA to fibrin,
or plasminogen to the ECM, dramatically enhances plasminogen activation (Ranby
1982; Knudsen et al. 1986; Lijnen and Collen 1995). The ability of plasmin to digest
fibrin therefore controls the extent of coagulation and is of central importance for
solubilisation of blood clots. It is also involved in the breakdown of ECM
components including laminin, fibronectin, vitronectin and heparin sulphate
proteoglycans, as well as activating matrix metalloproteases. Indirect plasmin
activation of procollagenases causes degradation of collagen that is otherwise not
susceptible to plasmin-mediated cleavage (Murphy et al. 1992). Plasmin-mediated
activation of the aforementioned ECM substrates is critical for many processes
including tissue remodeling events and inflammatory cell migration (Vassalli et al.
1992; Plow et al. 1995; Del Rosso et al. 2008). Additionally, the overexpression of
plasminogen activators has been linked to tumor cell invasion, and in particular, the
upregulation of uPA is a hallmark feature of cancer cells (Ulisse et al. 2009;
Mekkawy et al. 2014). The function of the plasminogen activation system, in

Page | 30

Chapter 1 Review of the Literature

particular the broad proteolytic capacity of plasmin, highlights its potential to be
exploited by pathogenic bacteria during invasive bacterial infections.
1.6

Interaction of GAS with the human plasminogen activation system

The ability to recruit and exploit host plasminogen is common amongst many
virulent bacterial pathogens (Sanderson-Smith et al. 2012). GAS express an array of
proteins that interact with and activate human plasminogen. Plasminogen acquisition
and activation at the bacterial cell surface enables GAS to breach tissue and host
barriers to promote systemic bacterial infection (Walker et al. 2005). Streptococcal
proteins that are involved in the interaction between GAS and plasminogen include
(1) secretion of the plasminogen activator, streptokinase; (2) direct binding with
surface proteins via specialised plasminogen receptors (plasminogen-binding GAS
M proteins, PAM; PAM-related protein, Prp), or the moonlighting enzymes of the
glycolytic pathway (GAPDH, SEN); or (3) indirectly by sequential binding of
fibrinogen and plasminogen via expression of fibrinogen-binding proteins (Figure
1.8) (Sanderson-Smith et al. 2012; De Oliveira et al. 2015).
1.6.1

Streptokinase

Streptokinase is a potent activator of plasminogen and is secreted by Group C and G
streptococci, and all GAS isolates (Boyle and Lottenberg 1997). Streptokinase is
encoded by the ska gene, and is a single-chain 414 amino acid, three domain, nonglycosylated protein (Wang et al. 1998). Streptokinase is a major virulence factor of
GAS, displays a high level of species specificity, showing little or no interaction
with plasminogen from other species including murine plasminogen (Sun et al.
2004). Two main sequence clusters of ska have been phylogenetically established;
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cluster types 1 and 2, with cluster 2 further subdivided into cluster 2a and 2b
(McArthur et al. 2008). These clusters display important functional differences;
cluster 2, but not cluster 1, requires fibrinogen to activate plasminogen (Figure 1.8)
(McArthur et al. 2008). Streptokinase activates plasminogen non-proteolytically,
inducing a conformational change in plasmin(ogen) via formation of a 1:1
stoichiometric complex (Reddy and Markus 1972). The streptokinase-plasmin(ogen)
complex has the ability to hydrolytically activate other free plasminogen molecules
to plasmin, or plasminogen already bound to the bacterial surface, resulting in
localised cell surface plasmin that circumvents regulation by host plasmin inhibitors
(Lottenberg et al. 1992; Parry et al. 2000).
1.6.2

GAS plasmin(ogen) receptors

1.6.2.1 Specialised cell surface plasminogen receptors
Approximately 15% of all GAS isolates express specialised plasminogen-binding M
proteins (PAM, Prp). PAM was initially isolated from the M53 GAS serotype, and is
strongly associated with isolates causing impetigo (Berge and Sjobring 1993;
Svensson et al. 1999). The plasminogen-binding region of PAM is located in the Nterminal A1 and A2 hypervariable region containing tandem repeats. In contrast to
other plasminogen-binding motifs, the high affinity and specificity of PAM with
plasminogen is dependent on positively charged arginine and histidine residues, but
not lysine, found within the two internal repeat domains (Wistedt et al. 1995;
Sanderson-Smith et al. 2006). A unique characteristic of plasminogen-binding M
proteins is the ability to directly capture plasminogen to the bacterial cell surface,
which is readily accessible to activation by host activators uPA and tPA, or
streptokinase (Figure 1.8) (Berge and Sjobring 1993). Furthermore, the resulting
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surface bound plasmin is protected from inactivation by circulating host plasmin
inhibitors (Wistedt et al. 1995). Prp is another high affinity plasminogen binding M
protein isolated from a severe GAS infection (McKay et al. 2004; Sanderson-Smith
et al. 2008). Plasminogen acquisition by PAM/Prp has been associated with the
propensity to cause invasive diseases (McKay et al. 2004; Sanderson-Smith et al.
2007). The susceptibility of human plasminogen transgenic mice was significantly
abolished following infection with a PAM-negative GAS strain compared to
littermate controls (Sun et al. 2004). Similarly, abrogation of plasminogen binding
and plasminogen acquisition by Prp significantly reduced the capacity of GAS to
cause a lethal infection in a humanised plasminogen mouse model of infection
(Sanderson-Smith et al. 2008). The ability of plasminogen-binding proteins to
readily capture plasminogen to the bacterial cell surface therefore significantly
enhances GAS host invasion.
1.6.2.2 Glycolytic moonlighting proteins as plasminogen receptors
Glycolytic pathway enzymes GAPDH and SEN are multifunctional, anchorless
proteins secreted by GAS and other bacterial species with plasminogen-binding
capabilities (Pancholi and Fischetti 1998; Knaust et al. 2007; Matta et al. 2010).
GAPDH, also referred to as streptococcal surface dehydrogenase or plasmin
receptor, was the first identified streptococcal receptor for plasmin (Winram and
Lottenberg 1996). It contains a carboxy-terminal lysine residue that is responsible for
the high binding affinity of GAPDH for plasmin, and to a lesser extent, plasminogen
(Winram and Lottenberg 1998). Site-directed mutagenesis of this region obliterated
plasmin binding activity by the protein, but did not affect the capacity of GAS to
bind plasminogen, strongly suggesting a significant role of other unidentified
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plasmin receptors of GAS (Winram and Lottenberg 1998). The high affinity of SEN
for plasminogen was originally thought to be mediated by lysine residues (Lys434 and
Lys435) located at the C-terminus (Pancholi and Fischetti 1998). However, a later
study examining the octameric structure of SEN revealed a second plasminogenbinding motif involving internal lysine residues (Lys252 and Lys255) (Cork et al.
2009). Abrogation of either binding sites eliminates plasminogen binding (Cork et
al. 2009), which strongly suggests the critical and concerted role that both motifs
play in plasminogen acquisition by SEN. The exact role of both enzymes in GAS
virulence and the mechanism by which these proteins are exported to the cell surface
are hitherto unknown (Jin et al. 2005). Despite this, these enzymes have been
discovered on other microbial surfaces (Bergmann et al. 2004; Jin et al. 2005). Due
to their house keeping functions, deletion of these enzymes has proven difficult. It
has been suggested however, that in GAS strains binding human plasminogen in a
non-M protein dependent manner, GAPDH and SEN may play an important role in
plasmin(ogen) recruitment to the cell surface (Sun et al. 2004; Cole et al. 2006).
1.6.3

GAS fibrinogen binding proteins

Human fibrinogen is a 340 kDa plasma glycoprotein synthesised in the liver and
plays an essential role in blood coagulation. Thrombin cleaves fibrinogen in the last
step of the coagulation cascade to form insoluble fibrin polymers (Blomback et al.
1978). For some GAS isolates, cell surface plasmin acquisition is dependent on
fibrinogen binding as a pre-requisite (Wang et al. 1995a). Streptococcal fibrinogen
binding proteins are exposed on the bacterial cell surface, and include M and Mrelated proteins, PrtF1 and PrtF2 variants, and the lipoprotein Spy_0591 (SandersonSmith et al. 2012; Sanderson-Smith et al. 2014). These proteins provide an anchor
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for the pre-assembled streptokinase-plasminogen complex that is mediated by lysinebinding sites. This resulting trimolecular complex composed of streptokinaseplasminogen-fibrinogen, possesses plasmin-like activity which can activate
additional fluid-phase plasminogen molecules, and lyse fibrin clots in the presence of
circulating host plasmin inhibitors (Figure 1.8) (Takada and Takada 1989; Wang et
al. 1995a; Wang et al. 1995b; Christner et al. 1997; D'Costa and Boyle 1998).

A

B

C

Trimolecular
complex

Fibrinogen
receptor

PAM/
Prp

GAS cell surface

Plasminogen

M1

GAS cell surface

Plasminogen
receptor

GAS cell surface

Streptokinase Fibrinogen Plasmin activity uPA/tPA/SK

Figure 1.8 Potential mechanisms of cell surface plasmin acquisition by GAS. Specialised
plasminogen binding M proteins (PAM, Prp) can (A) capture plasminogen directly to the cell surface,
which can then be activated by host (uPA/tPA) or bacterial (streptokinase, SK) plasminogen
activators; or a pre-formed trimolecular complex consisting of type 2b streptokinase, plasminogen and
fibrinogen. (B) Fibrinogen receptors, such as the M1 protein, require the pre-assembled trimolecular
complex composed of type 2a streptokinase, plasminogen and fibrinogen to facilitate cell surface
plasmin acquisition. (C) Type 1 streptokinase will combine with plasminogen to exhibit a complex
with plasmin activity, which can then bind to plasminogen receptors, or combine with fibrinogen to
interact with fibrinogen receptors. Adapted from McArthur et al. (2008).
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This indirect method of plasminogen acquisition is important for GAS strains that do
not possess high affinity plasminogen-binding receptors, and has been more
frequently associated with invasive than non-invasive GAS infections (McKay et al.
2004; Walker et al. 2014).
1.7

Plasminogen and invasive GAS disease

The broad substrate repertoire of plasmin and the high abundance of plasminogen
circulating in plasma renders the human plasminogen activation system an attractive
and vulnerable target for exploitation by pathogenic bacteria. Host plasminogen is
exploited by a number of bacterial species including, Borrlelia burgdorferi, Yersinia
pestis, and S. aureus (Kuusela et al. 1990; Sodeinde et al. 1992; Coleman et al.
1995; Sanderson-Smith et al. 2012). The role of the plasminogen activation system
and its involvement in bacterial virulence has largely focused on the ability of GAS
to degrade and facilitate the breakdown of ECM components, and fibrin clots via the
activation of plasminogen and accumulation of plasmin (Figure 1.9). The fibrin
network is essential in host defence against bacteria, and many pathogens including
GAS, have evolved to escape from fibrin encapsulation, aiding in bacterial
dissemination into sterile tissue sites (Lahteenmaki et al. 2005).
The critical role of plasminogen binding by GAS, and the potential to cause highly
invasive infection has been supported by several epidemiological studies and
utilisation of animal models (Sun et al. 2004; Sanderson-Smith et al. 2012). For a
subset of GAS isolates, the ability to accumulate cell surface plasmin is a prerequisite for systemic bacterial spread. The M1T1 GAS clone has been paralleled
with the outbreak of invasive GAS disease in recent decades, and is also the most
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frequently isolated serotype in invasive streptococcal infections globally (Aziz and
Kotb 2008). The ability of GAS to sequester and activate cell-bound plasminogen
was essential for invasive disease initiation of M1T1 GAS (Cole et al. 2006). In
contrast, GAS skin infections that are endemic in the Northern Territory’s Aboriginal
populations result from multiple M serotypes that are uncommon in the Western
world (Hassell et al. 2004). These non-M1T1 GAS serotypes have also shown
dependence on cell-bound plasmin activity for establishing bacterial virulence
(Sanderson-Smith et al. 2008; Tsatsaronis et al. 2015).
The importance of the interaction between human plasminogen and streptokinase
was first highlighted by Khil et al. (2003). In this study, subcutaneous co-infection
of plasminogen and GAS significantly decreased mice survival (Khil et al. 2003).
The development of a humanised plasminogen transgenic mouse model by Sun et al.
(2004) thereafter significantly enhanced the understanding of GAS-host interactions.
In this model, mice expressed approximately 17% of the human plasminogen of that
observed in normal human plasma (Sun et al. 2004). Infection of transgenic
humanised mice with ska-expressing GAS strain resulted in 75% mice mortality, in
distinct contrast to 27% mice mortality when infected with an isogenic ska-deleted
derivative (Sun et al. 2004). This model emphasised the importance of the species
specificity of streptokinase for human plasminogen, with little or no reactivity with
plasminogen derived from other species including mouse. Using this same murine
infection model, inoculation with a PAM-positive GAS strain resulted in increased
mice mortality compared to infection with PAM-negative GAS (Sun et al. 2004).
Similarly, abrogation of plasminogen binding by Prp resulted in a reduced capacity
of the highly invasive GAS strain NS88.2 to accumulate plasmin at the bacterial cell
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surface, and was subsequently avirulent in a mouse model of infection (SandersonSmith et al. 2008). Similar results were found in a mouse skin infection model that
showed the ability of GAS to initiate invasive disease was strongly correlated with
the presence of surface-associated plasmin activity (Li et al. 1999). The virulence of
M1T1 GAS was also found to be dependent on the presence of human plasminogen
in the mouse model (Cole et al. 2006).

Invading GAS

Site of infection

Epithelial cells
SK
Plg

Tissue destruction,
vascular leakage, fibrin
clot degradation

Dermis

GAS plasmin acquisition
Fibrin clot
Endothelial cells
GAS dissemination
Blood vessel
Red blood cells

Figure 1.9 Current proposed model of streptokinase-generated plasmin facilitating GAS host
invasion. The highly virulent GAS-secreted streptokinase facilitates bacterial invasion via hijacking
the host plasminogen (Plg) activation system. Streptokinase (SK) activates plasminogen attached to
the GAS cell surface, resulting in bacterium-bound plasmin that is protected from plasmin inhibitors.
Alternatively, streptokinase can complex with plasminogen that activates other free plasminogen
molecules to plasmin. After passing through the host cellular layer, plasmin at the GAS cell surface
facilitates local fibrin degradation to spread systemically. Adapted from Sun et al. (2006).

Page | 38

Chapter 1 Review of the Literature

Clearly, the ability of GAS to recruit plasminogen and accumulate plasmin at the
bacterial cell surface is important for the progression of GAS disease, and provides
another mechanism to exploit host fibrinolysis for bacterial invasion (Figure 1.9).
Other studies support a protective role for plasminogen in host immune evasion, and
colonization during streptococcal infection. Such studies describe a role for
plasminogen bound at the GAS surface to evade macrophage killing, and facilitate
adherence to laryngeal epithelial cells (Pancholi et al. 2003; Siemens et al. 2011).
1.8

Role of plasmin(ogen) in host defence

The plasminogen activation system and the innate immune system share a series of
serine activators that interact during the inflammatory response (Amara et al. 2008).
The exact molecular mechanisms involved in this interplay still remains elusive.
Plasmin has multiple substrates in the host, and thus affects a wide spectrum of
biological activities. It can readily degrade components of the ECM and activate
matrix metalloproteases, and more recent studies have established a role for plasmin
in complement activation, the bradykinin system and migration of leukocytes to
wound sites during infection (Bugge et al. 1996a; Del Rosso et al. 2008; Peetermans
et al. 2015). Plasmin(ogen) has a high affinity for endothelial cells and platelets, and
can induce neutrophil aggregation and adherence to the endothelium (Hajjar et al.
1986; Miles et al. 1986; Ryan et al. 1992). In vivo studies have highlighted the
importance of plasmin(ogen) in immune cell recruitment during inflammation. In
these studies, mice deficient in plasminogen are more resistant to inflammatory
stimuli, have diminished macrophage infiltration across the ECM, and have defective
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wound healing and tissue repair mechanisms (Schuster et al. 2007; Gong et al.
2008). This supports findings from earlier studies in an acute peritoneal murine
inflammation model, where recruitment of lymphocytes and monocytes was
markedly blunt in plasminogen-deficient mice compared to wild-types (Ploplis et al.
1998; Busuttil et al. 2004). Clearly, these studies established that plasmin(ogen)
strongly influences immune cell recruitment during an inflammatory response.
Fibrin is one of the most physiologically important targets of plasmin in vivo (Bugge
et al. 1996b). The presence of fibrin is an absolute critical host defence mechanism
for the containment of invading bacteria and promoting inflammation (Sun et al.
2004; Sun et al. 2009). Fibrin(ogen) can directly interact with integrins on a number
of innate immune cells including monocytes, macrophages, neutrophils and dendritic
cells, and also plays a significant role in their recruitment and activation (Delvaeye
and Conway 2009). Fibrinogen depleted mice display a dampened inflammatory
response when infected with plague agent Yersinia pestis, and reduced thrombin
generation has been linked with increased mice susceptibility to GAS infection
(Degen et al. 2007; Sun et al. 2009). Furthermore, cleavage of fibrinogen leads to
degradation products that can affect blood vessel permeability, promote adhesion,
and accumulation of immune cells (Leavell et al. 1996; Flick et al. 2004). Thus,
plasmin-mediated escape from fibrin clots can result in an overwhelming immune
response and can be detrimental for the host. More recently, studies have focused on
the interaction between plasmin and host proteins. In vitro studies have demonstrated
that plasmin is capable of degrading essential components of the complement
system, as well as immunoglobulins, resulting in the release of chemotactic
fragments (Lachmann et al. 1982; Schaiff and Eisenberg 1997). A recent study found
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that plasmin and coagulation factors Xa, XIa can cleave complement factors C5 and
C3 to generate the potent chemoattractants C5a and C3a (Amara et al. 2010).
Similarly, Barthel et al. (2012a) recently showed that plasminogen binds to
complement factors C3, C3b and C5, and when activated by uPA, plasmin cleaves
these proteins into inactivate fragments and inhibits complement activation in rabbit
and sheep erythrocytes. Thus, the inhibitory effects of plasmin on complement
activation further provides an explanation for the acquisition of plasmin(ogen) by
microorganisms to evade recognition by the host innate immune response.
1.9

Plasmin-mediated evasion of complement

The multifaceted nature of the complement cascade is difficult to overcome by
pathogenic bacteria. C3b is a key component of the complement system, and serves
to opsonise and prime bacteria for eradication by phagocytes via the recognition of
receptors on phagocytic cells (Lambris et al. 2008). In this way, C3b plays a critical
role in the initial stages of host immunity. Several pathogens have developed the
ability to manipulate the host plasminogen activation system to evade the
bactericidal activity of C3b. Plasmin has been shown to degrade important
complement factors (Seya and Nagasawa 1985; Ramu et al. 2007). More
importantly, recent studies have revealed a role for bacterial activation of
plasminogen and plasmin acquisition in complement evasion. PgtE-mediated
plasminogen activation at the surface of Salmonella enterica, a common food-borne
pathogen, leads to the degradation of C3b, as well as complement factors C4b and
C5 (Ramu et al. 2007). Whilst plasmin at the surface of S. aureus can cleave C3b,
and plasmin formed by the conversion of plasminogen by staphylokinase
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(plasminogen activator of S. aureus), leads to decreased opsonisation and enhanced
bacterial survival from neutrophil killing (Rooijakkers et al. 2005). More recently, a
novel plasminogen binding protein of Streptococcus pneumoniae (PepO) was
identified, which upon subsequent plasminogen binding and activation by uPA, led
to plasmin-mediated degradation of C3b (Agarwal et al. 2013). A large number of
other human pathogens share similar strategies of plasmin-mediated immune evasion
including Bacillus anthracis (Chung et al. 2011), Borrelia burgdorferi (Grosskinsky
et al. 2009), Pseudomonas aeruginosa (Kunert et al. 2007), Salmonella typhimurium
(Ramu et al. 2007) and Haemophilus influenzae (Barthel et al. 2012b; Koenigs et al.
2013). Furthermore, plasmin-bound to spores of Borrelia burgdorferi cleave C3b
molecules in rabbit bronchoalveolar fluid which led to a decrease in complementmediated macrophage phagocytosis (Grosskinsky et al. 2009). Over 50 years ago,
the addition of streptokinase to human serum was shown to digest complement
proteins C1, C2, C3 and C4, and inhibit complement activation (Pillemer et al.
1953). Potentially, there is a role for bacterial-associated plasmin in the evasion of
host complement attack. Whilst this has been demonstrated for some common
human pathogens, the contribution of plasminogen and plasmin acquisition in
complement evasion by GAS however, has received little attention. This thesis will
in part, explore whether similar complement evasion strategies are employed by
GAS.
1.10

Host activators in bacterial disease

The phenomenon of subverting host plasminogen has been well-described for several
invasive bacteria (Li et al. 1999; Magalhaes et al. 2007; Guo et al. 2008), viruses
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(Goto and Kawaoka 1998) and parasites (Rojas et al. 2008) via expression of surface
plasminogen receptors or acquisition of host activators. However, few bacterial
species produce their own activators, of which streptokinase of GAS and
staphylokinase of S. aureus are the most well-characterised. Human activators uPA
and tPA are therefore necessary to promote plasmin-mediated host invasion for
many other major pathogens that interact with the plasminogen activation system.
Enhanced tPA-mediated plasminogen activation occurs at the surface of E. coli,
Helicobactor pylori and Neisseria meningitides, while plasminogen at the surface of
Salmonella

typhyrium,

Salmonella

enteritidis,

Borrelia

burgdorferi

and

Streptococcus pneumoniae can be converted to plasmin by either uPA or tPA
(Sjobring et al. 1994; Klempner et al. 1995; Yavlovich et al. 2004; Lähteenmäki et
al. 2005; Magalhaes et al. 2007). The GAS M protein also binds plasminogen that
can be activated by host activators in vitro (Berge and Sjobring 1993). Even without
activation, recruitment of plasminogen to the bacterial cell surface has been linked to
pathogenicity (Lottenberg et al. 1994). These findings strongly suggest that host
activators are important in plasminogen activation and plasmin acquisition at the
bacterial surface, and therefore, play a significant role in bacterial pathogenesis. How
uPA and tPA are involved in GAS virulence in vivo remains to be determined. The
role of streptokinase has been well-studied however, whilst streptokinase is secreted
by all GAS isolates, this potent plasminogen activator is not present throughout the
entire course of streptococcal infection. Streptokinase was found absent from
supernatants harvested during the early phase of the GAS growth cycle (McArthur et
al. 2008). Additionally, the cysteine protease SpeB that is secreted during the later
stages of growth by GAS, has the ability to degrade streptokinase (Rezcallah et al.
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2004; McArthur et al. 2008). These observations further underscore the importance
that host activators may play in GAS virulence, and forms a major focus of this
thesis.
1.11

Conclusions

GAS is a versatile human-specific pathogen that has evolved numerous strategies to
infect the host, overcoming tissue and immune barriers to infection. Multiple
virulence factors expressed by GAS enable the organism to hijack the plasminogen
activation system by sequestering host plasminogen and acquiring localised
proteolytic plasmin activity. The presence of plasmin at the bacterial cell surface
leads to the degradation of fibrin clots and tissue barriers, and facilitates GAS
migration from primary sites of infection into more distant and sterile host tissue.
The ability to sequester cell surface plasmin is a pre-requisite for systemic invasive
disease for a subset of GAS isolates. Recently, cell surface plasmin acquisition by
other important human pathogens has been implicated in the degradation of major
opsonins, including immunoglobulins and complement. This supports the idea that
subversion of the plasminogen activation system by bacteria may not only facilitate
their ability to breakdown natural defence barriers, but also to avoid elimination by
innate immune phagocytic cells. GAS possesses many virulence factors that inhibit
multiple levels of complement activation, suggesting that avoidance of innate
immune surveillance is critical for GAS pathogenesis. Furthermore, the ability of
endogenous uPA or tPA to mediate bacterial cell surface plasmin acquisition impacts
on host survival for a number of pathogenic bacteria. There is little known about the
roles of these activators in the progression of GAS disease. Thus, investigating the
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interaction between GAS, the host fibrinolytic system and its impact on innate
immune effectors, is essential for the enhanced understanding of the pathogenesis of
GAS during the early stages of infection, and will be the foundation of this thesis.
1.12

Project aims

The present study aimed to explore the impact of plasmin acquisition by GAS on
evasion of host innate immunity, and the contribution of host plasminogen activators
in GAS virulence in vivo. Two clinically relevant GAS isolates were selected for
study; the highly invasive, globally disseminated M1T1 GAS isolate 5448 which has
been associated with the increased frequency of severe cases of invasive GAS
disease (Aziz and Kotb 2008), and NS88.2 which was isolated from an invasive
infection in the Northern Territory of Australia (McKay et al. 2004).
The specific objectives of this study were five-fold:
i.

Assess the impact of plasmin at the GAS cell surface on C3b
deposition in vitro and in vivo.

ii.

Establish a mouse model to examine how plasminogen acquisition
and activation at the GAS cell surface impacts on complementmediated neutrophil phagocytosis.

iii.

Elucidate the role of host activator uPA in a mouse model of invasive
GAS infection.

iv.

Assess the potential of commercial and novel drug inhibitors that
target uPA-mediated plasminogen activation as therapeutics against
GAS infection in a humanised plasminogen mouse infection model.
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v.

Elucidate the role of host activator tPA in a mouse model of invasive
GAS infection.

This thesis extends our understanding of the role of the human fibrinolytic system in
invasive GAS disease.
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This chapter contains general methods and resources that were used throughout this
study and is referenced accordingly. Methods that were used in specific studies are
described in the corresponding chapters. The components for all solutions and
buffers are listed in detail in Appendix A.
2.1

Bacterial strains and culture conditions

2.1.1

GAS

Unless otherwise noted, GAS strains used in this study were supplied by Dr. Martina
Sanderson-Smith (University of Wollongong, Australia), or constructed as discussed
in section 2.2. This study employed two clinically important sets of GAS strains
including NS88.2, derived from the Northern Territory of Australia, and the globally
disseminated M1T1 GAS clone, 5448. GAS strain NS88.2 was isolated from a case
of invasive blood infection and has been described previously (McKay et al. 2004).
The isogenic derivative NS88.2prp consists of mutated residues within the
plasminogen binding region of Prp, and is attenuated for plasminogen binding and
virulence in a mouse model of invasive infection (Sanderson-Smith et al. 2008).
Isogenic GAS mutant NS88.2∆ska was provided by Dr. Jason McArthur (University
of Wollongong, Australia). A precise, in-frame allelic replacement of the gene
encoding streptokinase (ska) with cat encoding chloramphenicol transferase was
created in wild-type GAS strain NS88.2 using established methods (Cook et al.
2012). Phenotypic characterisation of this isogenic mutant strain was performed
including analysis of growth rate, capsule production and streptokinase secretion as
described by Cook et al. (2012) (data not shown). GAS strain 5448 expresses the M1
protein, and is representative of the globally disseminated M1T1 clone that is
responsible for high rates of invasive disease (Aziz and Kotb 2008). The
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streptokinase-deficient GAS strain 5448Δska was created as detailed above by Dr.
Martina Sanderson-Smith, and has been previously described (Hollands et al. 2012).
The mutation was reversed by replacement of the cat gene with the wild-type ska
gene to create the reverse-complemented GAS strain 5448ΔskaRC, which displays
phenotypic characteristics akin to the parent strain 5448.
Streptococci were routinely cultured at 37 °C in static liquid cultures of Todd Hewitt
Broth (Difco, Liverpool, Australia) supplemented with 1% yeast extract (THBY) and
inoculated with single, hemolytic GAS colonies grown on horse blood agar (HBA),
(Oxoid, Hampshire, UK) or on Todd Hewitt agar (THA). In all experiments,
overnight starter cultures were used to inoculate pre-warmed THBY at a ratio of
1:10. Prior to the addition of GAS to various assays described in this project,
bacterial cultures were grown at 37 °C until an optical density of 600 nm at 0.5
(OD600 0.5) was reached.
2.1.2

E. coli

E. coli was propagated in Lysogeny broth (LB), or on LB agar at 37 C overnight.
For antibiotic selection, erythromycin was supplemented at 2 µg/mL for GAS and
500 µg/mL for E. coli.
2.2

Growth curves

GAS strains were initially characterised by measuring rates of bacterial growth in
THBY. GAS starter cultures were inoculated 1 mL into 40 mL of pre-warmed
THBY and grown at 37 ºC as described in section 2.1.1. Over an 8 h growth period,
the OD600nm of 1 mL samples of growth culture were recorded every 30 min. To
ensure that GAS numbers were uniform in all experiments, colony forming units per
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mL (CFU/mL) were calculated by harvesting exponential cultures of streptococci at
OD600 0.5. To a 96-well microtiter plate (Grenier Bio-one, Frickenhausen, Germany)
containing 180 µL of 0.75% (w/v) sterile saline, 20 µL of each bacterial suspension
was added and diluted in a 10-fold titration down the plate in triplicate. Ten
microliter volumes of each dilution (at 10-4, 10-5 and 10-6) were plated onto THA
with subsequent overnight incubation at 37 ºC. Colonies were enumerated and CFU
calculated as an average of triplicates.
2.3

DNA manipulation

2.3.1

Plasmid extraction

To facilitate flow cytometry studies, GAS strains NS88.2, NS88.2prp and
NS88.2∆ska expressing the Green Fluorescent Protein (GFP) were constructed using
the expression vector pDCermGFP, kindly provided by Professor Victor Nizet
(University of California, San Diego). This vector contains a gfp gene placed behind
the constitutive tet, cat and erm promoters (Jeng et al. 2003). pDCermGFP was
initially extracted from E. coli cells in a liquid culture using the Wizard® Plus SV
Minipreps DNA Purification System (Promega, Madison, WI). A volume of 20 mL
of LB supplemented with 500 ug/mL of erythromycin was inoculated with a single
bacterial colony and left growing at 37 ºC overnight at 190 rpm on an orbital shaker
(Bioline, Alexandria, Australia). Cells were harvested by centrifugation at 5,000 xg
for 10 min using a Heraeus Biofuge Primo centrifuge (Thermo Scientific, Waltham,
MA), prior to performing a plasmid extraction according to the manufacturers’
specifications. The extracted plasmid concentration was determined using agarose
gel electrophoresis as described in section 2.3.2.
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2.3.2

Agarose gel electrophoresis

Agarose gel electrophoresis was routinely used to visualise and confirm the
extraction of pDCermGFP. Samples were prepared by mixing 5 µL of DNA with 1
µL of loading dye prior to loading onto a 1% agarose egel. Electrophoresis was
performed at 100 V for 1 h in 1xTAE buffer using a MiniSub™ Cell GT
electrophoresis tank (Bio-Rad, Hercules, CA). Once electrophoresed, agarose gels
were stained in ethidium bromide solution (1 µg/mL) for 20 min with gentle
agitation followed by destaining in dH2O for 10 min. To visualise DNA bands, the
gel was placed under ultraviolet light in a Novaline Gel Documentation System
(Novex, Paddington, Australia). HyperLadder-1 DNA molecular weight marker
(Bioline) was used as a comparison to determine the approximate size, and
concentration of DNA samples via extrapolation from a standard curve.
2.4

Bacterial transformation

2.4.1

Preparation of electrocompetent GAS

Electrocompetent cells of GAS strains NS88.2 and NS88.2prp were prepared for
transformation by inoculating 120 mL of pre-warmed THBY with 4 mL of overnight
starter cultures of either GAS strain. Cultures were shaken at 190 rpm and grown
until an OD600nm 0.5 was reached. Cells were then harvested by centrifugation at
7,000 xg for 10 min and washed twice by subsequent resuspension in 5 mL and 2mL
of chilled 0.625 M sterile filtered sucrose. Following the final wash, cells were
resuspended in a volume of 500 µL of sucrose and were then used immediately or
stored in 50 µL aliquots at -80 ºC.
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2.4.2

Transformation of electrocompetent GAS

Transformation of GAS strains with pDCermGFP was initiated by adding
approximately 180 ng of plasmid DNA to 50 µL of fresh or thawed electrocompetent
NS88.2 or NS88.2prp GAS cells in a microfuge tube. The transformation mixture
was transferred to a pre-chilled electroporation cuvette. Immediately thereafter,
electroporation was conducted using the Gene Pulser™ electroporation apparatus
(Bio-Rad) with the following settings: 1.25 kV, 600 Ω and 25 µFD. Following
electroporation, the transformation mixture was diluted in 500 µL of 0.25 M sucrose/
THBY and grown for 1 h at 37 ºC. For each transformation culture, aliquots of 100
µL and 400 µL were plated onto THA plates containing 2 µg/mL of erythromycin
and grown overnight at 37 ºC. Positive transformants were screened by plating onto
HBA plates and incubating overnight at 37 ºC, and the presence of streptococci was
confirmed by haemolysis on HBA plates, while the insertion of pDCermGFP was
evaluated using flow cytometry.
2.5

Flow cytometry

Flow cytometry analysis was employed to confirm the insertion of pDCermGFP into
streptococci. A 1 mL aliquot of bacterial culture was harvested and pelleted at midlogarithmic phase (OD600 0.5) for 10 min at 5,000 xg. Following two wash steps in
PBS, cells were resuspended in 500 µL of PBS and fixed with an equal volume of
4% paraformaldehyde (PFA). To this mixture, a further 500 µL of PBS was added
and samples were analysed using a BD LSRII flow cytometer (Franklin Lakes, NJ).
A total of 10,000 cells were collected and gated for fluorescent streptococci at
excitation and emission wavelengths of 488 nm and 515/20 nm respectively. Gating
parameters used to detect fluorescent GAS remained consistent throughout this
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study. Data were collected using a BD FACSDiva Software version 6.1.3 and
analysed with FlowJo7 8.4.6 (TreeStar Inc., Ashland, OR).
2.6

Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-

PAGE)
Throughout this project, proteins were routinely separated using SDS-PAGE
performed in a PROTEAN™ Cell System (Bio-Rad). In order to denature proteins
and reduce disulphide linkages, protein samples, unless otherwise stated, were boiled
for 10 min in 1X reducing sample buffer and loaded onto 10% (w/v) acrylamide
resolving gels [with a 4% (w/v) stacking gel] in aliquots of 10 µL. Electrophoresis
was conducted at 200 V for 50 min in 1X SDS-PAGE running buffer using a
PowerPac300 supply unit (Bio-Rad). Protein bands were visualised via staining the
gel in excess amounts of Coomassie Brilliant Blue Rapid Stain overnight with
constant agitation on an orbital shaker (Edwards Instrument Co., Narellan,
Australia). Removal of excess dye from the background gel matrix was achieved by
destaining the gel with a methanol and glacial acetic acid solution with gentle
agitation. Frequent replacement of this solution was performed as required.
Molecular weights of proteins were estimated using a standard curve generated via
the Unstained PageRuler Protein Ladder (Fermentas, Lithuania), loaded into wells in
5 µL aliquots. Gels were scanned using a GS-800 calibrated densitometer (Bio-Rad).
2.7

Western blot analysis

Following SDS-PAGE sample separation, specific detection of C3b, plasminogen,
and

streptokinase

was

performed

via

Western

blotting.

Proteins

were

electrophoretically transferred onto Nitrocellulose BioTrace ™ membrane (Pall
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Corporation, Port Washington, NY) at 100 V for 1 h at 4 ºC in western transfer
buffer with constant stirring using a Mini Trans-Blot® apparatus (Bio-Rad). Posttransfer, blots were blocked overnight with 10% skim milk (Difco, Liverpool,
Australia) in PBS at 4 ºC to prevent nonspecific protein detection by primary and
secondary antibodies. To detect the presence of complement, plasminogen, or GASsecreted streptokinase, membranes were incubated with constant agitation for 1 h at
room temperature in a heat-sealed plastic lock bag containing polyclonal goat
antisera raised against human C3 (Calbiochem, San Diego, CA) diluted 1:6000,
rabbit anti-human plasminogen (Calbiochem) diluted 1:5000, or rabbit polyclonal
anti-streptokinase serum diluted 1:3000 in 1% (w/v) skim milk. Bound primary
antibodies were probed using horseradish peroxidase (HRP)-conjugated rabbit antigoat IgG (Invitrogen, Carlsbad, CA) diluted 1:6000 (for complement detection), goat
anti-rabbit IgG (Invitrogen) diluted in either 1:8000 (for plasminogen detection), or
1:4000 (for streptokinase detection) in 1% skim milk. Membranes were incubated for
1.5 h under the same conditions as above. Between all incubations, excess antibody
was removed by rinsing the membrane three times with PBS for 5 min with mild
agitation. After the final wash, the membrane was equilibrated with 100 mM Tris
(pH 7.6) for 2 min. Protein bands were visualised via the chromogenic, or enhanced
chemiluminescence detection methods. Visualisation was achieved using 3,3’diaminobenzadine tetrahydrochloride hydrate solution, and the reaction ceased by
several rinses with dH2O, the membrane light-protected and air-dried overnight. For
the enhanced chemiluminescence method, a Pierce Biotechnology kit (Rockford, Ill.,
USA) was used to visualise bands on Amersham Hyperfilm (GE Healthcare,
Sweden) following the manufacturers’ instructions. Membranes and exposed X-ray
films were analysed and scanned using the densitometer as per section 2.6.
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2.8

GAS cell surface plasmin acquisition

2.8.1

Streptokinase-mediated cell surface plasmin acquisition

Relative levels of plasmin accumulated at the cell surface of GAS were measured as
described (Cole et al. 2006). To facilitate cell surface plasmin acquisition, GAS were
harvested at mid-log phase (approximately 1 x 108 CFU/mL) and cultured in the
presence of 100 nM Glu-plasminogen (Haemotologic Technologies Inc., Essex
Junction, VT) for 2 h at 37 °C. Under these conditions, GAS virulence factors that
interact with plasminogen are secreted including streptokinase, which meditates the
activation of plasminogen to plasmin (Christner et al. 1997). Glu-plasminogen was
omitted from negative controls. Bacterial cultures were pelleted by centrifugation at
14,000 xg for 10 min and washed twice in PBS to remove any unbound
plasminogen. After the final wash, cells were resuspended in 45 µL of PBS followed
by the addition of the plasmin- and streptokinase-activated plasminogen-specific
chromogenic substrate S-2251 (Chromogenix, Bedford, MA), or Spectrozyme PL
(American Diagnostica, Stamford, CT) at a final working concentration of 0.5 mM
and incubated overnight at 37 °C. Bacteria were then centrifuged at 14,000 xg for 10
min, and the supernatant moved to a 96-well microtiter plate. Plasmin activity
produced by each GAS strain was measured spectrophotometrically at 405 nm (A405)
using a SpectraMax® plate reader (Molecular Devices, Sunnyvale, CA).
2.8.2

Host plasminogen activator-mediated cell surface plasmin acquisition

The ability of host-derived uPA and tPA to facilitate plasminogen activation at the
GAS cell surface was assessed. GAS was incubated for 3 h at 37 °C with 0.5 mg/mL
human Glu-plasminogen and a combination of either 3 IU human or mouse tPA
(Abcam, Melbourne, Australia) or human or mouse uPA (Calbiochem). Controls
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included the sole incubation of Glu-plasminogen, plasminogen activator and PBS
only. GAS were washed and subsequent levels of cell surface plasmin activity
measured as described in section 2.8.1.
2.8.3

Cell surface plasmin acquisition in plasma

GAS cell surface plasmin acquisition in human or mouse plasma ex vivo was
conducted as described elsewhere (Cole et al. 2006; Sanderson-Smith et al. 2008).
GAS were incubated in 10 mM sodium-citrated plasma obtained from human
(volunteer donors), or mouse (AlbPLG1, AlbPLG1/uPA-/- or AlbPLG1/tPA-/-) for 3 h
at 37 °C. Plasmin bound to the GAS cell surface was measured as described in
section 2.8.1.
2.9

Plasminogen acquisition in plasma

Plasminogen binding to the GAS cell surface was detected using Western blot
analysis following incubation of GAS in either human or mouse plasma (SandersonSmith et al. 2008). Plasminogen bound to the bacterial cell surface was eluted with
100 nM glycine-HCl (pH 2.0), and the eluent was screened for the presence of
plasminogen using rabbit anti-human plasminogen (Calbiochem) as described in
section 2.7.
2.10

Animal infection studies

2.10.1 Ethics statement
All animal experiments complied with the NHMRC Australian code for the care and
use of animals for scientific purposes, the NIH Guide for the care and use of
laboratory animals, and the University of Note Dame Institutional Animal Care and
Use Committee (IACUC). Permission to perform animal experiments was granted by
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the University of Notre Dame (Notre Dame, Indiana), and University of Wollongong
ethics committees. Animals were continuously monitored throughout experiments by
trained caretakers.
2.10.2 Animals
Male and female mice heterozygous (AlbPLG1+/-) for the human plasminogen
transgene were established and genotyped via standard PCR analysis as described in
section 2.10.3 (Sun et al. 2004; Cole et al. 2006). Mice homozygous (AlbPLG1+/+)
for the human plasminogen transgene were generated and characterised as described
in section 2.10.4). Characterisation of uPA and tPA in GAS virulence was assessed
using mice deficient in expression of uPA (AlbPLG1/uPA-/-), or tPA (AlbPLG1/tPA-/) in a humanised plasminogen heterozygous background. For studies assessing the
effect of uPA drug inhibitors in GAS pathogenesis, homozygous AlbPLG1 mice
were employed further as described in section 4.3. Mouse colonies were bred and
maintained at the University of Wollongong and Australian BioResources
(AlbPLG1+/+ and AlbPLG1+/-), or University of Notre Dame (AlbPLG1/uPA-/- and
AlbPLG1/tPA-/-).
2.10.3 Genotyping of heterozygous human plasminogen mice
Following overnight storage at -20 °C, DNA from ear cuttings of offspring was
extracted using REDextract-N-AMP Tissue PCR kit according to the manufacturer’s
instructions (Sigma-Aldrich, St. Louis, MO). Standard PCR was performed using the
following parameters: initial denaturation (94 °C for 2 min), [denaturation (94 °C for
40 s), annealing (55 °C for 40 s), extension (72°C for 2 min) x35 cycles], final
extension (72 °C for 4 min), and cooling (25 °C for 3 min). To distinguish between
transgenic human plasminogen mice and wild-type mice, PCR products underwent
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agarose electrophoresis on a 1.5% agarose gel (section 2.3.2). Transgenic humanised
plasminogen mice displayed two bands at approximately 160 bp and 340 bp,
indicative of human and mouse plasminogen respectively, while wild-type mice
display only a single band at 340 bp.
2.10.4 Generation and characterisation of homozygous humanised plasminogen
mice
A homozygous mouse line transgenic for human plasminogen was established and
kindly gifted by Dr. Nicholas West and Mercedes Monteleone (University of
Sydney, Australia). Male and female, heterozygous humanised plasminogen mice
were backcrossed, and the resultant litters were genotyped following DNA extraction
from ear cuttings. The tissue samples were incubated in 100 µL of lysis buffer [(100
mM Tris, pH 7.5, 5 mM EDTA, 200 mM NaCl, 0.5% (v/v) Tween-20, 15 µL
proteinase K (1 mg/mL)] at 56 ºC for 4 h. The DNA samples were then used directly
as templates for the detection of the transgene by PCR. Quantitative RT-PCR to
identify progeny from the cross with higher levels of the human plasminogen
transgene

was

performed

as

heterozygous

and

homozygous

mice

are

indistinguishable via standard PCR analysis. The primers plasminogen A (5’CAGCTCCCTGTGATTGAGAA-3’)

and

plasminogen

B

(5’-

GAAGTGACTCCTTGTAAAATG-3’) were designed and used for quantitative RTPCR. Two male and two female individual mice displayed elevated transgene levels
for human plasminogen, and were subsequently backcrossed to wild-type C57Bl/6J
mice for confirmation of the homozygous genotype. Transgenic parents that gave
rise to 100% heterozygous offspring (n ≥ 6 per litter), determined by standard PCR,
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were confirmed to be homozygous for the human plasminogen transgene
(AlbPLG1+/+) and retained to establish the breeding colony.
The level of mouse plasminogen in mouse plasma was assessed by Dr. Martina
Sanderson-Smith

using

a

mouse

plasminogen-specific

ELISA

kit

(CSB-

EL018188MO) according to the manufacturers’ instructions (Cusabio, Wuhan,
China). The level of activatable human plasminogen in both mouse lines were
assessed via diluting human and mouse plasma samples 1:10 in assay buffer (10 mM
HEPES, 150 mM NaCl, 0.01% Tween-20, pH 7.4). Activation of human
plasminogen present in the mouse plasma samples was assessed by Dr. Jason
McArthur. Briefly, human plasminogen was converted to plasmin by the addition of
5 nM group C streptokinase (Cook et al. 2012), and incubated for 15 min at room
temperature. Plasmin generation was then measured and monitored overtime as
described in section 2.8.1. Plasmin activity, expressed as a percentage of human
plasma, was calculated by [(A405 mouse plasma ÷ A405 human plasma) × 100]. All
reactions were linear over the initial 20 min of the reaction. Cell surface plasmin
acquisition by GAS strain NS88.2 in plasma derived from either mouse line was
determined as detailed in section 2.8.3.
2.10.5 GAS inoculum preparation
Prior to each GAS infection study, multiple practice inoculums were performed to
ensure that bacterial colony numbers were uniform across each study. Bacterial
inoculums were prepared via harvesting cultures at mid-log phase (OD600 0.5), and
washing twice with 0.7% (w/v) sterile saline. Pellets were then resuspended in saline
to a final volume appropriate for the desired inoculum concentration, and kept on ice
prior to mice administration.
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2.10.6 Mouse preparation
To facilitate the ease of injections, mice underwent hair removal on their right/left
flanks via shaving and application of depilatory cream. Immediately prior to
subcutaneous or intradermal GAS infections, mice were anaesthetised via isoflurane
(Lyppard, Castle Hill, Australia) inhalation.
2.10.7 Assessment of GAS virulence using a mouse model of infection
In order to investigate the role of host activators uPA and tPA in GAS pathogenesis,
GAS virulence was assessed using transgenic AlbPLG1 mice expressing human
plasminogen, and mice deficient in either uPA (AlbPLG1/uPA-/-) or tPA
(AlbPLG1/tPA-/-). Individual cohorts of mice were age and gender-matched between
6-12 weeks old, and were selected in cohorts of eight or ten mice for tPA and uPA
studies respectively. For tPA studies, AlbPLG1+/- and AlbPLG1/tPA-/- mice were
subcutaneously inoculated in the right flank with 1 x 109 CFU/mL of parent GAS
strain 5448, while a higher dose of 1 x 1010 CFU/mL of GAS strains 5448 and
5448∆ska were inoculated in AlbPLG1+/- and AlbPLG1/uPA-/- mice for uPA studies
in 100 µL injection volumes. To confirm GAS virulence in mice homozygous for the
human plasminogen transgene, cohorts of ten age and sex-matched AlbPLG1+/-, or
AlbPLG1+/+ mice were subcutaneously infected with GAS as described previously
(Sanderson-Smith et al. 2008). In all studies, mice were closely monitored over a
ten-day period, and moribund mice were sacrificed via CO2 asphyxiation.
2.10.8 Bacterial dissemination
In order to determine the progression of invasive GAS disease, bacterial load at the
initial site of infection, in internal organs and in the bloodstream were assessed.
Cohorts of three mice (AlbPLG1 and AlbPLG1/tPA-/- or AlbPLG1/uPA-/-) were
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subcutaneously infected with a high bacterial load of 4 x 109 CFU/mL or 4 x 1010
CFU/mL GAS for tPA or uPA studies, respectively. Approximately 48-72 h postinfection, the liver, spleen and skin at the site of infection were harvested and kept
ice-cold in 0.7% (w/v) sterile saline at all times, whilst blood was collected and
diluted 1:10 in sterile saline at room temperature. Immediately after, homogenates of
these organs were prepared using the Bio-Gen PRO200 (PRO Scientific, Oxford,
CT). For each sample, organs were homogenised for approximately 2 x 30 s or until
completely uniform. In between each sample, the homogeniser was cleaned three
times with 70% (v/v) ethanol and PBS. Tweezing to completely remove any tissue
remnants was performed before proceeding with the next sample. Bacterial load was
determined by plating serial 10-fold dilutions overnight on HBA, and the CFU
enumerated the following day. Lesion sizes at the site of infection were also
recorded, and the mean skin lesion calculated as Area = [π (Length x Width)/4]
according to the method of Khil et al. (2003).
2.11

Statistical analysis

All statistical analysis was performed using GraphPad Prism version 5.0 (GraphPad
Software Inc., San Diego, CA). Differences in the level of plasmin acquisition at the
GAS cell surface were determined using Student’s t-test. Animal survival studies
were determined by log-rank test. All other data were analysed using one-way
analysis of variance with Tukey’s multiple comparison test. Data sets were
considered statistically significant at P < 0.05.
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generated by co-authors, as outlined on page x, and will be acknowledged
accordingly.
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Ranson, Mark J. Walker, Jason D. McArthur, Martina L. Sanderson-Smith (2014).
Plasmin(ogen) acquisition by Group A Streptococcus protects against C3b-mediated
neutrophil killing. Journal of Innate Immunity. 6: 240-250.
3.1

Abstract

The acquisition of host protease plasmin to the bacterial cell surface is critical during
invasive disease initiation by GAS. Recent evidence has shown that localised
plasmin activity prevents opsonisation of several bacterial species by key
components of the innate immune system in vitro. Here, we demonstrate that
plasmin at the GAS cell surface is able to degrade complement factor C3b, and that
plasminogen acquisition is associated with a decrease in C3b opsonisation and
neutrophil-mediated killing in vitro. Furthermore, the ability of GAS to acquire cell
surface plasmin(ogen) correlates directly with a decrease in C3b opsonisation,
neutrophil phagocytosis, and increased bacterial survival in a humanised
plasminogen mouse model of infection. These findings demonstrate that localised
plasmin(ogen) plays an important role in facilitating GAS escape from the host
innate immune response and increases bacterial virulence in the early stages of
infection.
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3.2

Introduction

Superficial infections including pharyngitis and impetigo follow from GAS
colonising epithelial surfaces of the upper respiratory tract and skin, while further
dissemination into sterile tissue sites can lead to life-threatening conditions such as
necrotising fasciitis and STSS (Walker et al. 2014). The high global disease burden
of invasive GAS infections necessitates identification of key mechanisms of
pathogenesis, particularly in the early stages of infection.
Subversion of the host plasminogen activation system is critical to the initiation of
invasive infection by GAS (Sun et al. 2004; Cole et al. 2006; Sanderson-Smith et al.
2008). Plasminogen circulates as a 92 kDa zymogen in blood and extracellular fluids
at an approximate concentration of 2 µM (Ogston 1980). Activation of plasminogen
to the broad spectrum protease plasmin can be mediated by mammalian activators
uPA and tPA, or bacterial activators including the GAS secreted protein
streptokinase. GAS expresses multiple cell surface receptors for plasmin(ogen),
including GAPDH, SEN and PAM/Prp (Sanderson-Smith et al. 2012). Once
localised to the bacterial cell surface, plasmin is able to facilitate degradation of
ECM components, fibrin clot and host tissue barriers, leading to widespread bacterial
dissemination. More recently, plasmin-mediated evasion of host immunity has
emerged as a key mechanism in bacterial pathogenesis (Hollands et al. 2012;
Sanderson-Smith et al. 2012).
The complement system is a critical component of the innate immune response
against pathogenic organisms and involves the coordinated action of over 30
proteolytic plasma enzymes (Beutler 2004). Activation of the complement cascade
occurs via three distinct routes, comprising the classical, alternate and lectin
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pathways. Each of these pathways however, converge at a central step involving the
cleavage product of C3 convertase, C3b, a key opsonin that binds to microbial
surfaces. Phagocytes such as macrophages and neutrophils recognise opsonised
bacteria via specific complement receptors, leading to phagocytosis and microbial
killing.
Plasmin has been shown to degrade C3b, and streptokinase-generated plasmin
inactivates complement components C1, C2, C3 and C4 (Pillemer et al. 1953; Seya
and Nagasawa 1985). Additionally, plasmin-mediated C3b degradation by human
bacterial pathogens has been observed in vitro (Rooijakkers et al. 2005). In this
study, we demonstrate for the first time that plasmin localised at the GAS surface
degrades human C3b, and that cell surface plasminogen acquisition correlates with
decreased C3b deposition and resistance to complement-mediated neutrophil killing
in vitro. Furthermore, we show that surface-associated plasmin(ogen) correlates with
reduced C3b deposition, C3b-mediated neutrophil killing, and increased bacterial
survival in vivo.
3.3

Methods and materials

3.3.1

Characterisation of GAS strains

In vitro characterisation was performed to confirm the phenotypic properties of wildtype GAS strain NS88.2 and its isogenic mutants, NS88.2prp and NS88.2∆ska.
These GAS strains are described in detail previously (section 2.1.1). Growth kinetics
and streptokinase-mediated cell surface plasmin acquisition by GAS were assessed
as described in sections 2.2 and 2.8.1 respectively. The level of hyaluronic acid
capsule produced by GAS was confirmed previously by Dr. Martina SandersonSmith (Sanderson-Smith et al. 2008; Cook et al. 2012).
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3.3.1.1 Screening for streptokinase expression
Detection of streptokinase was performed according to the method of Cook et al.
(2012). Briefly, GAS were grown to mid-logarithmic phase, and cultures were
subjected to centrifugation to sediment bacterial cells. Five millilitres of GAS
supernatant was collected and sterile filtered using a 0.22 µm filter (Millipore).
Proteins underwent trichloroacetic acid (TCA) precipitation, whereby supernatant
was incubated with 10 % (v/v) TCA in a 1:1 ratio on ice for 20 min, followed by
centrifugation for 15 min at 14,000 xg and resuspended in ice-cold 100 % (v/v)
ethanol. After 5 min centrifugation, supernatant was removed by aspiration and the
remaining protein pellet dried in the fume-hood. Finally, the pellet was resuspended
in 100 mM Tris-HCl (pH 7.6) and the sample subjected to Western blotting (section
2.7).
3.3.2

Human C3b degradation

The ability of exogenous plasmin to degrade C3b was assessed according to the
methods described by Rooijakkers et al. (2005). In 50 µL reaction volumes, 1 µg
human C3b (Calbiochem) was incubated alone in PBS (positive control), or in PBS
containing either 100 nM Glu-plasminogen, 100 nM group C streptokinase (SKc;
Sigma Aldrich), 100 nM human plasmin (Haemotologic Technologies Inc.), or a
combination of 100 nM Glu-plasminogen and 100 nM SKc. Following overnight
incubation at 37 ºC, samples were centrifuged and the supernatants collected and
separated on a 10% SDS-PAGE gel under reducing conditions. Protein bands were
visualised using enhanced chemiluminescence reagents as described in section 2.7.
Similarly, the impact of GAS cell surface plasmin activity on C3b was assessed
following an overnight incubation of GAS with or without cell surface plasmin in the
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presence of 0.5 µg C3b in a total volume of 10 µL. C3b, and its degraded fragments
were analysed as above.
3.3.3

Characterisation of C3b deposition in vitro

Whole-cell ELISA was used to analyse the influence of fluid-phase plasmin on C3b
deposition according to the methods of Rooijakkers et al. (2005). Washed bacteria
were resuspended in ELISA coating buffer, and 100 µL of this suspension was used
to coat wells of a microtiter plate for 2 h at 37 ºC followed by an overnight
incubation at 4 ºC. Between all incubations, wells were washed thrice with PBS
containing 0.05% (v/v) Tween-20 (PBST). Unsaturated binding sites were then
blocked with 100 µL of 1% (w/v) bovine serum albumin (BSA) in PBS for 1 h at 37
ºC. To facilitate C3b deposition on bacterial surfaces, citrated human plasma was
serially diluted 1:3 across the plate in 1% (w/v) BSA and incubated for 20 min at 37
ºC. Negative controls did not receive aliquots of human plasma. Following washing,
50 µL of 100 nM human plasmin or 1% (w/v) BSA were added to each well, and the
plate incubated for 1 h at 37 ºC. An overnight incubation at 37 ºC was conducted
after the addition of 50 µL of goat anti-C3 polyclonal primary antibody diluted
1:1000 in 1% (w/v) BSA to allow detection of bound C3b. Anti-C3 antibodies were
probed using 50 µL HRP-conjugated rabbit anti-goat IgG diluted 1:2000 for 1 h at
37 ºC. Thereafter, the assay was visualised by the addition of 50 µL of substrate
solution containing o-phenylenediamine, the reaction stopped with 1 M HCl, and the
absorbance measured spectrophotometrically at 490 nm. GAS-coated wells were
confirmed with polyclonal rabbit anti-M antisera diluted 1:1000 in 1% (w/v) BSA,
which has previously been shown to specifically detect GAS M proteins in microtiter
assays (Sanderson-Smith et al. 2006). HRP-conjugated goat anti-rabbit IgG
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(Millipore, Billerica, MA) diluted 1:2000 in 1% (w/v) BSA was used to detect any
bound antibodies.
The impact of GAS localised plasmin activity on C3b deposition was analysed by
incubating fluorescent GAS in 100 µL of 50% human or mouse plasma diluted in
PBS for 10 min at 37 ºC. Following two washes with PBST, non-specific binding
sites were blocked by incubating bacteria with human IgG (Invitrogen, Carlsbad,
CA) diluted 1:500 in PBS for 30 min on ice without light. Washed bacteria were
resuspended in 200 µL of PBS, which was subsequently divided into two 100 µL
samples. Under light protection, surface bound C3b was detected by incubation of
samples for 1 h on ice with 0.2 µg of phycoerythrin (PE)-conjugated anti-human C3
monoclonal antibody (Cederlane Laboratories Ltd., Burlington, Canada), or 0.2 µg
of PE-labelled mouse IgG1 isotype control (Cederlane Laboratories Ltd.) to identify
background fluorescence. Prior to flow cytometry analysis, bacterial cells were
resuspended in 100 µL PBS, fixed in 100 µL 4% (w/v) paraformaldehyde (PFA) and
made up to a final volume of 400 µL with PBS. Alternatively, to confirm the
presence or absence of bacterial cell surface plasmin activity, opsonised bacteria
were incubated with the plasmin-specific substrate S-2251 for 1 h at 37 ºC and
absorbance read at 405 nm. Gating for fluorescent GAS and attached C3b molecules
was performed using an argon laser with an excitation wavelength of 488 nm
(excitation wavelength of GFP and PE). GFP-expressing GAS were detected at an
emission wavelength of 515/20 nm, while PE-labelled monoclonal antibodies
generated against human C3 and mouse IgG1 isotype control were gauged with an
emission intensity at 575/26 nm. The amount of C3b deposited on bacterial surfaces
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was expressed as a percentage of fluorescent GAS. A total of 10, 000 cells were
collected for each sample.
3.3.4

C3b deposition and neutrophil phagocytosis in vivo

Transgenic humanised plasminogen mice (AlbPLG1+/+) aged 6-8 weeks were
intradermally injected into right and left shaved flanks with eGFP-expressing GAS
strains NS88.2 (n = 8), NS88.2prp (n = 4) or NS88.2∆ska (n = 4) at approximately 1
x 108 CFU. Mice were sacrificed by CO2 asphyxiation 4 h thereafter, and the
intradermal layer at the site of infection was lavaged twice with 500 µL of 0.7%
(w/v) saline. C3b deposition on recovered GAS was assessed by flow cytometry as
described in section 3.3.3. Supernatants collected from mice injected with saline only
served as controls for background fluorescence. Lavage fluid recovered from the
right and left flanks of each mouse were pooled to increase the yield of bacterial
cells.
The uptake of GAS by mouse neutrophils ex vivo was assessed by Dr. Jude Taylor
(University of Wollongong, Australia). Briefly, recovered cells from each flank were
blocked with Fc Block (anti-mouse CD16/32; Biolegend, San Diego, California).
Cells were then added to a cocktail of Ly6C, Ly6G, and CD45 (Biolegend) diluted in
FACS buffer according to the manufacturers’ instructions (Dulbecco’s PBS, 0.2%
(w/v) BSA, 1 mM NaN3). After incubation for 20 min on ice, cells were washed and
resuspended in a final volume of 0.5 mL of FACS buffer prior to analysis via flow
cytometry. Phagocytosis was determined by fluorescent GAS uptake by mouse
neutrophils.
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3.3.5

GAS survival in vivo

The ability of NS88.2 (n = 6), NS88.2prp (n = 5) and NS88.2∆ska (n = 5) to survive
in vivo was determined via pelleting collected bacteria following infection at 14,000
xg for 10 min as described in section 3.3.4. In a microtiter plate, resuspended
bacteria were serially diluted in sterile Milli-Q water and plated onto HBA overnight
at 37 °C and the number of bacterial colonies enumerated.
3.3.6

Complement-mediated neutrophil killing

3.3.6.1 Ethics statement
All volunteers provided informed consent prior to donating blood samples according
to the conditions outlined in HE08/250 approved by the University of Wollongong
Human Ethics Committee, Wollongong, Australia.
3.3.6.2 Preparation of GAS
The ability of plasmin-coated GAS to resist the phagocytic killing by human
neutrophils was assessed in vitro according to Hollands et al. (2012). GAS with or
without cell surface plasmin activity were opsonised with autologous human plasma
for 10 min at 37 °C. Following two washes with PBS, bacteria (2 x 104 CFU) were
serially diluted in RPMI 1640 media (Invitrogen) containing 2% heat inactivated
plasma and placed on ice until required. Alternatively, bacteria were also screened
for the presence or absence of cell surface plasmin activity as described in section
2.8.1.
3.3.6.3 Isolation of neutrophils
Human neutrophils were freshly isolated from 20 mL of citrated (0.5 M sodium
citrate) venous blood of healthy volunteers. To separate blood into distinct cellular
fractions, 5 mL of anticoagulated whole blood was carefully layered over an
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equivalent volume of Polmorphprep™ (Axis-Shield, Oslo, Norway) in four separate
falcon tubes to create a density gradient of sodium diatrizoate containing neutrophils.
The tubes were centrifuged for 25 min at 500 xg using a swing-out rotor bucket of
the Heraeus Multifuge X3R Centrifuge (Thermo Scientific, Waltham, MA) with
acceleration and deceleration set at 9 and 0 respectively. Following this, the upper
plasma layer was collected and stored at -20 ºC, while neutrophils were harvested
from the leukocyte-rich fraction using a 1 mL pipette tip. The cell suspension was
then diluted in 50 mL of PBS, followed by centrifugation for 10 min at 180 xg with
full deceleration. Cells were washed twice by resuspending in 200 µL of PBS,
followed by gentle inversion in a hyptonic solution of 5 mL sterile water for 10 sec
to lyse residual contaminating erythrocytes. Lysis was stopped by the addition of 45
mL of PBS and cells pelleted as above. To determine the number of isolated
neutrophils, standard haemocytometer techniques was employed. Briefly, neutrophils
were diluted 1:10 in PBS, and 10 µL of this suspension was allowed to stain for 3
min with an equal volume of 0.4% (w/v) trypan blue dye (Sigma-Aldrich, St. Louis,
MO). The trypan blue cell suspension was then transferred to the haemocytometer
chamber and the number of viable cells (opaque coloured) was analysed by
exclusion of trypan blue dye under a light microscope (Leica, Wetzlar, Germany).
Cell concentration was then adjusted to 2 x 105 neutrophils by dilution in RPMI
1640 media supplemented with 2% heat inactivated plasma.
3.3.6.4 Neutrophil killing of GAS
To a 96-well flat-bottomed cell culture plate (Greiner Bio-one, Frickenhausen,
Germany), 100 µL of 2 x 104 CFU of GAS was mixed with 100 µL of 2 x 105
neutrophils suspended in RPMI 1640 containing 2% heat inactivated plasma
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(multiplicity of infection = 1:10). To synchronise bacterial contact with neutrophils,
the plate was centrifuged at 180 xg for 10 min. Phagocytosis was facilitated at 37 ºC
for 30 min. Hypertonic lysis of neutrophils was performed by immediately
transferring the reaction mixture in sterile water and serially diluted 1:10. The
appropriate dilutions (10-1-10-3) were plated on THA overnight and CFU/mL
enumerated the following day. Growth controls consisted of bacteria incubated under
the same conditions in the absence of neutrophils. The percent of surviving GAS was
calculated by: [(experimental well) ÷ (control well)] x 100.
3.4

Results

3.4.1

Phenotypic characterisation of GAS strain NS88.2 and its isogenic mutants

The phenotypic properties of GAS strain NS88.2 and the isogenic mutants,
NS88.2prp and NS88.2Δska, were confirmed via examining the growth kinetics,
capsule expression and the ability to acquire cell surface plasmin in vitro of each
strain. Mutation of Prp, or deletion of streptokinase did not alter the growth in
THBY of NS88.2prp or NS88.2Δska compared to the parent strain NS88.2 (Figure
3.1A). Western blot analysis confirmed the lack of streptokinase secretion by
NS88.2Δska, whilst strains NS88.2 and NS88.2prp expressed equivalent amounts of
streptokinase (Figure 3.1B). All strains produced similar levels of hyaluronic acid
capsule at the cell surface, and plasmin acquisition assays showed that as expected,
NS88.2prp and NS88.2Δska accrued significantly less plasmin at the bacterial
surface compared to NS88.2 (Figure 3.1D). These strains were therefore deemed
appropriate for this study.
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Figure 3.1 In vitro characterisation of NS88.2, and the isogenic prp and ska deletion mutants. (A)
Growth of NS88.2, NS88.2prp and NS88.2∆ska. (B) Western blot analysis of streptokinase secreted
into culture supernatants. An arrow indicates the major immunoreactive band. (C) NS88.2,
NS88.2prp and NS88.2∆ska produce equivalent levels of hyaluronic acid capsule. (D) GAS cell
surface plasmin acquisition in culture supernatants with the addition of Glu-plasminogen. Data
represents the mean ± SEM of two independent experiments performed in triplicate. Asterisks
indicate statistical significance, ***P < 0.001.

3.4.2

Plasmin at the GAS cell surface degrades human C3b

GAS-secreted streptokinase mediates plasminogen activation by the formation of a
1:1 stoichiometric complex with plasminogen, resulting in a complex equipped with
plasmin and plasminogen activator activity (Reddy and Markus 1972). To confirm
that streptokinase-mediated plasminogen activation could degrade C3b, as reported
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for plasmin generated using host activators, we employed a solution phase
degradation assay followed by Western blot analysis. Streptokinase-generated
plasmin degraded C3b, whereas no degradation was seen in the presence of either
streptokinase or plasminogen alone (Figure 3.2A). To further assess the ability of
plasmin sequestered to the GAS cell surface to degrade C3b, we employed a wildtype parent GAS strain (NS88.2), and its isogenic mutants abrogated for either cell
surface plasmin acquisition (NS88.2prp), or streptokinase expression (NS88.2∆ska).
C3b degradation by GAS was dependent on the presence of cell surface plasmin.
Following pre-incubation with plasminogen, wild-type GAS strain NS88.2 degraded
C3b, however, incubation of C3b with NS88.2prp or NS88.2∆ska, which do not
accumulate plasmin under these conditions, did not result in detectable C3b
degradation (Figure 3.2B). Likewise, all GAS strains were not able to degrade C3b
without a source of cell surface plasmin activity (Figure 3.2B). These data clearly
demonstrate that streptokinase-generated plasmin, and plasmin localised to the GAS
cell surface is sufficient for complement C3b degradation.
3.4.3

Plasmin(ogen) reduces C3b deposition on GAS in vitro

Analysis of GAS cell surface plasmin acquisition assays confirmed that as expected,
neither NS88.2prp nor NS88.2Δska bound significant levels of plasmin at the
bacterial surface (Figure 3.3A). Western blot analysis of proteins eluted from the
GAS cell surface confirmed that both NS88.2 and NS88.2Δska bound plasminogen
in human plasma, whilst NS88.2prp did not (Figure 3.3B). To determine if fluidphase plasmin was able to deplete C3b from the bacterial surface, C3b deposition on
the GAS cell surface in the presence or absence of plasmin was measured using
whole-cell ELISA. C3b deposition was found to be dose-dependent, with saturation
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A
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Figure 3.2 Streptokinase-generated plasmin and GAS cell surface plasmin degrade C3b. In both
panels, protein samples were resolved by SDS-PAGE under reducing conditions and transferred onto
a nitrocellulose membrane. Cleavage of C3b was analysed via Western blotting using goat anti-C3
IgG and HRP-conjugated rabbit anti-goat secondary antibody. (A) Human C3b was incubated
overnight singly (lane 1), or together with plasminogen (Plg; lane 2); streptokinase (SK; lane 3);
human plasmin (lane 4), or a combination of plasminogen and streptokinase (lane 5). (B) GAS were
pre-incubated with (+) or (-) without 100 nM Glu-plasminogen for 2 h at 37 °C, followed by an
overnight incubation with 1 µg C3b. Intact C3b is visible as the α- and β-chain (lane 1). Plasmin at
the cell surface of NS88.2 partially cleaved C3b into smaller degradation products (lane 2). C3b
remained intact and was not cleaved in the absence of plasmin at the cell surface of NS88.2 (lane 3),
or when NS88.2prp or NS88.2Δska was incubated with C3b (lanes 4-7).

occurring in 33% human plasma. The addition of exogenous plasmin after
opsonisation resulted in a significant decrease in the amount of C3b detected at the
GAS cell surface (P < 0.001; Figure 3.3C). No signal was detected when GAS was
incubated with 1% BSA alone (data not shown). We next assessed the impact of
bacterial cell surface plasmin activity on C3b deposition. Each isogenic GAS strain
set was transformed with an eGFP-expressing plasmid, opsonised with human
plasma, and C3b deposition measured via flow cytometry. Significantly less C3b
was detected at the surface of wild-type strain NS88.2, which accumulates
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plasmin(ogen) on its cell surface, than NS88.2prp (P < 0.01), which does not
accumulate plasmin(ogen) at the cell surface. However, no significant difference was
seen in C3b deposition between NS88.2 and NS88.2Δska (Figure 3.3D). No
significant fluorescence was detected using an isotype-matched control antibody
(data not shown). These data suggest that plasminogen binding by NS88.2 and
NS88.2Δska, which showed decreased levels of C3b at the cell surface, while
NS88.2prp was readily opsonised by C3b, rather than plasmin activation or
acquisition is responsible for the decrease in C3b deposition.
3.4.4

Plasminogen at the GAS cell surface impairs complement-mediated

neutrophil killing
One consequence of C3b deposition on microbial surfaces is phagocytosis and
killing by neutrophils. Therefore, to further examine the functional significance of
observed decreases in C3b deposition, bacteria were opsonised with human plasma
and survival in the presence of human neutrophils was measured. Wild-type strain
NS88.2 was significantly more resistant to neutrophil killing compared to NS88.2prp
(P < 0.05). There was no significant difference between the survival of NS88.2 and
NS88.2Δska in the presence of human neutrophils (Figure 3.4A). To confirm that
this observation was complement dependent, the assay was repeated using complement-depleted plasma. No significant differences in survival of wild-type and mutant
GAS strains were observed in the absence of complement (Figure 3.4B). Incubation
of bacteria with Spectrozyme PL after opsonisation confirmed that wild-type GAS
strain NS88.2 sequestered significantly higher levels of cell surface plasmin than
either the NS88.2prp (P < 0.001) or NS88.2Δska (P < 0.01) mutants (Figure 3.4C),
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Figure 3.3 Plasmin(ogen) decreases C3b deposition on GAS in vitro. The acquisition of plasmin or plasminogen at the GAS cell surface was confirmed via (A)
incubating bacteria with the plasmin-specific substrate Spectrozyme PL overnight, or (B) Western blot analysis of proteins eluted from the bacterial cell surface following
incubation in human plasma. (C) The impact of fluid-phase plasmin on C3b deposition on the GAS cell surface was assessed using whole-cell ELISA. The addition of
exogenous plasmin after bacterial opsonisation led to a significant decrease in C3b attachment to the bacterial surface (P < 0.001). (D) In order to assess the impact of cell
surface plasmin on C3b deposition, bacteria were opsonised at 37 °C for 10 min in 50% human plasma as a source of complement and plasmin(ogen). Nonspecific binding
sites were blocked by incubating bacteria with human IgG and surface-bound C3b was probed using PE-conjugated monoclonal antibody raised against human C3. Alternatively, cells were stained with PE-labelled mouse IgG isotype control. C3b deposition on the bacterial surface was analysed using flow cytometry. C3b deposition was
significantly reduced on the surface of NS88.2 compared to NS88.2prp (P < 0.001), but not NS88.2Δska. Histograms show the shift in mean fluorescence intensity (MFI)
between GAS stained with the isotype control (grey) and an anti-C3 antibody (white). Bars indicate means ± SEM of triplicates expressed in MFI. Data are representative
of two independent experiments performed in triplicate. Asterisks indicate statistical significance, ***P < 0.001; n.s., non-significant.
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Figure 3.4 Plasminogen at the GAS cell surface confers protection to C3b-mediated killing.
Bacteria were opsonised with 50% human plasma for 10 min at 37 °C as a source of plasminogen and
complement. Washed bacteria were co-cultured with purified human neutrophils for 30 min at 37 °C
to allow for phagocytic uptake, with phagocytosis disrupted by hypotonic lysis of neutrophils. The
numbers of viable bacterial colonies were enumerated after overnight incubation at 37 °C. Negative
controls consisted of bacteria incubated under the same conditions without neutrophils. (A) NS88.2
was significantly more resistant to complement-mediated neutrophil killing than NS88.2prp (P <
0.01), but not NS88.2Δska. (B) Bacteria were alternatively incubated with C3-depleted plasma. GAS
strains showed no differences in neutrophil killing. (C) Opsonised bacteria were also incubated with
the plasmin-specific substrate Spectrozyme PL overnight to confirm levels of cell surface plasmin
activity. Bars indicate means ± SEM of triplicate determinations from three independent experiments
with different plasma donors. Asterisks indicate statistical significance, **P < 0.01; ns, nonsignificant.

supporting the hypothesis that increased bacterial survival does not correlate with
plasmin acquisition.
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3.4.5

Plasmin(ogen) acquisition is associated with immune evasion in vivo

To extend the investigation of the effect of GAS cell surface plasminogen acquisition
on C3b deposition in vivo, an animal model of infection was established in mice
expressing the human plasminogen transgene. Previously published work has
indicated that mice heterozygous for the AlbPLG1 transgene are more susceptible to
infection with GAS strain NS88.2 (Sanderson-Smith et al. 2008). Here, a
homozygous mouse line was employed, which expresses two copies of the AlbPLG1
gene. Both mouse lines expressed equivalent levels of mouse plasminogen (197.46 ±
19.37 and 169.55 ± 28.22 μg/ml for heterozygous and homozygous mice,
respectively). Mice heterozygous for the AlbPLG1 transgene express approximately
17% the level of human plasminogen found in human plasma (Sun et al. 2004). The
level of activatable human plasminogen in the homozygous mouse line was found to
be 34% (±2.3%) that of the level in human plasma. Plasma from the homozygous
mouse line displayed higher levels of streptokinase-mediated plasminogen activation
and resulted in increased cell surface plasmin acquisition by GAS compared with
plasma from heterozygous mice (Appendix B). Overall virulence of GAS strain
NS88.2 was equivalent in the two mouse lines (Appendix B). Cohorts of 4 sexmatched mice aged between 8 and 10 weeks were intradermally inoculated with 1 ×
8

10 CFU of eGFP-expressing NS88.2, NS88.2prp or NS88.2Δska GAS strains. The
site of infection was lavaged 4 h after inoculation, and C3b deposition analysed by
flow cytometry. Significantly lower levels of C3b were detected at the surface of
wild-type strain NS88.2 compared to mutant NS88.2prp (P < 0.001; Figure 3.5A).
The significance of decreased C3b deposition was further assessed by comparing the
number of eGFP-positive neutrophils isolated from the flank 4 h after infection with
eGFP-expressing NS88.2, NS88.2prp

or NS88.2Δska. NS88.2prp
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significantly higher levels of association with neutrophils than NS88.2 or
NS88.2Δska (P < 0.001; Figure 3.5B), suggesting that increased C3b deposition at
the surface of this strain results in an increase in uptake by neutrophils. Finally, the
bacterial load following infection with wild-type and mutant GAS strains was
compared. A significantly higher bacterial load at the site of infection was seen for
NS88.2 compared with NS88.2prp (P < 0.01), however there was no significant
difference between the number of bacteria recovered for NS88.2 and NS88.2Δska
after infection, as expected (P > 0.05; Figure 3.5C). The propensity to acquire cell
surface plasmin(ogen) therefore correlates with reduced complement deposition and
increased bacterial survival in vivo. Thus, we were able to establish a mouse model
to examine the impact of plasmin(ogen) acquisition by GAS on complementmediated neutrophil phagocytosis. To further investigate the mechanism behind the
findings in vivo, C3b deposition, cell surface plasmin acquisition, and cell surface
plasminogen acquisition in vitro using humanised mouse plasma was compared.
Consistent with the findings of both the in vitro studies using human plasma and the
in vivo findings, C3b deposition in mouse plasma was significantly lower for NS88.2
compared with NS88.2prp, but not NS88.2Δska (Figure 3.6A). However, subsequent
analysis of cell surface plasmin acquisition by GAS in mouse plasma revealed that
NS88.2Δska accumulated significantly higher levels of plasmin compared to
NS88.2prp (P < 0.05; Figure 3.6B). Western blot analysis of proteins eluted from the
GAS cell surface confirmed that both NS88.2 and NS88.2Δska, which showed
decreased levels of C3b at the cell surface, bound plasminogen in mouse plasma,
whilst NS88.2prp, which was readily opsonised by C3b, did not (Figure 3.6C). The
observed similarity in C3b deposition in vivo between NS88.2Δska and the wild-type
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parent strain may therefore be due to either cell surface plasmin or cell surface
plasminogen acquisition.
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Figure 3.5 Plasmin(ogen) at the GAS cell surface is associated with immune evasion in an
intradermal infection model. Transgenic humanised plasminogen mice were inoculated with 1 × 108
CFU of eGFP-expressing GAS strains NS88.2, NS88.2prp or NS88.2Δska via intradermal injection
into the right and left flanks. Four hours after infection, wound sites were lavaged with saline and the
recovered supernatants collected. (A) C3b deposition on the surface of NS88.2 was significantly
reduced compared to NS88.2prp (P < 0.001), while C3b deposition levels were comparable between
NS88.2 and NS88.2Δska. Bars indicate means ± SEM of duplicates in three independent experiments
(n = 6) expressed as MFI for C3b deposition. (B) GAS strain NS88.2prp was phagocytosed by mouse
neutrophils 4 h after infection when compared to NS88.2 or NS88.2Δska (P < 0.0001). (C) A
significantly lower bacterial load was obtained for NS88.2prp compared to NS88.2 and NS88.2Δska
(P < 0.01). Data are combined from four (NS88.2prp and NS88.2Δska) and five (NS88.2)
independent experiments performed in duplicate. Asterisks indicate statistical significance, ***P <
0.001; **P < 0.01; ns, non-significant.
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Figure 3.6 Plasmin(ogen) decreases C3b deposition on GAS in mouse plasma. (A) In order to assess the impact of cell-surface plasmin (ogen) on C3b deposition,
bacteria were opsonised at 37 °C for 10 min in 50% mouse plasma as a source of complement and plasmin(ogen). Non-specific binding sites were blocked by incubating
bacteria with human IgG and surface-bound C3b was probed using phycoerythrin (PE)-conjugated monoclonal antibody raised against human C3. Alternatively, cells
were stained with PE-labelled mouse IgG isotype control. C3b deposition on the bacterial surface was analysed using flow cytometry. C3b deposition was significantly
reduced on the surface of NS88.2 compared to NS88.2prp (P < 0.01), but not NS88.2Δska. Histograms show the shift in mean fluorescence intensity (MFI) between GAS
stained with the isotype control (grey) and an anti-C3 antibody (white). Bars indicate mean ± SEM of triplicates expressed in MFI, representative of two independent
experiments. (B) GAS cell surface plasmin activity was confirmed by incubating bacteria with the plasmin-specific substrate Spectrozyme-PL overnight. (C) GAS cell
surface plasminogen acquisition was confirmed by Western blot analysis of proteins eluted from the GAS cell surface following incubation in mouse plasma. Data is
representative of two independent experiments performed in triplicate. Asterisks indicate statistical significance, **P < 0.01; *P < 0.05; ns, non-significant.
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3.5

Discussion

The ability of GAS to activate and sequester the host protease plasmin to the cell
surface has been linked to bacterial dissemination and degradation of host tissue
barriers during invasive disease initiation (Sun et al. 2004; Sanderson-Smith et al.
2012). Here, we establish a mouse model to demonstrate for the first time that
plasmin(ogen) acquisition protects GAS from complement-mediated neutrophil
phagocytosis and results in increased bacterial load during the early stages of
infection.
During the initial stages of infection, invading pathogens must overcome innate
immune barriers, including the bactericidal effects of complement. C3b plays a
pivotal role in the innate immune response to bacterial infection, and opsonisation of
bacteria with C3b facilitates neutrophil phagocytosis. GAS has evolved a wealth of
strategies to reduce complement deposition at the bacterial cell surface, including
expression of M protein (Kwinn and Nizet 2007). The presence of M6 and M49 at
the GAS cell surface has been linked to protection from C3b-mediated phagocytosis
(Jacks-Weis et al. 1982), while fibrinogen and factor H binding by certain M
serotypes has been shown to block C3b deposition at the bacterial cell surface
(Kwinn and Nizet 2007). To date, over 234 different M protein types have been
identified, and M protein function is highly diverse (McMillan et al. 2013;
Sanderson-Smith et al. 2014). This study defines a new role for plasminogen-binding
M proteins in GAS resistance to phagocytosis.
Plasmin exhibits broad-spectrum protease activity, which is central to its
involvement in inflammation, fibrinolysis, and tissue remodeling (Saksela and Rifkin
1988). However, these properties necessitate strict regulation of proteolysis under
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normal conditions. Secretion of streptokinase by GAS facilitates plasmin generation
independent of host activators, while attachment of plasmin to the bacterial cell
surface protects plasmin from circulating inhibitors such as α2-antiplasmin. In this
way, GAS are able to acquire a source of unregulated surface proteolytic activity
(Sanderson-Smith et al. 2012). This study shows that the ability of GAS strain
NS88.2 to degrade C3b is dependent on the presence of cell su.rface plasmin
activity. However, our data suggest it is the ability of NS88.2 to accumulate
plasminogen at the cell surface, rather than plasmin, that is protective against C3bmediated phagocytosis. Minimal C3b degradation was seen following overnight
incubation of GAS with C3b. This suggests that the activity of surface-localised
plasmin for soluble C3b is low. Interestingly, a number of studies assessing C3b
degradation by surface-localised plasmin show similar results, with intact C3b still
visible after 24 h (Barthel et al. 2012a; Barthel et al. 2012b). This may explain the
findings in this study that there is limited correlation between cell surface plasmin
acquisition and C3b deposition. Subsequent in vitro analyses using human plasma
indicated no correlation between cell surface plasmin accumulation and C3b
deposition at the GAS cell surface. Rather, decreased C3b deposition correlated with
the ability of GAS to sequester plasminogen to the cell surface. However, assays
performed using plasma from humanised plasminogen mice revealed that reduced
C3b deposition correlates with both cell surface plasmin and cell surface
plasminogen acquisition. This may be indicative of differences between mouse
plasma and human plasma, even in this humanised mouse model. It is therefore
difficult to rule out a role for plasmin acquisition in the in vivo model, and it may be
that in this context, both plasminogen and plasmin at the GAS cell surface provide
protection against C3b deposition. Given the low level of soluble C3b degradation
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detected by surface-localised plasmin, it may be that localised plasmin is more
efficient at cleaving surface-deposited C3b, and our data clearly show that soluble
plasmin can facilitate the removal of C3b from the GAS cell surface. Alternatively, it
has been shown that degradation of C3b by plasmin inhibits complement activation
by preventing the formation of the C3 convertase C3bBb (Barthel et al. 2012a). It is
therefore possible that plasmin-mediated removal of C3b from the GAS cell surface
blocks this pathway and is responsible for the reduced levels of C3b deposition seen
in vivo.
Recently, it has been demonstrated that plasminogen binds to complement
components C3, C3b and C3d, and when activated to plasmin by host uPA, plasmin
cleaves C3b, inhibits complement activation, and prevents complement-mediated
hemolysis of rabbit erythrocytes (Barthel et al. 2012a). The cleavage fragments of
C3b generated in this study using streptokinase-activated plasminogen or
commercially obtained exogenous plasmin were found to be of similar but not
identical in size to those reported by Barthel et al. (2012a). Differences in
electrophoretic mobility may reflect different commercial sources of C3b, or
differences in the length of time C3b was incubated with a plasmin source between
the two studies. However, both the previous study and the current study indicate that
surface-localised plasmin degrades C3b.
GAS is equipped with an arsenal of virulence factors that together exert antiphagocytic properties. Both M and M-like proteins have been linked to the survival
of certain GAS strains inside human neutrophils and blood (Kihlberg et al. 1995;
Staali et al. 2003), while pore-forming streptolysin S and O exert cytotoxic activity
on host neutrophils and impair their recruitment to the site of bacterial infection
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(Andersen and Duncan 1980; Lin et al. 2009). Furthermore, loss of the GAS surface
hyaluronic acid capsule is also associated with decreased resistance to neutrophil
phagocytosis and reduced virulence in mice (Moses et al. 1997). Thus, GAS is
protected from different stages of the innate immune response via coordinated
expression of multiple virulence factors. This is reflected in the finding that even in
the presence of cell surface plasmin(ogen), GAS strain NS88.2prp retains
approximately 80% survival compared with the wild-type parent GAS strain in our
in vitro neutrophil killing assays. Nevertheless, the ability of GAS to coopt
plasmin(ogen) correlated to a significant increase in bacterial survival and a decrease
in association with neutrophils during the early stages of infection in a wellcharacterised murine infection model. Inactivation of C3b via cleavage into smaller,
nonfunctional products as a result of plasmin activation has been described for
several additional human pathogens including S. aureus (Rooijakkers et al. 2005),
Bacillus anthracis (Chung et al. 2011), and Borrelia burgdorferi (Grosskinsky et al.
2009). Recently, a novel plasminogen binding protein, PepO for Streptococcus
pneumoniae has been shown to mediate C3b degradation upon plasminogen
activation by uPA (Agarwal et al. 2013). However, to our knowledge, this is the first
time this potential virulence mechanism has been linked to bacterial survival in vivo.
The ability of GAS to initiate invasive disease has been shown to be dependent on
cell surface plasmin acquisition (Sun et al. 2004; Cole et al. 2006; Sanderson-Smith
et al. 2008), however, few studies of the role of plasminogen in GAS infection have
looked at the early stages of disease, where the innate immune response is critical.
Recently, GAS surface-bound plasmin was shown to cleave the cathelicidin
antimicrobial peptide LL-37 (Hollands et al. 2012). The current study clearly
demonstrates that, in addition to facilitating tissue degradation and bacterial
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dissemination, localisation of plasmin at the GAS cell surface via the M protein is
critical for bacterial survival in the early stages of infection. These data provide new
insight into the antiphagocytic role of the GAS M protein and add to our
understanding of how plasmin(ogen) acquisition contributes to virulence of a
significant human pathogen.
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4.1

Abstract

Activation of human plasminogen to the broad spectrum protease plasmin is
mediated by either of two physiological activators, uPA and tPA. A role for host
activators in the pathogenesis of multiple bacterial species has been reported,
however there is little known about their contribution to GAS virulence. Here, we
assessed the role of uPA-mediated plasminogen activation in GAS pathogenesis in
vivo. We show that in the absence of the GAS secreted plasminogen activator
streptokinase, uPA can facilitate GAS cell surface plasmin acquisition during
incubation with plasminogen in vitro, or in human plasma ex vivo. Furthermore,
plasmin-coated GAS were able to mediate a significant increase in the activation of
the zymogen of uPA (pro-uPA) in human plasma. We next investigated the
contribution of uPA to invasive GAS disease using a previously undescribed
transgenic mouse model of infection. We found that humanised plasminogen mice
deficient in uPA (AlbPLG1/uPA-/-) were less susceptible to GAS infection compared
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to wild-type mice (AlbPLG1). This observation correlated with a reduced ability of
GAS to disseminate to internal organs in vivo, and acquire cell surface plasmin ex
vivo in the absence of uPA. Our findings demonstrate that endogenous uPA plays a
significant role during GAS infection. We further evaluated the therapeutic potential
of commercial (amiloride, tranexamic acid, 5-N,N-hexamethylene amiloride; HMA)
and novel (BB2-50F and BB2-31F) inhibitors directed against uPA activity during
GAS infection in vivo. Minimum inhibitory concentration (MIC) in vitro data
indicated antimicrobial potential, however treatment with these inhibitors did not
correlate with decreased bacterial dissemination, or mice survival in an invasive
model of GAS disease.
4.2

Introduction

uPA is a serine protease activator of plasminogen, the key proenzyme of the
fibrinolytic system. uPA is synthesised by the kidneys and secreted as a single-chain
zymogen (pro-uPA) that displays very little intrinsic activity (Pannell and Gurewich
1987; Kristensen et al. 1991). Plasmin or other proteases subsequently cleave prouPA to form a fully functional HMW two-chain uPA that contains a noncatalytic
amino-terminal fragment, responsible for mediating binding of uPA to a specific
high affinity cell surface receptor, uPAR (Vassalli et al. 1985). Plasminogen
activation can also be facilitated by the other major host activator, tPA, although this
mechanism is generally restricted to fibrin clots in the vascular injury region due to
its high binding affinity for fibrin (Kooistra et al. 1994). The physiological role of
plasmin is widespread and involves degradation of fibrin clots, extracellular matrix
proteins, and orchestrating the recruitment of immune cells to wound sites. uPAmediated plasminogen activation on cellular surfaces leads to increased plasmin
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formation and localised proteolytic activity, thereby facilitating cell invasion and
tissue remodeling. The concomitant overexpression of uPA or uPAR has been linked
to cancer invasion and metastasis (Ossowski and Reich 1983; Duffy et al. 1999;
Ranson and Andronicos 2003).
Several lines of evidence suggest a role for uPA and tPA in bacterial pathogenesis
(Sjobring et al. 1994; Klempner et al. 1995; Yavlovich et al. 2004; Lähteenmäki et
al. 2005; Magalhaes et al. 2007). Many important pathogens including Borrelia
burgdorferi (Coleman et al. 1995), Yersina pestis (Sodeinde et al. 1992),
Haemophilus influenza (Virkola et al. 1996) and Streptococcus pneumoniae
(Bergmann et al. 2005), recruit human plasminogen to the cell surface, and
subsequent conversion to plasmin can be mediated by endogenous plasminogen
activators, leading to bacterial invasion and escape from innate immunity
(Sanderson-Smith et al. 2012). Plasminogen activation and plasmin acquisition is
central to the establishment of invasive GAS disease (Sun et al. 2004; Cole et al.
2006; Sanderson-Smith et al. 2008). The role of secreted streptococcal plasminogen
activator streptokinase has been well-established during GAS infection, and uPA has
been shown to mediate plasminogen activation at the GAS cell surface in vitro
(Berge and Sjobring 1993; Sun et al. 2004). However, the exact contribution of uPA
to GAS pathogenesis remains unknown.
Given the potential role of uPA in bacterial disease, manipulation of uPA-mediated
plasminogen activation may be a promising therapeutic strategy in invasive GAS
infection. Several commercial inhibitors of uPA and plasminogen activation have
been shown to be effective as anticancer drugs in animal models including amiloride
and tranexamic acid (Dunbar et al. 2000; Matthews et al. 2011a; Ding et al. 2012).
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Amiloride is a known moderate competitive inhibitor of uPA (Ki = 7 µM) (Matthews
et al. 2011a), while tranexamic acid targets plasmin(ogen) more effectively than eaminocaproic acid, from which it is derived (Markus et al. 1979; Vassalli and Belin
1987), thereby preventing plasminogen activation and binding of plasmin to fibrin.
Both these inhibitors are currently approved for clinical use; amiloride as an oral
potassium-sparing diuretic (Matthews et al. 2011a), and tranexamic acid to prevent
peri- and post-operative bleeding in humans (Dunn and Goa 1999).
In order to further explore the role of uPA in GAS disease, we employed a
humanised plasminogen infection mouse model to investigate the therapeutic
potential of these drugs to block uPA-mediated plasminogen activation, and
therefore prevent the development of invasive infection. In addition, we employed a
derivative of amiloride, hexamethylene amiloride (HMA) (Matthews et al. 2011a),
and two novel HMA derivatives, BB2-50F (Buckley et al. unpublished) and BB231F (Buckley et al. unpublished) that exhibit enhanced inhibitory effects against the
proteolytic activity of uPA in vitro compared to HMA.
4.3

Methods and materials

4.3.1

Ethics statement

Plasma samples were collected from healthy volunteers as stated in section 3.3.6.1,
and animal infection studies complied with regulations as stated in section 2.10.1.
4.3.2

GAS strains

This study employed the globally disseminated invasive M1T1 GAS strain 5448 and
its isogenic mutants, 5448∆ska, and reverse-complemented 5448∆ska (designated
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5448∆skaRC). Details of GAS strains and culture methods are described in section
2.1.1.
4.3.3

Humanised plasminogen uPA-knockout mouse model of GAS infection

The role of uPA in GAS virulence was assessed in vivo using uPA-deficient
humanised plasminogen mice as described in section 2.10.2. All survival and
bacterial dissemination data was generated at the University of Notre Dame by Dr.
Martina Sanderson-Smith, Dr. Yueling Zhang and Mrs. Debra Donahue (University
of Notre Dame, Notre Dame), and are detailed in section 2.10.
4.3.4

Activation of pro-uPA by GAS in human plasma

The activation of pro-uPA by plasmin-bound GAS in human plasma was assayed
using a synthetic fluorogenic peptide substrate Z-Gly-Gly-Arg-AMC (Calbiochem).
Fluorescence in this assay correlates directly with uPA activity due to the high
specificity of uPA for Z-Gly-Gly-Arg-AMC. Bacterial cultures were harvested at
mid-logarithmic phase, washed twice in PBS, and resuspended in 50 µL human
plasma or PBS in duplicate. The cell suspension was transferred to a non-transparent
96-well flat-bottom plate (Interpath, Heidelberg West, Australia) where an equal
volume of 1 M Z-Gly-Gly-Arg-AMC was overlayed for a final working
concentration of 0.5 mM of the fluorogenic substrate and a total reaction volume of
100 µL per well. Fluorescence emission was recorded immediately at 3 min intervals
with shaking to resuspend the bacterial cells over 120 min at 37 ºC, using the
Fluostar Optima (BMG Labtech, Offenburg, Germany). Excitation and emission
wavelengths were measured at 360 and 440 nm respectively, with multiple gains set
to detect uPA activity. Wells containing a mixture of GAS and fluorogenic substrate
in PBS indicted background fluorescence, which was subtracted from each reading
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before statistical analysis. The initial rate of change in fluorescence.min -1 was
generated from a linear curve during the first 30 min of the assay, where the
fluorescence increment at each time-point was plotted against time. The final
concentration of uPA generated in each assay was determined from a corresponding
standard curve of known concentrations of uPA incubated in the presence of the
fluorogenic substrate.
4.3.3

Treatment of GAS infected mice with amilorde and tranexamic acid

In order to assess the potential of blocking uPA-mediated plasminogen activation to
inhibit the development of invasive GAS disease, two commercially available uPA
inhibitors, amiloride and tranexamic acid, were selected for treatment against GAS
infection. Cohorts of 10 sex-matched AlbPLG1 mice aged between 8 to 12 weeks old
were treated with 100 µL of either amiloride (Sigma-Aldrich) at 5, 10 or 20 mg/kg,
tranexamic acid (Santa Cruz Biotechnology, Dallas, TX) at 20 or 800 mg/kg, or
0.7% (w/v) saline control via an intraperitoneal (IP) route. Immediately following
pretreatment, mice were subcutaneously infected with 100 µL of 1 x 109 CFU/mL
GAS strain 5448. Daily treatment of either drug dose was administered on
alternating sides of the abdominal cavity, and mice monitored for 10 days. Lesions
formed at the initial site of infection were also measured daily.
4.3.4

Determining MIC of novel uPA inhibitors

The MIC of amiloride, HMA (Sigma-Aldrich), BB2-50F (unpublished) and BB231F (unpublished) was determined against GAS in vitro. uPA inhibitors BB2-50F
and BB2-31F were developed and provided by Ben Buckley (University of
Wollongong, Australia). Bacteria were harvested at mid-logarithmic phase, washed
twice, and transferred to a 96-well plate in duplicate 100 µL aliquots. To produce
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inhibition profiles, uPA inhibitors in 100% (v/v) DMSO were serially diluted 1:2
across a 96-well plate starting from a stock concentration of 500 µM. Diluted drug
samples in 100 µL volumes were then directly transferred into wells already
containing GAS, and the samples mixed well. The combination of GAS and
inhibitors was incubated overnight at 37 ºC. Control wells consisted of THBY media
only. Samples from each well were spot plated onto THYA, and the concentration of
inhibitor where there was no bacterial growth was determined as the MIC.
4.3.5

Acute toxicity dose determination

To determine the possible toxicity of uPA drug inhibitors in AlbPLG1 mice, cohorts
of 4 age and sex-matched mice were injected IP with 100 µL of HMA, or its novel
drug analogues, BB2-50F and BB2-31F at 2.5, 5 or 10 mg/kg/day. Alternatively, 10
or 20% (v/v) DMSO in 0.7% (v/v) saline was administered as a vehicle control.
Mouse survival was monitored over a 10-day period. Due to the varying solubility of
the compounds, different solvent vehicles were required; compounds were dissolved
in 10% (v/v) DMSO/saline (for 2.5 mg/kg toxicity trial), or 20% (v/v) DMSO/saline
(for 5 and 10 mg/kg toxicity trials). Mice were closely observed twice daily for any
acute adverse responses. Clinical signs of moribund mice such as impaired mobility,
prolonged hunched posture, the ability to remain upright, or severe and rapid weight
loss greater than 20% of initial body weight, resulted in euthanasia.
4.3.6

Efficacy of novel uPA inhibitors against GAS infection

The efficacy of uPA inhibitors in controlling invasive GAS pathogenesis was
initially determined by assessing the bacterial load at the site of infection, and
dissemination of bacteria in internal organs as described in detail in section 2.10.6.
Given that the maximum tested drug dose of 10 mg/kg was well tolerated in mice,
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this dose was considered safe for administration and was therefore selected for the
GAS challenge study. Cohorts of five AlbPLG1 sex-matched mice aged between 812 weeks were pre-treated with either HMA, BB2-50F or BB2-31F at 10 mg/kg in
20% (v/v) DMSO/saline, 20% (v/v) DMSO/saline only (vehicle control), or
erythromycin at 50 mg/kg (positive control) in 10% (v/v) DMSO/saline via an IP
route. An erythromycin treatment group was included as it is a clinically used
antibiotic and provides mice with complete protection against invasive GAS
infection (unpublished). In order to establish a profile examining the effect of these
compounds on GAS pathogenesis, two endpoints were selected; two and three days
post-bacterial infection. Mice were subcutaneously infected with approximately
100µL of 1 x 109 (for two and three day trials), or 100µL of 1 x 107 (three day trial)
CFU/mL GAS strain 5448 under anaesthesia following pre-treatment with each
compound. Mice then received daily IP injections of drugs post-bacterial infection
for the duration of the trial. Alternatively, mice were co-administered with 100µL of
1 x 109 CFU/mL GAS strain 5448 and HMA, BB2-31F, BB2-50F at 80% of their
MIC (section 4.4.5) in 20% (v/v) DMSO/saline, 20% (v/v) DMSO/saline only, or
erythromycin at 50 mg/kg in 10% (v/v) DMSO/saline at a single dose. Mice were
sacrificed at 48 h post-bacterial infection. In all trials, mouse weight and skin lesion
size at the site of infection were recorded daily. Mice were sacrificed at end-point,
and post-sacrifice, skin at the site of initial infection, spleen, liver and blood were
collected in ice-cold sterile PBS and homogenised as described in 2.10.4. Following
serial dilution, wells containing blood, homogenised liver and spleen were plated
onto THYA, while wells containing homogenised skin lesions were plated onto
HBA in order to differentiate between natural flora and GAS colonies. Bacterial
colonies were enumerated the following day.
Page | 96

Chapter 4 Investigating the Potential of uPA as a Therapeutic Target in Invasive
GAS Disease
4.4

Results

4.4.1

uPA can mediate cell surface plasmin acquisition by GAS

The ability of M1T1 GAS strain 5448 to accumulate cell surface plasmin was
assessed in human plasma as described previously (Cole et al. 2006). As expected,
following 3 h incubation in human plasma, the M1T1 parental strain 5448 accrued
significantly higher levels of cell surface plasmin compared to when streptokinase
was absent (5448∆ska), which was only partially attenuated for plasmin acquisition
(Figure 4.1A). When streptokinase function was restored, 5448∆skaRC accumulated
similar levels of plasmin at the surface as wild-type strain 5448 (Figure 4.1A). This
strongly suggests that in the absence of streptokinase, host activators in plasma can
contribute to GAS cell surface plasmin acquisition. We therefore incubated GAS
with purified human plasminogen, uPA or PBS only, or a combination of uPA and
plasminogen. Both GAS strains 5448 and 5448∆skaRC accumulated plasmin at the
cell surface when incubated with plasminogen, while minimal plasmin was acquired
at the cell surface by 5448∆ska, with levels comparable to that of when GAS was
incubated with uPA or PBS only (Figure 4.1B). Upon co-incubation with
plasminogen and uPA, GAS strains bound significantly higher levels of plasmin than
incubation with plasminogen alone (Figure 4.1B). The presence of uPA was
sufficient for GAS mutant 5448∆skaRC to accumulate cell surface plasmin activity.
These data demonstrate that host-activator uPA can mediate GAS cell surface
plasmin acquisition in vitro.
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Figure 4.1 uPA can facilitate GAS cell surface plasmin acquisition. Wild-type GAS strain 5448
(black) and its isogenic mutants 5448∆ska (white) and 5448∆skaRC (grey) were incubated in (A)
human plasma or (B) in the presence of exogenous Glu plasminogen (Glu Plg), uPA or PBS only, or a
combination of Glu Plg and uPA for 3 h at 37 ºC. Upon incubation in human plasma, the absence of
streptokinase partially attenuated cell surface plasmin acquisition by GAS. Co-incubation with
exogenous human Glu Plg and uPA demonstrated that host activator uPA is able to facilitate GAS cell
surface plasmin acquisition in vitro. Bars indicate mean ± SEM, and data represent two independent
experiments performed in triplicate (n = 3). Unpaired two-tailed Student’s t-test was used for analysis
and asterisks indicate statistical significance, **P < 0.005; ***P < 0.001.

4.4.2

Plasmin at the GAS surface can facilitate pro-uPA activation in human

plasma
uPA is synthesised as a single polypeptide chain pro-enzyme (pro-uPA) that
possesses low levels of intrinsic catalytic activity (Pannell and Gurewich 1987). ProuPA is catalysed by plasmin, or other trypsin-specific proteases (but not ska), to
generate the fully active dual-chain uPA. This reciprocal relationship between
plasmin, a result of plasminogen activation and pro-uPA activation, acts as a positive
feedback mechanism that allows for the accumulation of plasmin at the GAS surface.
We therefore investigated the ability of plasmin bound to the GAS cell surface to
catalyse pro-uPA to active uPA, which can lead to a source of unprotected plasmin
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activity, thereby enhancing bacterial dissemination. The presence of GAS in human
plasma resulted in a significant 3-fold enhancement of plasma-derived uPA activity,
monitored using a uPA-specific fluorescent substrate, compared to the activity in
plasma alone (Figure 4.2). In the presence of GAS strains 5448, 5448∆ska and
5448∆skaRC, the initial rate of pro-uPA activation was 10.6±0.928 fluorescence
units (fu)/min, 9.812±0.957 fu/min and 8.635±1.078 fu/min respectively, whilst the
rate in plasma alone was 4.921±0.0215 fu/min. By comparison to a uPA activity
standard curve, the amount of uPA generated by 30 min incubation in plasma was
0.183±0.035 nM in the presence of 5448, 0.144±0.023 nM in the presence of
5448∆ska, or 0.166±0.031 nM in the presence of 5448∆skaRC compared to
0.054±0.018 nM in plasma only. These results show that plasmin accumulated at the
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GAS cell surface can facilitate pro-uPA activation in human plasma.
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Figure 4.2 GAS cell surface plasmin facilitates enhanced pro-uPA activation in human plasma.
In a fluorescence plate assay, human plasma was incubated with or without GAS, and the conversion
of pro-uPA to uPA was monitored overtime with a uPA-specific fluorogenic substrate Z-Gly-GlyArg-AMC. Plasmin bound to the surface of GAS strains 5448, 5448∆ska and 5448∆skaRC were
found to enhance pro-uPA cleavage, where greater uPA activity was detected compared to when
plasma was incubated alone. Background fluorescence containing GAS incubated with PBS only was
subtracted from all values. Assay is representative of four independent experiments performed in
duplicate wells.
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4.4.3

A key role for uPA in a mouse model of GAS infection

Plasminogen acquisition and activation is a key process in a number of bacterial
infections (Sanderson-Smith et al. 2012). However, the exact role of host activators
in GAS pathogenesis remains unclear. Recognising that streptokinase interacts
specifically with human plasminogen, we assessed the contribution of endogenous
uPA in humanised plasminogen transgenic mice (Sun et al. 2004). The ability of
mouse uPA to activate human plasminogen and mediate plasmin acquisition at the
GAS cell surface was first determined in vitro. As expected, significantly higher
levels of plasmin accrued at the bacterial surface when GAS was co-incubated with
human plasminogen and murine uPA than incubation with either plasminogen, or
murine uPA, or PBS alone (Figure 4.3A). This confirmed the ability of murine uPA
to facilitate GAS cell surface human plasmin acquisition in the absence of
streptokinase. We next investigated the survival of mice 10 days post-infection with
GAS strain 5448 in wild-type (AlbPLG1), or uPA-knockout (AlbPLG1/uPA-/-) mice
in a humanised plasminogen background. Mortality of uPA-knockout mice was
significantly lower than wild-type mice following GAS infection (P < 0.01; Figure
4.3B). Deletion of uPA however, did not completely attenuate bacterial virulence in
this infection model, which strongly suggests a potential role for streptokinase, and
potentially the other major host plasminogen activator tPA. Nonetheless, uPA clearly
plays a central role in GAS virulence in vivo as the absence of both streptokinase and
uPA significantly increased the survival rate of mice from 20% to 80% (Figure
4.3B). This was reflected in the reduced ability of GAS to disseminate from the point
of infection into sterile tissue sites. Following subcutaneous inoculation with GAS
strain 5448, significantly less bacteria were recovered in the bloodstream and spleen
of uPA-knockout mice than in wild-type mice 72 h post-infection (Figure 4.3C).
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Bacterial load at the site of infection was equivalent in both mouse lines, indicating
that the differences observed in bacterial dissemination was not reflective of the
ability of GAS to survive at the point of injection (Figure 4.3C). These observations
correlated with the ability of GAS to accumulate significantly less plasmin at the
bacterial surface in plasma harvested from AlbPLG1/uPA-/- than AlbPLG1 mice ex
vivo (Figure 4.3D). These data clearly highlight an important role for uPA in GAS
virulence in vivo, and demonstrate that uPA-mediated plasmin acquisition is
associated with bacterial dissemination.
4.4.4

uPA inhibitors amiloride and tranexamic acid do not inhibit GAS

pathogenesis
Given the role of uPA in facilitating plasminogen activation during invasive GAS
infection in vivo, we next investigated the therapeutic potential of inhibitors targeting
uPA activity and plasminogen activation to control the development of invasive
bacterial infection. We selected amiloride and tranexamic acid due to their extensive
use in humans with minimal adverse effects (Matthews et al. 2011a). In our model,
AlbPLG1 were infected with GAS strain 5448, given daily IP treatment, and the
survival rate and lesion size recorded for 10 days. There were no significant
differences between the survival of mice treated with saline (n = 6-10, depending on
the cohort of treated mice), and mice treated with amiloride at 5 (n = 6), 10 (n = 8) or
20 (n = 8) mg/kg, or tranexamic acid at 20 (n = 12), or 800 (n = 10) mg/kg (Figure
4.4A and C). However, mice treated with 10 mg/kg amiloride showed significantly
smaller lesion sizes than those of control mice. No other significant differences were
observed between lesion sizes for any other dose of amiloride or tranexamic acid
compared to saline control groups (Figure 4.4B and D).
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Figure 4.3 Host plasminogen activator uPA plays a key role in GAS virulence in vivo. (A) Mouse
uPA can activate human plasminogen and facilitate plasmin acquisition to the bacterial surfaces of
5448 (black) and 5448Δska (white). (B) AlbPLG1 mice (n = 10) infected with 5448 (solid line), or
AlbPLG1/uPA-/- (n = 10) infected with 5448 (dashed line) and 5448Δska (dotted line) were monitored
10-days post-subcutaneous GAS infection. The survival of uPA-knockout mice was significantly
increased compared to wild-type mice (P < 0.01). These observations correlated with the ability of
GAS to disseminate in vivo. (C) Tissues of mice (n = 2) were harvested 72 h post-inoculation with
GAS strain 5448. In the absence of uPA, bacterial load in the bloodstream and spleen of
AlbPLG1/uPA-/- (empty circles) was significantly lower than in wild-type AlbPLG1 mice (filled
circles; P < 0.05). Equivalent bacterial counts were recovered at the site of infection in both mouse
lines. (D) Significantly lower levels of plasmin was accumulated at the bacterial surfaces of 5448 (P <
0.001) and 5448Δska (P < 0.05) following incubation in plasma obtained from AlbPLG1/uPA-/- than
in AlbPLG1. Plasmin acquisition assays are representative of two independent experiments performed
in triplicate (n = 3). Bars are mean ± SEM, and significance was determined by unpaired two-tailed
Student’s t-test. Survival data is combined from two independent experiments (n = 20) and analysed
using log-rank test. Dissemination data was combined from three independent experiments (n = 6).
Asterisks indicate statistical significance, ***P < 0.001; *P < 0.05.
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Figure 4.4 Treatment of GAS-infected mice with commercial uPA inhibitors. AlbPLG1 mice
were intradermally infected with approximately 1 x 10 9 CFU/mL GAS strain 5448 and given daily
treatment of amiloride at 5 (■), 10 (▲) or 20 (▼) mg/kg, or tranexamic acid at 20 (■) or 800 (▲)
mg/kg, or 0.7% (w/v) sterile saline control (●) for 10-days. (A and C) Mice survival rate and (B and
D) lesion size formed at the focal point of infection were recorded daily following treatment with
amiloride (n = 6 at 5 mg/kg; n = 8 at 10 mg/kg; n = 8 at 20 mg/kg) or tranexamic acid (n = 12 at 20
mg/kg; n = 10 at 800 mg/kg). Lesion sizes represent data recorded on day 2 and show mean ± SEM
from independent experiments. Asterisks indicate statistical significance, **P < 0.01; n.s., nonsignificant.

4.4.5

Novel uPA inhibitors have antibacterial properties in vitro

The finding that treatment with amiloride may decrease lesion size during GAS
infection suggested the inhibitor may be reducing bacterial burden at the site of
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infection. To explore this further, we employed the amiloride derivative HMA,
which has been used extensively in mouse models and shown to be non-toxic at low
levels (Matthews et al. 2011b). Furthermore, we added to our study the two novel 6substituted HMA analogues, BB2-50F and BB2-31F. These compounds exhibit
approximately 10-fold enhanced inhibitory activity against the proteolytic activity of
purified uPA in vitro compared to HMA, and demonstrate high selectivity for uPA
over other closely related serine ‘off-targets’ (Buckley et al. unpublished).
Additionally, these compounds are non-toxic against mouse or human cell lines in
vitro at concentrations at or below 10 µM (Buckley et al. unpublished). Prior to
assessing the potential therapeutic effect of these inhibitors during GAS infection in
vivo, the MIC of these compounds, in addition to amiloride, against GAS was
assessed in vitro. Overnight incubation of GAS strain 5448 with either drug resulted
in complete growth inhibition of bacteria at 250 µM for HMA and BB2-31F, and at
32 µM for BB2-50F. Amiloride lacked any antimicrobial activity against GAS.
These data demonstrate that HMA, BB2-50F and BB2-31F are more potent than
amiloride, and have antimicrobial effects against GAS in vitro.
4.4.6

Novel uPA inhibitors are non-toxic in humanised plasminogen mice

The tolerability of HMA and its novel analogues, BB2-50F and BB2-31F, was
assessed in AlbPLG1 mice. Mice were administered IP with either drug at 2.5, 5 or
10 mg/kg/day for up to 10 days. At all three doses, mice showed complete survival
following treatment (Figure 4.5A). Signs of normal behavior and no adverse
responses to any treatment including weight loss were observed in mice (Figure
4.5B-D). The delivery of these drugs in AlbPLG1 mice was therefore deemed safe,
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and thus the maximum dose tested, 10 mg/kg, was selected for use in the GAS
infection model.
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Figure 4.5 Survival and weight loss of AlbPLG1 mice during treatment with HMA and
analogues. Cohorts of four age and sex-matched mice were given IP injections of 10 or 20% (v/v)
DMSO/saline (●), HMA (■), BB2-50F (▼) or BB2-31F (▲) at varying doses over 10 days. Mice
were monitored for (A) survival or weight loss during administration of compounds at (B) 2.5 mg/kg,
(C) 5 mg/kg or (D) 10 mg/kg. Each drug dose was administered until completion of each individual
trial. Survival curve is representative of all three drug doses. Weight data are presented as mean ±
SEM (n = 4) of initial body weight.

4.4.7

Novel uPA inhibitors lack systemic antimicrobial effects against GAS in

vivo
To investigate the efficacy of uPA inhibitors against the invasive pathogenesis of
GAS, AlbPLG1 mice were pre-treated IP with uPA inhibitors, erythromycin
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(positive control), or 20% (v/v) DMSO in saline (vehicle control), followed by
subcutaneous infection with GAS strain 5448. The mice then received daily IP
treatment with either drug over 48 or 72 h. No significant difference was observed
for bacterial dissemination (Figure 4.6), lesion size at the point of infection (Figure
4.7), or mean weight loss (Figure 4.8), between treated or control mice for all
endpoints. As expected, erythromycin-treated mice exhibited significantly smaller
lesions at the site of infection (at 48 h, but not 72 h post-GAS infection), and
demonstrated minimal weight loss when compared to the other cohorts (Figure 4.7
and Figure 4.8). To rule out the possibility that a high bacterial inoculum was
interfering with the functions of these compounds in this highly invasive mouse
model, we lowered the GAS infection dose two-fold. As observed for mice infected
with a higher GAS dose, there were no significant differences in bacterial
dissemination, or the bacterial load at the site of infection 72 h post-infection (Figure
4.9A). Similarly, there were no significant differences in lesion size (Figure 4.9B), or
weight loss (Figure 4.9C) for either treatment compared to control mice following a
low GAS infection dose. Erythromycin-treated mice did not display obvious signs of
weight loss (Figure 4.9C). These results demonstrate that under the dosing schedule
and regimen used in this study, administration of HMA and its analogues did not
delay, or prevent the progression of invasive GAS disease in this humanised
plasminogen mouse infection model. However, a trend in the reduced lesion size at
the site of infection following treatment of mice with BB2-31F and BB2-50F,
particularly following a low GAS infection dose was observed, suggesting that an
alternative mode of drug delivery should be considered.
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Figure 4.6 HMA and analogues do not effect the progression of invasive GAS disease in
AlbPLG1 mice given a high dose of GAS. Cohorts of five age and sex-matched mice were pretreated IP with 20% (v/v) DMSO/saline (vehicle control) (●), erythromycin at 50 mg/kg (positive
control) (■), HMA (▲), BB2-31F (▼), or BB2-50F (♦) at 10 mg/kg. Mice were then subcutaneously
infected with GAS strain 5448 at 1 x 109 CFU/mL, and received daily treatment for 48 or 72 h postinfection. Bacterial dissemination was determined in internal organs and in the bloodstream. Data are
presented as Log10 of colony forming units (CFU), and show mean ± SEM (n = 5). Experiments at 48
and 72 h infection time-points were performed independently.
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Figure 4.7 HMA and analogues do not significantly effect lesion size at the site of infection in
AlbPLG1 mice given a high dose of GAS. Cohorts of five age and sex-matched mice were pretreated IP with 20% (v/v) DMSO/saline (vehicle control), erythromycin at 50 mg/kg (positive
control), HMA, BB2-31F, or BB2-50F at 10 mg/kg. Mice were then subcutaneously infected with
GAS strain 5448 at 1 x 109 CFU/mL, and received daily treatment for 48 or 72 h post-infection. Data
show mean lesion size ± SEM (n = 5) at (A) 48 h and (B) 72 h post-GAS infection. Asterisks indicate
statistical significance, ***P < 0.001; **P < 0.01; *P < 0.05.
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Figure 4.8 HMA and analogues do not effect mouse weight in AlbPLG1 given a high dose of
GAS. Cohorts of five age and sex-matched mice were pre-treated IP with 20% (v/v) DMSO/saline
(vehicle control), erythromycin at 50 mg/kg (positive control), HMA, BB2-31F, or BB2-50F at 10
mg/kg. Mice were then subcutaneously infected with GAS strain 5448 at 1 x 10 9 CFU/mL, and
received daily treatment for 48 or 72 h post-infection. Weight data are presented as mean ± SEM (n =
5) of initial body weight at (A) 48 h and (B) 72 h post-GAS infection.
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Figure 4.9 HMA and analogues do not effect the progression of invasive GAS disease in
AlbPLG1 mice given a low dose of GAS. Cohorts of five mice were subcutaneously infected with
GAS strain 5448 at approximately 1 x 107 CFU/mL, following pre-treatment with 20% (v/v)
DMSO/saline (vehicle control) (●), erythromycin at 50 mg/kg (positive control) (■), HMA (▲), BB231F (▼), or BB2-50F (♦) at 10 mg/kg. Mice received daily IP treatment for 72 h. (A) Bacterial counts
in the skin, liver, spleen and bloodstream, (B) mean lesion size recorded on day 3 post-bacterial
infection, and (C) mean mice weight were recorded. Bacterial dissemination is presented as Log10 of
colony forming units (CFU). Data show mean ± SEM (n = 5). Asterisks indicate statistical
significance, *P < 0.05.
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4.4.8

Co-administration of uPA inhibitors and GAS do not have significant

effects against bacterial infection in vivo
It was postulated that the limited effect of the novel uPA inhibitors on systemic GAS
infection may have been due to drug delivery issues resulting in a reduction in the
availability or effective concentration at the site of infection. In a pilot study to
address this, a single dose of the inhibitors were subcutaneously co-administered
with 1 x 109 CFU/mL GAS inoculum, and mice then euthanised at 48 h. As observed
with mice receiving daily treatment, co-administration of GAS and uPA inhibitors
did not affect bacterial dissemination to the liver and spleen, or bacterial load at the
point of infection after 48 h (Figure 4.10A). However, the presence of GAS in the
bloodstream of mice treated with BB2-31F and BB2-50F was significantly reduced,
and complete bacterial clearance was observed in mice treated with HMA. Lesions
in mice treated with either HMA or erythromycin were not measureable, while a
trend in reduced lesion sizes was observed in mice treated with BB2-31F and BB250F (Figure 4.10B). No significant differences in weight loss were observed between
treated and control mice (Figure 4.10C).
4.5

Discussion

The recruitment and activation of plasminogen at the bacterial cell surface is critical
for establishing invasive GAS infection (Sun et al. 2004; Cole et al. 2006;
Sanderson-Smith et al. 2008). Previous studies have highlighted the importance of
host plasminogen activators in plasminogen-mediated bacterial invasion and innate
immune evasion by other pathogens (Lahteenmaki et al. 2001; Sanderson-Smith et
al. 2012). Using a humanised plasminogen mouse infection model, our study
establishes a role for uPA, likely acting in synergy with streptokinase, during GAS
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Figure 4.10 Co-administration of HMA and analogues with GAS strain 5448 did not affect the
progression of invasive GAS disease. Cohorts of five age and gender-matched AlbPLG1 mice were
subcutaneously infected at a single dose of 5448 GAS inoculum at 1 x 109 CFU/mL combined with
20% (v/v) DMSO/saline (control) (●), erythromycin at 50 mg/kg (positive control) (■), HMA (▲),
BB2-31F (▼), or BB2-50F (♦) at 80% of their MIC. Mice were sacrificed two days post-bacterial
infection and (A) bacterial dissemination, (B) mean lesion size, and (C) weight loss determined.
Bacterial dissemination is presented as Log10 of colony forming units (CFU). Data show mean ± SEM
(n = 5). Asterisks indicate statistical significance, **P < 0.01; ***P < 0.001.
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infection. The global significance of GAS associated disease necessitates the
development of safe and effective therapeutics. Given the key role of uPA during
streptococcal infection, the potential to pharmacologically inhibit uPA activity as a
means for delaying GAS infection was investigated.
In the present study, we demonstrate that host uPA significantly increased mice
mortality during invasive GAS infection. Bacterial counts in the bloodstream and
spleen were significantly lower in uPA-knockout compared to wild-type mice. This
correlated with significantly reduced GAS cell surface plasmin acquisition levels in
plasma from uPA-knockout mice, thereby confirming a role for uPA in plasminmediated dissemination. However, uPA-knockout mice in this model developed
subcutaneous skin infection even in the absence of bacterial plasminogen activator
streptokinase. Given the many virulence factors expressed by GAS that contribute to
GAS survival in mice, this finding was not unexpected (Nizet 2007).
Streptokinase is one of the best characterised bacterial plasminogen activators, and
its role in GAS virulence has been extensively studied. Co-administration of GAS
with human plasminogen considerably increases virulence in subcutaneously
infected mice, while inactivation of ska significantly reduces virulence (Khil et al.
2003). Deletion of ska in a humanised skin mouse infection model similarly leads to
a loss in virulence (Svensson et al. 2002). Sun et al. (2004) later confirmed the
species specificity of streptokinase for human plasminogen. The present study
showed that streptokinase-deficient GAS was able to accumulate plasmin at the
bacterial cell surface following incubation in human plasma, and thus streptokinase
was not absolutely necessary for plasminogen activation in vivo. This further
highlights that when streptokinase expression is downregulated during the course of
Page | 112

Chapter 4 Investigating the Potential of uPA as a Therapeutic Target in Invasive
GAS Disease
GAS infection, uPA may act as an alternative source for plasmin generation.
Neutrophils are the first line of innate immune cells to migrate to bacterial infection
sites, and in addition to macrophages and monocytes, have been shown to express
uPA and uPAR on the plasma membrane (Plesner et al. 1994; Kumar and Sharma
2010). The increased expression levels of uPA by these immune cells that circulate
in abundance during infection are therefore advantageous for plasminogen
acquisition and activation by GAS. Furthermore, GAS localised plasmin is protected
from circulating plasmin inhibitors (Sanderson-Smith et al. 2012). Thus, with a high
concentration of unregulated proteolytic activity at the bacterial cell surface, prouPA activation is enhanced by plasmin accrued at the GAS cell surface, leading to a
positive feedback mechanism that results in increased uPA production, and
plasminogen activation by uPA which can both be exploited by GAS.
The role of uPA is not only limited to its function in proteolysis and fibrinolysis. The
uPA system also contributes to inflammation and immunity during bacterial
infection. uPAR is critical for the chemotaxis of neutrophils and monocytes to
infection sites, while uPA has been linked to potentiating neutrophil activation in
vitro (Sitrin et al. 1996; Blasi 1997; Blasi and Carmeliet 2002). In pulmonary mouse
infection models, the deletion of uPA reduced accumulation of inflammatory cells in
response to intratracheal infection with Pneumocystis carinii, and prevents the
clearance of bacteria, resulting in uncontrolled infection (Beck et al. 1999; Rijneveld
et al. 2002). Similar results have been described for the opportunistic fungus
Cryptococcus neoformans (Gyetko et al. 1996). A later study found that in the
absence of uPA, phagocytosis, respiratory burst, and degranulation by neutrophils is
impaired (Gyetko et al. 2004). In another study, antibacterial properties by uPA have
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been described against staphylococcal infection in a sepsis mouse model (Jin et al.
2005). Thus, uPA may act as a pro-inflammatory mediator during the course of
bacterial infection, or promote bacterial dissemination during GAS infection in vivo.
Given the contribution of uPA to GAS pathogenesis, we attempted to modulate uPA
activity in vivo to potentially improve host defence against GAS in the humanised
plasminogen mouse model. We assessed the efficacy of commercial inhibitors
amiloride and tranexamic acid that target uPA and plasminogen activation
respectively, and found that treatment of mice with either of these inhibitors at
increasing doses was not associated with significantly increased mouse survival.
Whilst amiloride selectively inhibits uPA, and not tPA or other serine protease
members of the trypsin superfamily, it displays only moderate potency against uPA
activity (Nienaber et al. 2000; Matthews et al. 2011b). Despite this, treatment with
amiloride resulted in a reduction in lesion size at the site of infection in AlbPLG1
mice. We extended this observation with the use of new uPA inhibitors including the
amiloride derivative HMA, and two previously undescribed novel derivatives of
HMA, BB2-31F and BB2-50F, that were developed in-house. HMA belongs to a
family of 6-substituted amiloride, has a reported two-fold higher potency than
amiloride as a uPA inhibitor, and demonstrates robust anticancer effects in animal
models (Matthews et al. 2011a; Matthews et al. 2011b). Preliminary data
demonstrates significantly increased potency against uPA (in nanomolar range) by
BB2-50F and BB2-31F in vitro (Buckley et al. unpublished). We found that HMA,
BB2-50F and BB2-31F had antimicrobial activity against GAS in vitro, whilst
amiloride did not. These compounds therefore displayed dual activity; inhibition of
uPA proteolytic activity, and an antimicrobial effect against GAS in vitro. However,
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in our GAS challenge model, targeting uPA-mediated plasminogen activation and
GAS by these compounds did not significantly diminish bacterial dissemination in
humanised plasminogen mice following 48 and 72 h post-bacterial infection at a high
or low (72 h only) infection dose. It may be that daily IP administration of these
compounds was not sufficient to inhibit uPA activity in this mouse infection model.
Subsequent to these in vivo studies, detailed analyses of BB2-31F and BB2-50F
indicated that these particular HMA derivatives have a short metabolic half-life
when compared to amiloride, which is reported to have a plasma half-life of
approximately six to nine hours (Vidt 1981). This suggests that low levels of active
compound reached the point of infection (Buckley, personal communication). We
therefore investigated an alternative mode of drug delivery via subcutaneously coadministering GAS and inhibitors at a single dose. While there was no significant
difference in bacterial dissemination to the liver and spleen in treated versus control
mice, GAS in the bloodstream of mice treated with BB2-31F and BB2-50F was
significantly reduced compared to control mice, with complete clearance in HMAtreated mice observed. Although not significant, lesion sizes were also noticeably
reduced in mice following co-administration of HMA derivatives and GAS. In all
trials, erythromycin treatment completely cleared GAS infection within 48 h in the
bloodstream. While the mechanism of action for erythromycin is well-known, this
antimicrobial aspect of HMA, BB2-31F and BB2-50F has yet to be explored.
Furthermore, these compounds are less effective against mouse uPA than human
uPA in vitro (Buckley et al. unpublished). However, BB2-31F and BB2-50F have
similar potencies to amiloride against murine uPA (Buckley et al. unpublished), and
thus may affect the efficacy of these compounds in a mouse model in vivo. Since
these studies, more stable HMA derivatives with potent uPA inhibitory activity and
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longer metabolic half-lives have been identified, which may be of interest in future
studies. Additionally, intravenous administration of these compounds following
GAS infection would ensure that active compounds were reaching the site of
infection. To date, mice expressing human uPA have yet to be established. However,
Lund et al. (2008) have generated a murine inhibitory monoclonal antibody (mU1)
specifically targeting mouse uPA that exhibits therapeutic potential. Systemic
administration of recombinant mU1 rescues mice infected with a uPA activitydependent bacterial pro-toxin, while its administration in tPA-deficient mice
successfully impairs uPA-mediated fibrinolysis, as well as delaying skin wound
healing (Carmeliet et al. 1994; Lund et al. 2008; Jogi et al. 2010). Further testing
with murine uPA antagonists may therefore better control GAS infection in vivo.
A functional overlap between uPA and tPA has been suggested in several studies.
Skin wound healing in uPA- or tPA-deficient mice was found to be indistinguishable
from the healing of wild-type mice (Lund et al. 2006), and in an earlier study, uPA
was shown to be capable of fibrin clearance in the absence of tPA in vivo (Bugge et
al. 1996a). Furthermore, disruption of genes encoding either uPA or tPA, did not
affect the phenotype of these mice when compared to wild-type mice. These findings
may therefore reflect the ability of tPA to act as a substitute in the absence of uPA,
or when uPA-mediated plasminogen activated is inhibited. In the mouse model
presented in this study, both streptokinase and the other major host activator tPA are
available as mediators of plasminogen activation, and may therefore provide an
alternative source for plasminogen activation and acquisition by GAS. Thus,
therapeutics that target and inactivate these potent plasminogen activators may be
required to fully control invasive GAS infection.
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In conclusion, our study reveals for the first time a key role for uPA in invasive GAS
disease in a newly described uPA-knockout humanised plasminogen mouse infection
model. Whilst treatment with the selected compounds appeared to have no
immediate effect on the progression of invasive GAS disease following bacterial
challenge, compounds that are more potent against murine uPA with improved
pharmacokinetic properties should be pursued in future studies.
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Reference:
Diane Ly, Deborah Donahue, Mark J Walker, Victoria A Ploplis, Jason D McArthur,
Marie Ranson, Frank J Castellino, Martina L Sanderson-Smith (2016).
Characterising the role of tissue-type plasminogen activator in a mouse model of
Group A streptococcal infection. Submitted to Virulence as a Brief Report (April,
2016).
5.1

Abstract

The glycoprotein plasminogen is central to the human fibrinolytic system, and
recruitment of its active form plasmin to the bacterial cell surface is critical for
invasive disease initiation by GAS. A key role for uPA in bacterial dissemination
was recently reported. However, the contribution of the other major host activator,
tPA, to GAS pathogenesis remains largely unexplored. Using tPA-deficient
humanised plasminogen mice, we show that whilst exogenous sources of either
human or mouse tPA alone were sufficient to mediate human plasminogen activation
at the bacterial surface, no significant difference in the survival of AlbPLG1
compared to AlbPLG1/tPA-/- mice was seen 10-days post-infection. Similarly, no
difference was detected in bacterial dissemination, skin lesion size or the pathology
of GAS infection in the absence of tPA. These data suggest that host tPA plays a
limited role in this humanised subcutaneous mouse model of invasive GAS
infection, and further highlights the importance of its counterpart uPA in invasive
GAS disease.

Page | 119

Chapter 5 Investigating the Role of tPA in a Mouse Model of Invasive GAS Disease
5.2

Introduction

One of the central mechanisms of host-GAS invasion is immobilisation of
plasminogen to the GAS cell surface. The subsequent conversion to plasmin drives
the unregulated proteolytic destruction of surrounding host-tissue barriers, and thus
facilitates bacterial dissemination and evasion of the host innate immune response
that contributes to GAS pathogenesis and the global disease burden (Coleman and
Benach 1999; Carapetis et al. 2005; Nizet 2007; Walker et al. 2014).
The secreted GAS plasminogen activator, streptokinase, plays an integral role in
plasminogen-dependent streptococcal virulence, whilst the contribution of hostderived uPA in invasive GAS disease was recently demonstrated using a humanised
plasminogen uPA-knockout mouse model of GAS disease (Sanderson-Smith et al.
2013). Whether host plasminogen activator tPA contributes to GAS infection is
unclear. However, for a number of other highly pathogenic organisms, the activation
of cell-bound plasminogen can be mediated by host-derived uPA or tPA. Enhanced
tPA-mediated activation of cell-bound plasminogen has been demonstrated for E.
coli, Helicobactor pylori, Neisseria meningitides and Group A, C and G
streptococci, while either uPA- or tPA-mediated plasminogen activation at the
surfaces

of

Salmonella

typhimurium,

Borrelia

burgdorferi,

Streptococcus

pneumoniae, Streptococcus agalactiae, and Mycoplasma fermentans promotes
degradation of ECM components and leads to plasmin-mediated migration through
endothelial and epithelial cell layers (Kuusela et al. 1992; Yavlovich et al. 2001;
Lahteenmaki et al. 2005; Magalhaes et al. 2007; Sanderson-Smith et al. 2012).
Whilst uPA and tPA share the common ability to activate human plasminogen, they
have distinct protein structures, tissue specificity, and biological activities, which
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suggests that these host activators may play different roles during bacterial infection
(Collen 2001). We therefore explored the contribution of tPA during invasive GAS
disease using a novel mouse model of infection.
5.3

Methods and materials

5.3.1

Animals

The role of tPA in GAS virulence was assessed using humanised plasminogen
transgenic mice (AlbPLG1) (Sun et al. 2004) and mice deficient in tPA on the same
genetic background (AlbPLG1/tPA-/-). tPA-knockout mice on a C57BL/6 background
were constructed by replacing tpa (PLAT) with a neomycin-resistant cassette
(Carmeliet et al. 1994), and subsequently backcrossed with AlbPLG1 mice to
generate humanised plasminogen mice depleted in tPA expression. Plasminogen and
tPA-deficient mouse genotypes were confirmed via PCR of an ear punch as
described previously (Carmeliet et al. 1994; Sun et al. 2004). In our animal
experiments, cohorts of eight age and sex-matched mice between 6-10 weeks old
were intradermally inoculated with approximately 1 x 109 CFU/mL of wild-type
GAS strain 5448, and their survival monitored over a 10-day period.
5.3.2

Histology

Cohorts of five (AlbPLG1/tPA-/-) or four (AlbPLG1) mice were infected with 4 x 109
CFU/mL of wild-type GAS strain 5448 and after 48 h, lesions at the site of infection
were excised for histopathology analysis. Following overnight fixing in 4% (w/v)
PFA, tissues were processed using an ASP200 automated vacuum tissue processor
(Leica) according to the protocol outlined in Table 5.1. Skin lesions were embedded
in paraffin blocks using an EG1150 paraffin-embedding station (Leica), and were
subsequently sectioned at 5 µm onto lysine-coated Snowcoat microscope slides
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(Leica). Microscope slides were incubated at 65 °C for 20 min prior to staining to
facilitate adherence of paraffin-embedded tissue sections to the microscope slide.
Skin lesions were stained with hematoxylin and eosin (H&E) for gross examination,
Gram’s violet solution for identification of GAS, or probed for fibrin(ogen) via
immunohistochemistry.
Table 5.1 Automated tissue processing protocol.

Solution
1. Formalin
2. 70% ethanol
3. 90% ethanol
4. 100% ethanol
5. 100% ethanol
6. 100% ethanol
7. 100% ethanol
8. Xylene
9. Xylene
10. Xylene
11. Paraffin
12. Paraffin
13. Paraffin

Time (min)
5
10
10
20
20
30
45
20
30
45
20
30
45

Temperature (°C)
37
37
37
37
37
37
37
37
37
37
65
65
65

For H&E staining, sections were manually processed as outlined in Table 5.2. For
GAS detection, slides were initially stained with crystal violet (1 min), followed by
iodine (1 min), decolourisation with 95% (v/v) ethanol (30 sec), and counterstained
with safranin (1 min). GAS (Gram positive bacterium) stained as purple using this
method. For the detection of fibrin(ogen), the heat induced epitope retrieval (HIER)
method was utilised. Firstly, tissue sections were deparaffinised (Table 5.3) to
facilitate optimal tissue staining. Antigen retrieval was performed via incubating
tissue sections in sodium citrate buffer (Appendix A) for 20 min at 95 °C. Between
all incubations, slides were washed thrice for 5 min in tris-buffered saline (TBS;
Appendix A). Endogenous peroxidase activity was quenched by incubating slides
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with 1% (v/v) H2O2 in PBS for 20 min, followed by blocking overnight with normal
goat serum (1:5 dilution in TBS with 1% (w/v) BSA; Life Technologies).
Fibrin(ogen) was probed with rabbit anti-fibrinogen (1 µg/mL in TBS; Abcam) at 4
°C overnight, followed by HRP-conjugated goat anti-rabbit IgG (1:250 in TBS) for 1
h. Bound HRP was visualized via 3,3 diaminobenzidine tetrachloride (DAB) staining
and counterstained with haematoxylin for approximately 1 min. Coverslips were
mounted onto microscope slides using Safety Mount (Fronine, Riverstone. Australia)
and sealed with varnish. All stained slides were examined using the Leica Leitz
DMRB microscope.
Table 5.2 Haematoxylin and eosin staining protocol.

Solution
1. Xylene
2. Xylene
3. 100% ethanol
4. 100% ethanol
5. Water bath
6. Harris haematoxylin
7. dH2O
8. Acid alcohol
9. dH2O
10. Scotts blueing solution
11. dH2O
12. 1% aqueous eosin
13. 100% ethanol
14. 100% ethanol
15. Xylene
16. Xylene

Time (sec)
90
60
90
10
60
120
120
1
60
60
60
20
60
45
10
60

Table 5.3 Deparaffinisation of paraffin-embedded tissue protocol.

1.
2.
3.
4.
5.
6.
7.

Solution
Xylene (x2)
100% ethanol
95% ethanol
85% ethanol
70% ethanol
50% ethanol
dH2O (x2)
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5.4

Results

5.4.1

Host activator tPA mediates GAS cell surface plasmin acquisition in vitro

GAS sequesters high levels of cell surface plasmin when incubated in human plasma
and we have previously demonstrated that this mechanism can be mediated by host
activator uPA (Sanderson-Smith et al. 2013). The activation of plasminogen bound
to the GAS cell surface by exogenous tPA was previously shown (Kuusela et al.
1992). We therefore confirmed the ability of tPA to mediate cell surface plasmin
acquisition by GAS via incubation in the presence or absence of exogenous tPA. As
expected, wild-type GAS strain 5448, which expresses the potent plasminogen
activator streptokinase, accumulated high levels of cell surface plasmin when
incubated with human Glu-plasminogen (Figure 5.1A). However, in the absence of
streptokinase, human tPA was able to mediate cell surface plasmin acquisition by
GAS strain 5448Δska, with levels comparable to that of wild-type GAS strain 5448
and reverse-complemented ska strain 5448ΔskaRC (Figure 5.1A). In the absence of
streptokinase, mouse tPA was also able to facilitate plasmin acquisition at the cell
surface of GAS strain 5448Δska (Figure 5.1B). These results confirm that exogenous
sources of both human and mouse-derived tPA can facilitate human plasminogen
activation at the bacterial cell surface in vitro, suggesting a potential role for tPA in
the development of GAS disease.
5.4.2

tPA plays a limited role in GAS survival and bacterial dissemination in vivo

We next investigated whether tPA contributes to invasive GAS disease in vivo using
humanised

plasminogen

tPA-knockout

mice

(AlbPLG1/tPA-/-).

Mice

were

intradermally inoculated with 1 x 109 CFU/mL of GAS strain 5448 and their survival
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Figure 5.1 Host-derived tPA mediates cell surface plasmin acquisition by GAS. GAS strains 5448
(black), 5448∆ska (white) and 5448ΔskaRC (grey) were incubated for 1 h at 37 °C with either 3 IU
(A) human or (B) mouse tPA, 0.5 mg/mL Glu-plasminogen (Glu-Plg), tPA and Glu-Plg, or PBS only.
After removing unbound plasmin(ogen), bacteria were incubated overnight with the plasmin-specific
chromogenic substrate S-2251, and subsequent plasmin activity levels were measured at 405 nm. Data
represent three independent experiments performed in triplicate (n = 3). Asterisks indicate statistical
significance, ***P < 0.001; *P < 0.05.

monitored over 10 days. No significant difference was seen in the survival rates of
AlbPLG1 versus AlbPLG1/tPA-/- mice, with infection resulting in 50% and 56%
mortality, respectively (Figure 5.2A). Similarly, no differences were detected in
bacterial loads in the spleen, liver and blood harvested from AlbPLG1 versus
AlbPLG1/tPA-/- mice (Figure 5.2B), or the ability of GAS to sequester plasmin at the
cell surface in plasma obtained from tPA-deficient mice in the absence of
streptokinase (Figure 5.2C). These results strongly suggest that in this particular
mouse model of infection, tPA does not significantly contribute to GAS
dissemination and invasive disease progression.
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Figure 5.2 tPA does not contribute to disease progression in a mouse model of invasive GAS
infection. Cohorts of eight aged and sex-matched AlbPLG1 (●) and AlbPLG1/tPA-/- (▪) mice were
intradermally inoculated with 1 x 109 CFU/mL wild-type GAS strain 5448 and (A) the survival of
mice monitored over 10 days, or (B) infected with 4 x 109 CFU/mL GAS and the bacterial load
determined in organs and blood of mice 48-72 h post-infection. (C) GAS cell surface plasmin
acquisition was performed ex vivo by incubating GAS strains 5448 (black) or 5448Δska (white) in
plasma from AlbPLG1 or AlbPLG1/tPA-/- mice, or PBS only for 3 h at 37 °C. Survival data represent
two independent experiments (n = 16), dissemination data represent three independent experiments (n
= 9) and cell surface plasmin acquisition data represent two independent experiments performed in
triplicate (n = 2).

5.4.3

Pathology of GAS infection is unaffected by the absence of tPA

Central to host defence against invading pathogens is the infiltration of immune cells
to the site of bacterial infection. To further elucidate the impact of tPA in GAS
disease, the presence of bacteria and histopathological changes at the site of GAS
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infection were examined. Following infection of mice with wild-type GAS strain
5448, all excised skin lesions revealed hallmarks of invasive infection including
severe inflammation of muscle and necrosis of fascia, dermis and epidermis in both
wild-type and tPA-knockout mice. Both mouse lines displayed an influx of
infiltrating immune cells, which was most abundant at the boundaries of necrotic
fascia, but was less evident in GAS-enriched regions. Gram staining confirmed a
high bacterial load in fascia, and fibrin deposits were comparable in all sections of
both AlbPLG1 and AlbPLG1/tPA-/- mice (Figure 5.3A). Furthermore, there were no
significant differences observed in the bacterial load (Figure 3B), or lesion sizes at
the site of GAS infection of AlbPLG1 compared with AlbPLG1/tPA-/- mice (Figure
5.3C).
5.5

Discussion

GAS is a highly significant human pathogen, and understanding host-pathogen
interactions is central to the development of potential therapeutics for the treatment
of severe GAS infection. GAS has evolved to interact with multiple components of
the host fibrinolytic system, and the ability of GAS to sequester and activate cellbound plasminogen is important for bacterial cell migration and invasive disease
initiation (Sun et al. 2004; Cole et al. 2006; Sanderson-Smith et al. 2008). We
therefore sought to characterise the role of the eukaryotic plasminogen activator tPA
in a mouse model of invasive GAS infection. This is the first study to report on the
contribution of tPA in a mouse model of GAS virulence. Despite being able to
mediate plasminogen activation at the GAS cell surface in vitro, tPA depletion did
not significantly alter the pathology of GAS invasive disease following subcutaneous
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Figure 5.3 Immune cell recruitment and fibrin deposition was unaffected in AlbPLG1/tPA-/- mice
compared to AlbPLG1. Mice were challenged with 4 x 109 CFU/mL GAS and 48-72 h postinfection, skin wounds were (A) prepared for histological analysis, (B) enumerated for bacterial load
or (C) measured for size. Photomicrographs are representative of paraffin-embedded sections from
five (AlbPLG1/tPA-/-) or four (AlbPLG1) mice stained with Gram’s crystal violet solution, H&E or for
fibrin deposition. Fibrin deposits were detected using HIER antibody retrieval method, followed by
labelling with rabbit anti-fibrinogen and HRP-conjugated anti-rabbit, and the reaction visualised via
DAB staining methods. Numbered arrows indicate the following: 1, streptococci; 2, infiltrating
inflammatory cells; 3, fibrin deposition. All magnifications are 50x. Images are representative of six
sections from four (AlbPLG1) or five (AlbPLG/tPA-/-) mice.

challenge in a humanised plasminogen mouse model of infection. As previously
shown, both human and mouse tPA were able to facilitate GAS cell surface plasmin
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acquisition in the absence of streptokinase and uPA (Berge and Sjobring 1993;
Sanderson-Smith et al. 2013). However, mortality and bacterial dissemination did
not differ between wild-type AlbPLG1 and AlbPLG1/tPA-/- mice following GAS
infection. Likewise, histological analysis showed no differences in the inflammatory
response in the absence of tPA at the site of initial GAS skin infection. These data
indicate that the absence of tPA alone is insufficient to attenuate GAS virulence
following subcutaneous challenge in this humanised mouse model of infection.
In studies of other bacterial infections, a dual role has been reported for tPA. In E.
coli, Klebsiella pneumoniae and Mycobacterium avium infection models, tPA is an
important factor for the survival of the host. E. coli commonly causes abdominal
sepsis and urinary tract infections (Barnett and Stephens 1997; Bosscha et al. 1997).
tPA deficiency during abdominal sepsis is associated with reduced survival and
increased bacterial dissemination from the primary site of infection in a mouse
model (Renckens et al. 2006), while Roelofs et al. (2009) reported that bacterial
clearance by neutrophils in tPA-depleted mice was significantly impaired during
acute pyelonephritis. Similarly, treatment of mice with high levels of recombinant
tPA improved host survival and attenuated damage of organs against infection with
Klebsiella pneumoniae, while recombinant tPA was found to prevent abdominal
abscess formation in a rat model of secondary peritonitis (Buyne et al. 2008;
Renckens et al. 2008). Furthermore, bacterial dissemination was found to progress
faster in the absence of endogenous tPA in a systemic model of Mycobacterium
avium infection (Sato et al. 2003). In contrast to the aforementioned studies, an
adverse role has been described for host tPA during sepsis caused by Burkholderia
pseudomallei, the causative agent for melioidosis. Plasma samples obtained from
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patients diagnosed with melioidosis have elevated levels of tPA, and a recent study
found that in a mouse model of sepsis, tPA deficiency resulted in higher survival
rates, reduced bacterial burden in lung tissue, and attenuated lung injury (Wiersinga
et al. 2008; Kager et al. 2012). Collectively, these studies clearly demonstrate
diverse roles for tPA during inflammation and sepsis, whereby it can either enhance
bacterial invasion or host defence. This duality may result from differences in the
pathogenic mechanisms employed by the various infectious agents, such as the
intracellular or extracellular residency of the bacterium (Kager et al. 2012).
Despite divergence in their basic biological functions, a growing body of evidence
has shown that uPA and tPA can function as complementary plasminogen activators
by regulating the formation of plasmin. Previous studies have shown that while tPA
mediates clot-restricted plasminogen activation and increases the efficiency of fibrin
clearance, it is not essential for fibrin degradation or skin wound healing (Hoylaerts
et al. 1982; Bugge et al. 1996a). This supports the observation in the present study
that extravascular fibrin deposition appears to be equivalent in both wild-type and
tPA-knockout mice in response to GAS infection. Studies in skin wound healing
show that mice lacking tPA have reduced thrombolytic potential as well as a slight
delay in skin wound closure (Carmeliet et al. 1994; Bugge et al. 1996a; Lund et al.
2006). Similar characteristics were also reflected in uPA-deficient mice (Carmeliet et
al. 1994). In contrast, uPA and tPA double deficient mice display characteristics akin
to mice depleted of plasminogen, where higher incidences of spontaneous fibrin
deposition and in more organs than singly deficient mice were observed, as well as a
significant impediment in skin wound healing time (Carmeliet et al. 1994; Lund et
al. 2006). Thus, in the absence of tPA, uPA can produce sufficient fibrinolytic
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activity to mediate clearance of fibrin deposits from tissues and also support gross
skin wound healing (Bugge et al. 1996a; Lund et al. 2006). Furthermore, circulating
plasma kallikrein also activates plasminogen, albeit less efficiently than uPA and
tPA in vitro (Miles et al. 1983). A role for plasma kallikrein as a plasminogen
activator during skin wound healing in mice has been identified (Lund et al. 2006).
In addition to host activators, GAS secretes the potent human-specific plasminogen
activator streptokinase (Marcum and Kline 1983). The interaction between
streptokinase and plasminogen is critical for the pathogenesis of GAS and represents
one of the most well-studied streptococcal virulence mechanisms (Sun et al. 2004;
McArthur et al. 2012; Cook et al. 2014). Local fibrin formation is essential for GAS
containment and preventing bacterial spread. The ability of streptokinase to hijack
the host fibrinolytic system to overcome immune surveillance and barrier functions
renders streptokinase-dependent plasminogen activation a key process in GAS
virulence (Sun et al. 2004; Sun et al. 2009). Furthermore, streptokinase-mediated
plasminogen activation is shielded from circulating scavengers of plasmin, and
therefore provides an unregulated source of plasmin activity for acquisition by GAS.
In the mouse model described in this work, both uPA and streptokinase were
available as mediators of plasminogen activation and plasmin acquisition to the
bacterial cell surface. Therefore, the limited contribution of tPA in disease
progression further emphasises the importance of uPA and streptokinase as
plasminogen activators during GAS virulence. Further, our data highlights the ability
of eukaryotic plasminogen activators to serve as complementary factors that can
individually function in the absence of one another.
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Despite the findings of the current study, we are unable to rule out a role for tPA
during human infection with GAS. The humanised plasminogen mouse model is the
most commonly used animal infection model for exploring host-GAS interactions
and understanding GAS virulence mechanisms. In contrast to the in vivo model used
in this study, the use of other streptococcal infection mouse models which employ
alternative routes of bacterial challenge might reveal a role for tPA in GAS
virulence.
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GAS is a globally significant, human-restricted bacterial pathogen responsible for
high rates of morbidity and mortality. GAS is placed amongst the world’s top ten
human pathogens, and is ranked as the fourth most significant cause of bacterialassociated deaths (WHO 2005). Uncomplicated throat and skin infections including
pharyngitis and impetigo are common clinical manifestations of GAS colonisation
and despite being treatable, the cost of pharyngitis in the USA alone is estimated to
be an unprecedented $538 million per year (Pfoh et al. 2008). GAS can also cause
systemic infection, resulting in serious and life-threatening conditions, of which
STSS and necrotising fasciitis are the major burden of morbidity and mortality
worldwide (Walker et al. 2014). GAS infections impact countries on a global scale,
with over 600 million infections reported annually (Carapetis et al. 2005). Thus,
understanding GAS virulence mechanisms and development of suitable and effective
treatment to control GAS infection is necessary. Despite intensive research efforts to
understand the GAS-host relationship, the precise molecular mechanisms of GAS
virulence and pathogenesis remain elusive. In this study, we employed animal
models to elucidate the impact of plasmin acquisition by GAS on innate immune
factors, and characterised the role of host plasminogen activators in invasive GAS
disease (Figure 6.1).
Whilst GAS exhibits multiple virulence factors that contribute to complement
evasion, here we describe for the first time that the acquisition of surface-associated
host plasmin(ogen) confers GAS protection from neutrophil killing and increased
GAS survival in vivo. We cannot exactly pinpoint whether it is the contribution of
plasminogen or active plasmin to these findings. It is likely that a combination of
both plasminogen at the GAS surface acting as a blocking molecule, and plasmin-
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Figure 6.1 Proposed model for the impact of plasmin(ogen) acquisition on complement-mediated neutrophil killing by GAS in the host. (A) The NS88.2 M protein
Prp binds plasminogen (plg) at the GAS cell surface which can be activated to plasmin by uPA, tPA, or streptokinase (SK) in vitro. The present study found that (B)
plasmin at the GAS cell surface partially degraded C3b in vitro, and surface-associated plasminogen acquisition correlated with decreased (C) C3b deposition on the
bacterial surface and (D) complement-mediated neutrophil killing in vitro. We hypothesise that the reduced bacterial opsonisation is due to either plasmin-mediated
degradation and/or plasminogen blocking of C3b at the GAS surface. Altogether, in a humanised plasminogen GAS infection mouse model, plasmin(ogen) acquisition by
GAS paralleled decreased C3b deposition, protection from neutrophil phagocytosis, and increased GAS survival in vivo. This was dependent on the presence of uPA/SK,
but not tPA.
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mediated C3b degradation preventing effective opsonisation. Recently it was shown
that plasminogen binds to C3b (Barthel et al. 2012a). However, active plasmin both
in fluid-phase and surface-bound, although incompletely cleaving C3b, lead to
complement inhibition via blocking C3 convertase activity, as also shown for C5.
Thus, in addition to deactivating complement proteins in plasma, plasmin is also
capable of blocking all three major complement pathways (Pillemer et al. 1953;
Barthel et al. 2012a). This highlights the potential for plasmin at the GAS cell
surface to impact on other complement pathways, and suggests that GAS-generated
plasmin may be utilised to avoid different stages of complement attack. Degradation
of other critical complement factors by bacterial-associated plasmin has been
demonstrated for some pathogens (Ramu et al. 2007), as well as a role for plasmin in
the infiltration of inflammatory cells to sites of a bacterial infection (Ploplis et al.
1998; Busuttil et al. 2004). Thus, the consequence of protease activity at the GAS
surface on other major immune cells including macrophages, and innate immune
effectors involved in bacterial clearance should be pursued. Expansion of the present
study in C3-deficient mice on a humanised plasminogen background would also be
beneficial. Previous data has shown that host defence in C3-deficient mice is
significantly impaired following infection with Streptococcus agalactiae or
Streptococcus pneumoniae (Wessels et al. 1995; Circolo et al. 1999). The role of the
complement system in host defence against GAS infection in vivo is yet to be fully
explored.
In addition to the regulatory role of uPA and tPA as activators in fibrinolysis,
research in the past few decades has focused on the significance of plasminogen
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activation in thrombolytic therapy (tPA) and cancer invasion (uPA). Only recently
has the contribution of these activators to bacterial pathogenesis received attention.
Our study using a uPA-deficient humanised plasminogen mouse model provides
strong evidence that uPA may serve as an alternative source for plasmin generation
during the course of GAS infection when streptokinase expression is downregulated. Thus we conclude that host uPA significantly contributes to GAS invasive
infection. Interestingly, Borrerlia burgdorferi, which does not secrete its own
protease, binds human plasminogen and uPA to the bacterial cell surface as a
mechanism to facilitate dissemination and localisation of spirochetes to sites of
vascular injury (Klempner et al. 1995). In our own investigations, we were unable to
identify any GAS cell surface receptors for uPA (data not shown). During infection
with S. aureus, PAI-1 levels were inversely related to active uPA levels (Jin et al.
2005). Investigation of PAI-1 levels in plasma during streptococcal infection, as well
as the analysis of C3b deposition on the bacterial surface following GAS infection in
uPA-deficient mice should be considered.
Given our findings of a role for uPA in GAS virulence, we investigated the selective
inhibition of plasmin activity to potentially control GAS infection in vivo. Based on
previous studies, the use of small molecules to block uPA-driven activity in mice has
exhibited therapeutic potential (Lund et al. 2008; Jogi et al. 2010). We found that in
a humanised plasminogen mouse model, commercially available and novel uPA
inhibitors developed in-house lacked systemic effect against GAS infection.
However, a reduction in lesion size was observed in mice treated with BB2-31F and
BB2-50F, which displayed antimicrobial activity against GAS in vitro. This suggests
that an alternative mode of drug delivery, such as an intravenous route, might reveal
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a significant effect on the development of skin lesions during infection. Identification
of other compounds, or fine-tuning of the current compounds with improved plasma
half-life and increased potency against mouse uPA may also be necessary to better
control GAS infection in this mouse model. Future studies evaluating the candidacy
of these compounds as antimicrobial treatments against GAS skin infections can be
performed using the murine tape-stripping superficial skin infection model
(Kugelberg et al. 2005). This model has successfully identified a topical treatment
for S. aureus infections (Hu et al. 2010).
In the mouse model employed in our study, host tPA had a limited role in invasive
GAS disease. Despite being able to mediate plasminogen activation at the bacterial
cell surface in the absence of streptokinase and uPA in vitro, tPA depletion did not
influence the survival of mice, or alter the pathology of invasive GAS disease. This
suggests that tPA is not predominantly involved in GAS infection in this highly
invasive humanised plasminogen mouse model, however, a role for tPA in GAS
virulence cannot be completely dismissed.
To date, there is no single comprehensive animal model that accurately mimics the
pathogenesis of any GAS disease (Watson et al. 2016). The mouse model is the most
utilised in vivo system for the dissection of GAS-host interactions. Components of
the murine and human fibrinolytic system are largely similar, however, there are
some differences to be noted, such as a greater resistance to activation by human tPA
of murine plasminogen than human plasminogen (Lijnen et al. 1994). It is also
known that the susceptibility to GAS infection varies significantly between mouse
strains, as a result of differences in host genetic factors (Medina and Lengeling
2005). tPA is a clot-restricted plasminogen activator, and has a high affinity for
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fibrin. It may be that the highly invasive, systemic mouse model used in this study
was not sufficient to assess the contribution of tPA. A previous study has
demonstrated a role for fibrin clots in host defence against GAS pathogenesis (Sun et
al. 2004). The formation of a blood clot in either an abrasive or incisional superficial
skin wound healing model in tPA-knockout mice following GAS infection may
elucidate a possible role for tPA-mediated plasminogen activation in GAS virulence
(Dai et al. 2011; Watson et al. 2016). Alternatively, intravenous infection, whereby
GAS gain direct access to tPA expressing endothelial cells may also provide
additional insight. Moreover, infection of tPA-knockout mice with a ska-deficient
GAS strain would address the possibility that the presence of streptokinase may be
masking the role of tPA. However, in our studies in uPA-knockout mice, there was a
clear decrease in GAS virulence, even in the presence of ska expression (SandersonSmith et al. 2013).
uPA and tPA can function as complementary plasminogen activators (Carmeliet et
al. 1994; Carmeliet and Collen 1996). In the absence of tPA, uPA provides sufficient
proteolytic activity to facilitate clearance of fibrin deposits and support skin wound
healing (Miles et al. 1983; Lund et al. 2006). A future endeavor may therefore be to
challenge doubly deficient plasminogen activator mice with GAS to further elucidate
the roles of uPA and tPA in GAS pathogenesis. However, these mice demonstrate
shorter lifespan, reduced fertility and commonly experience rectal prolapse and
fibrin deposition in multiple organs, which suggests that they would be significantly
compromised upon GAS infection (Carmeliet et al. 1994). Additionally, a role for a
third plasminogen activator, plasma kallikrein, in plasminogen activation during skin
wound healing in mice has been reported (Lund et al. 2006). The role of plasma
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kallikrein in plasmin-mediated bacterial pathogenesis remains unexplored. Despite
its poor catalytic efficiency for plasminogen activation when compared to the main
activators in vitro, its precursor, prekallikrein, circulates at an abundance of
approximately 20-fold higher than pro-uPA (Colman 1969). Thus, plasma kallikrein
may contribute to plasmin generation during the initiation of invasive GAS disease.
The pathological importance of plasminogen activation and acquisition by GAS is
well-established (Sun et al. 2004; Cole et al. 2006; Sanderson-Smith et al. 2008).
Bacterially acquired plasmin acts as a key molecule that potentiates and initiates
systemic bacterial infection. Here, we provide further evidence that GAS sequesters
host plasmin(ogen) as a protective mechanism to escape from complement-mediated
neutrophil killing. Furthermore, we show for the first time that host uPA, but not its
counterpart tPA, significantly contributes to developing invasive GAS infection in a
humanised plasminogen mouse model. Systemic treatment of GAS-infected mice
with commercial and newly developed analogue inhibitors of uPA activity however,
did not alleviate or abolish GAS infection in this mouse model of infection. The use
of other animal models may address the shortcomings in this study. Our data fuels
further knowledge that the ability to capture and/or activate plasminogen not only
enhances the ability of this bacterium to surmount tissue barriers and facilitate
invasion, but also provides an opportunity to modulate host defence and increase
bacterial survival. The present study broadens the scope of research that continues on
defining the pathogenic mechanisms of GAS, for it is imperative that therapeutic
strategies are developed in order to improve host defence against the devastating
impact of this global pathogen.
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Appendix A: Media, Buffers and Solutions
Nutrient and growth media
 Todd-Hewitt broth (THBY)
Todd Hewitt broth

10 g/L

Yeast extract

1% (w/v)

 Todd-Hewitt agar (THYA)
THY
Agar

15 g/L

 Lysogeny-Broth (LB)
Tryptone

10 g/L

Yeast extract

5 g/L

NaCl

10 g/L

 LB agar
LB
Agar

15 g/L

All media was made up to the desired volume in distilled H20.
Agarose gel electrophoresis
 1X Tris-acetate-EDTA buffer
Tris-base

40 mM

Glaciel acetic acid

20 mM

EDTA (pH 8.0)

1 mM

 1 % agarose gel
1X TAE buffer

100 mL

Agarose LE analytical grade

1% (w/v)
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 DNA loading dye
Bromophenol blue

0.005% (w/v)

Glycerol

75% (v/v)

1X TAE buffer (pH 8.0)

25% (v/v)

 Ethidium bromide staining solution
Ethidium bromide

1 µg/mL

SDS-PAGE gel electrophoresis
 2X Protein cracking buffer
Tris-HCl (pH 6.8)

90 mM

Glycerol

20% (v/v)

SDS

2% (w/v)

Bromophenol blue

0.02% (w/v)

 1X SDS-PAGE running buffer
Tris-HCl

25 mM

SDS

0.1% (w/v)

Glycine

190 mM

 Coomassie Blue rapid stain
Coomassie™ Blue R-250

0.2% (w/v)

Glacial acetic acid

10% (v/v)

Methanol

40% (v/v)

 Rapid destain
Glacial acetic acid

10% (v/v)

Methanol

40% (v/v)

 10 % resolving gel
40 % acrylamide/bis solution (37.5:1)

1.25 mL

1.5 M Tris-HCl (pH 6.8)

1.25 mL

Page | 169

Chapter 8 Appendices
10 % SDS

50 µL

Distilled H2O

2.4 mL

N, N, N’, N’ – tetramethylethylenediamine

25 µL

10 % ammonium persulphate

25 µL

Components were added in the order as listed above.
 4 % stacking gel
40 % acrylamide/bis solution (37.5:1)

225 µL

0.5 M Tris-HCl (pH 6.8)

600 µL

10 % SDS

25 µL

Distilled H2O

1.6 mL

N, N, N’, N’ – tetramethylethylenediamine

12.5 µL

10 % ammonium persulphate

12.5 µL

Components were added in the order as listed above.
Western transfer
 Transfer buffer
Tris-base

23 mM

Glycine

190 mM

Methanol

20% (v/v)

 Developing solution
Tris-base (pH 7.6)

100 mM

3,3’-diaminobenzadine tetrahydrochloride hydrate (DAB)

1.4 mM

Hydrogen peroxide

0.06% (w/v)

 1X Phosphate buffered saline (PBS) pH 7.4
NaCl

135 mM (w/v)

Na2HPO4

10 mM (w/v)

KCl

2.7 mL (w/v)

KH2PO4

1.75 mM (w/v)
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 1X PBS Tween20 (PBST)
PBS
Tween-20

0.05% (v/v)

Enzyme-linked immunosorbent assay (ELISA)
 Coating buffer
PBS (pH 8.5)

100 mL

NaCO3

0.1 M

 Washing buffer
PBS
Tween-20

0.05% (v/v)

 Blocking buffer
PBS
Bovine serum albumin

1% (w/v)

 Citrate buffer
Na2HPO4

8 mM

Adjusted to pH 5.0 with solid citric acid.
 Substrate solution
Citrate buffer

50 µL/well

o-phenylenediamine

0.4% (w/v)

Hydrogen peroxide

0.4% (v/v)

Neutrophil phagocytosis assay
 RPMI 1640 media
[+] L-glutamine

25 mM

[+] HEPES

25 mM

 Trypan blue solution
NaCl

0.81% (w/v)

K2HPO4

0.06% (w/v)
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Histology
 Sodium citrate buffer pH 6.0
Tri-sodium citrate (dehydrate)

10 mM

Tween-20

0.05% (v/v)

 Tris-buffered saline (TBS)
Tris

50 mM

NaCl

13.8 mM

Tween-20

0.05% (v/v)

KCl

0.27 mM
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Appendix B: Characterisation of Homozygous Humanised Plasminogen Mice
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Figure 8.1 Characterisation of homozygous humanised plasminogen mice. (A) Streptokinasemediated plasminogen activation and (B) cell surface plasmin acquisition by NS88.2 in plasma
collected from AlbPLG+/- (heterozygous; n = 1) and AlbPLG1+/+ (homozygous; n = 2) mice.
Streptokinase-mediated plasminogen activation data represent the mean ± SD of duplicate assays.
Cell surface plasmin acquisition data represent the mean ± SEM of two independent experiments
performed in triplicate. (C) Cohorts of 10 age and sex-matched AlbPLG1+/- or AlbPLG1+/+ mice were
subcutaneously infected with NS88.2 and the survival monitored over a 10-day period. Asterisks
indicate statistical significance, **P < 0.01, ***P < 0.001.
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